
<html lang="en"     class="pb-page"  data-request-id="b73d449d-7ef0-419e-8cd0-ec6281a5599e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-8;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02150;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity" /></meta><meta name="dc.Creator" content="Wensheng  Yu" /></meta><meta name="dc.Creator" content="Jian  Liu" /></meta><meta name="dc.Creator" content="Dane  Clausen" /></meta><meta name="dc.Creator" content="Younong  Yu" /></meta><meta name="dc.Creator" content="Joseph L.  Duffy" /></meta><meta name="dc.Creator" content="Ming  Wang" /></meta><meta name="dc.Creator" content="Shouning  Xu" /></meta><meta name="dc.Creator" content="Lin  Deng" /></meta><meta name="dc.Creator" content="Takao  Suzuki" /></meta><meta name="dc.Creator" content="Christine C.  Chung" /></meta><meta name="dc.Creator" content="Robert W.  Myers" /></meta><meta name="dc.Creator" content="Daniel J.  Klein" /></meta><meta name="dc.Creator" content="James I.  Fells" /></meta><meta name="dc.Creator" content="M. Katharine  Holloway" /></meta><meta name="dc.Creator" content="Jin  Wu" /></meta><meta name="dc.Creator" content="Guoxin  Wu" /></meta><meta name="dc.Creator" content="Bonnie J.  Howell" /></meta><meta name="dc.Creator" content="Richard J. O.  Barnard" /></meta><meta name="dc.Creator" content="Joseph  Kozlowski" /></meta><meta name="dc.Description" content="We describe the discovery of histone deacetylase (HDACs) 1, 2, and 3 inhibitors with ethyl ketone as the zinc-binding group. These HDACs 1, 2, and 3 inhibitors have good enzymatic and cellular acti..." /></meta><meta name="Description" content="We describe the discovery of histone deacetylase (HDACs) 1, 2, and 3 inhibitors with ethyl ketone as the zinc-binding group. These HDACs 1, 2, and 3 inhibitors have good enzymatic and cellular acti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 2, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02150" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02150" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02150" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02150" /></link>
        
    
    

<title>Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02150" /></meta><meta property="og:title" content="Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0016.jpeg" /></meta><meta property="og:description" content="We describe the discovery of histone deacetylase (HDACs) 1, 2, and 3 inhibitors with ethyl ketone as the zinc-binding group. These HDACs 1, 2, and 3 inhibitors have good enzymatic and cellular activity. Their serum shift in cellular potency has been minimized, and selectivity against hERG has been improved. They are also highly selective over HDACs 6 and 8. These inhibitors contain a variety of substituted heterocycles on the imidazole or oxazole scaffold. Compounds 31 and 48 stand out due to their good potency, high selectivity over HDACs 6 and 8, reduced hERG activity, optimized serum shift in cellular potency, and good rat and dog PK profiles." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02150"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02150">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02150&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02150&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02150&amp;href=/doi/10.1021/acs.jmedchem.0c02150" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4709-4729</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02069" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02163" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wensheng Yu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wensheng Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e7908289948f828980c99e92a78a8295848cc984888a"><span class="__cf_email__" data-cfemail="0c7b69627f6469626b2275794c61697e6f67226f6361">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wensheng++Yu">Wensheng Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Liu">Jian Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dane Clausen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dane Clausen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dane++Clausen">Dane Clausen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Younong Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Younong Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Younong++Yu">Younong Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph L. Duffy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph L. Duffy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+L.++Duffy">Joseph L. Duffy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ming Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ming Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Wang">Ming Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shouning Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shouning Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shouning++Xu">Shouning Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lin Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lin Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lin++Deng">Lin Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takao Suzuki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takao Suzuki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 288 Fute Zhong Road, Shanghai 200131, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takao++Suzuki">Takao Suzuki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine C. Chung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine C. Chung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine+C.++Chung">Christine C. Chung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert W. Myers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert W. Myers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+W.++Myers">Robert W. Myers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel J. Klein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel J. Klein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+J.++Klein">Daniel J. Klein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James I. Fells</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James I. Fells</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+I.++Fells">James I. Fells</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">M. Katharine Holloway</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">M. Katharine Holloway</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M.+Katharine++Holloway">M. Katharine Holloway</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Wu">Jin Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guoxin Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guoxin Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guoxin++Wu">Guoxin Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bonnie J. Howell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bonnie J. Howell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bonnie+J.++Howell">Bonnie J. Howell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard J. O. Barnard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard J. O. Barnard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+J.+O.++Barnard">Richard J. O. Barnard</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joseph Kozlowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph Kozlowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Kozlowski">Joseph Kozlowski</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02150&amp;href=/doi/10.1021%2Facs.jmedchem.0c02150" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4709–4729</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 2, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 December 2020</li><li><span class="item_label"><b>Published</b> online</span>2 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02150" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02150</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4709%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWensheng%2BYu%252C%2BJian%2BLiu%252C%2BDane%2BClausen%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D8%26contentID%3Dacs.jmedchem.0c02150%26title%3DDiscovery%2Bof%2BEthyl%2BKetone-Based%2BHighly%2BSelective%2BHDACs%2B1%252C%2B2%252C%2B3%2BInhibitors%2Bfor%2BHIV%2BLatency%2BReactivation%2Bwith%2BMinimum%2BCellular%2BPotency%2BSerum%2BShift%2Band%2BReduced%2BhERG%2BActivity%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4729%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02150"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">999</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02150" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wensheng&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Dane&quot;,&quot;last_name&quot;:&quot;Clausen&quot;},{&quot;first_name&quot;:&quot;Younong&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;L. Duffy&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shouning&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lin&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Takao&quot;,&quot;last_name&quot;:&quot;Suzuki&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;C. Chung&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;W. Myers&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;J. Klein&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;I. Fells&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Katharine Holloway&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Guoxin&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Bonnie&quot;,&quot;last_name&quot;:&quot;J. Howell&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;J. O. Barnard&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Kozlowski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4709-4729&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02150&quot;},&quot;abstract&quot;:&quot;We describe the discovery of histone deacetylase (HDACs) 1, 2, and 3 inhibitors with ethyl ketone as the zinc-binding group. These HDACs 1, 2, and 3 inhibitors have good enzymatic and cellular activity. Their serum shift in cellular potency has been minimized, and selectivity against hERG has been improved. They are also highly selective over HDACs 6 and 8. These inhibitors contain a variety of substituted heterocycles on the imidazole or oxazole scaffold. Compounds 31 and 48 stand out due to their good potency, high selectivity over HDACs 6 and 8, reduced hERG activity, optimized serum shift in cellular potency, and good rat and dog PK profiles.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02150&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02150" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02150&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02150" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02150&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02150" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02150&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02150&amp;href=/doi/10.1021/acs.jmedchem.0c02150" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02150" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02150" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02150%26sid%3Dliteratum%253Aachs%26pmid%3D33797924%26genre%3Darticle%26aulast%3DYu%26date%3D2021%26atitle%3DDiscovery%2Bof%2BEthyl%2BKetone-Based%2BHighly%2BSelective%2BHDACs%2B1%252C%2B2%252C%2B3%2BInhibitors%2Bfor%2BHIV%2BLatency%2BReactivation%2Bwith%2BMinimum%2BCellular%2BPotency%2BSerum%2BShift%2Band%2BReduced%2BhERG%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D8%26spage%3D4709%26epage%3D4729%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292035" title="Viruses">Viruses</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/jmcmar.2021.64.issue-8/20210422/jmcmar.2021.64.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We describe the discovery of histone deacetylase (HDACs) 1, 2, and 3 inhibitors with ethyl ketone as the zinc-binding group. These HDACs 1, 2, and 3 inhibitors have good enzymatic and cellular activity. Their serum shift in cellular potency has been minimized, and selectivity against hERG has been improved. They are also highly selective over HDACs 6 and 8. These inhibitors contain a variety of substituted heterocycles on the imidazole or oxazole scaffold. Compounds <b>31</b> and <b>48</b> stand out due to their good potency, high selectivity over HDACs 6 and 8, reduced hERG activity, optimized serum shift in cellular potency, and good rat and dog PK profiles.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">World Health Organization estimated that globally 37.9 million people are living with Human Immunodeficiency Virus (HIV), which causes Acquired Immune Deficiency Syndrome (AIDS).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Even though the current treatment of combined antiretroviral therapy (cART) can reduce the virus to undetectable levels, due to the existence of HIV latency, life-long treatment is required for patients as any disruption will lead to the rebound of HIV. HIV latency is HIV-infected memory CD4+ T-cells that are resting and transcriptionally silent.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The half-life of these latently infected resting memory CD4+ T-cells has been calculated to be 44 months,<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> leading to estimates that it would take in excess of 70 years of cART therapy to fully eradicate this reservoir. Life-long cART treatment causes multiple issues for patients, including financial burden, side effects, and long-term toxicities. Complete cure of HIV infection remains an unmet medical need and is the focus of much research effort. One approach toward a complete HIV cure is a strategy known as “shock and kill”.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In this strategy, the latently infected CD4+ T-cells are first “shocked” to induce the production of viral proteins. Once decorated with viral proteins, the HIV-infected memory T-cells can be distinguished from uninfected CD4+ T-cells and become susceptible to any selective “kill” strategies. The “shock” part of the strategy can be achieved by latency-reversing agents (LRAs). Known LRAs are histone deacetylase (HDAC) inhibitors, protein kinase C (PKC) agonists, histone methylation (HMT) inhibitors, DNA methyltransferase (DNMT) inhibitors, bromodomain and extra terminal (BET) domain proteins (BET) inhibitors, and disulfiram.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">HDACs are enzymes that are essential for histone deacetylation.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Deacetylation of the lysine residues in histones results in a condensed chromatin structure and therefore reduces the gene expression. HDAC inhibitors prevent the deacetylation of lysine residues in histones, and therefore prevent the chromatin from transitioning into the condensed status. Through this mechanism, HDAC inhibitors can be used to regulate gene expression. Early studies on HDAC inhibitors were focused on oncology programs and several inhibitors have been approved to treat cancers.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Recently HDAC inhibitors have been used in the “shock” therapy for the eradication of HIV latency. Proof of concept for shocking the HIV latency in clinical studies has been achieved by HDAC inhibitors vorinostat (suberoylanilide hydroxamic acid/SAHA),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> panobinostat,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and romidepsin.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> After administration of HDAC inhibitors, statistically significant increases of HIV mRNA level in resting CD4+ T-cells as well as plasma viraemia were observed.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Clinical studies with “shock and kill” strategies combined so far resulted in mixed results. A clinical trial with a combination of romidepsin, Vacc-4x, and recombinant human granulocyte macrophage colony-stimulating factor (rhuGM-CSF) vaccination reduced the total HIV-1 DNA level and infectious units per million (IUPM), but not the integrated HIV-1 DNA level.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Another clinical trial evaluating antiretroviral therapy alone versus antiretroviral therapy with a “kick and kill” approach on patients with recent HIV infection identified no statistically difference in the mean total HIV DNA between the two groups. However, the efficacy of the “kick and kill” strategy has not been disproved, instead, more powerful kick or kill agents would be desired for future clinic studies.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">HDACs are zinc-dependent enzymes with four classes. Early HDAC inhibitors using the hydroxamic acid group as the zinc-binding group. They are not selective and potent on both class I (HDACs 1, 2, 3, and 8) and II (HDACs 4, 5, 6, 7, 9, and 10) isozymes. Due to the known on- and off-target undesired effects, their use as chronic treatments remains a concern.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Recent research has focused on the development of isozyme selective HDAC inhibitors. Our initial effort in this field established ethyl ketone-based HDAC inhibitor <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) for oncology purpose.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Our continued effort has shifted to HIV latency reactivation. The Jurkat model of HIV latency using 2C4 cells was adopted as the latency reactivation assay to evaluate the cellular potency against HIV latency. This assay measures the reactivation of a quiescent HIV provirus by quantification of the luciferase reporter gene. The cell line was generated according to the same method as Jurkat HIV T-cell line, which used an eGFP reporter gene.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> The assay was performed with 0.1 or 5% normal human sera (NHS). Addition of 0.1% NHS is necessary for Jurkat 2C4 cells to live longer. Addition of 5% NHS was to measure the serum shift of the compounds’ cellular potency. Minimum serum shift in cellular potency is desirable. Recently, we have reported that inhibitions of HDACs 1, 2, and 3 are sufficient to show cellular latency reactivation activity in 2C4 cells. In that effort, compound <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was identified as an early lead.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>2</b> also utilizes an ethyl ketone group (the hydrate form) as the zinc-binding group. Compared to <b>1</b>, compound <b>2</b> had improved HDACs 1, 2, and 3 enzymatic activity as well as cellular potency. However, compound <b>2</b> is an inhibitor of cardiac hERG.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The ratio of its hERG IC<sub>50</sub> to its cell EC<sub>50</sub> with 5% NHS is only 100×. It also shows a serum shift (3.2×) in cellular potency between 0.1% NHS and 5% NHS. The rat PK profile of <b>2</b> needs further improvement. The unbound <i>C</i><sub>max</sub> in the rat PK study at 10 mg/kg (mpk) dose was 7.5 nM (<i>C</i><sub>max</sub> = 627 nM, plasma protein binding (PPB) = 98.8%), which is only 0.09x of the cell EC<sub>50</sub> with 5% NHS. Its unbound <i>C</i><sub>24h</sub> in the same rat PK study is 0.11 nM (<i>C</i><sub>24h</sub> = 9 nM), which cannot cover its IC<sub>50</sub> against HDAC 2. Among the potency against HDACs 1, 2, and 3, the IC<sub>50</sub> value against HDAC 2 is normally the highest among the HDAC inhibitors in the series explored in this study. On the other side, these inhibitors are normally more active against HDAC 6 than HDAC 8. Therefore, the IC<sub>50</sub> ratio between the HDAC 6 over HDAC 2 is used to assess the selectivity of HDACs 1, 2, and 3 over HDACs 6 and 8. The IC<sub>50</sub> ratio of HDAC 6 over HDAC 2 for <b>2</b> is 114×, which is only marginally acceptable.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HDAC inhibitors <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reported Potency Data of HDAC Inhibitors <b>1</b> and <b>2</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">HDAC IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center">2C4 cell EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center">6</th><th class="colsep0 rowsep0" align="center">8</th><th class="colsep0 rowsep0" align="center">0.1% NHS</th><th class="colsep0 rowsep0" align="center">5% NHS</th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">680</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">480</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left"><0.30</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left"><0.30</td><td class="colsep0 rowsep0" align="left">160</td><td class="colsep0 rowsep0" align="left">3 400</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">8.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p last">To move an HDAC inhibitor to further development, we were targeting an inhibitor with reduced serum shift (<1.5×) between the cellular potency data in 0.1% NHS and 5% NHS, improved selectivity over hERG IC<sub>50</sub> (>500× over cell EC<sub>50</sub>), and improved selectivity of HDAC 2 over HDAC 6 (>100×). Ideally, we are also targeting to achieve the unbound <i>C</i><sub>max</sub> in rat PK study at 10 mpk dose covers the cell EC<sub>50</sub>, and the unbound C<sub>24h</sub> covers the IC<sub>50</sub>’s against HDACs 1, 2, and 3. These requirements had been established to ensure a good efficacy and safety profiles of the lead compounds moving to the next stage of development.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our initial effort was to explore different heterocycles as the substituents on the imidazole moiety, and their potency profiles are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compound <b>3</b> was a side product obtained during the preparation of <b>2</b>, and it was potent against HDACs 1, 2, and 3 but 3× less potent than <b>2</b> in the latency reactivation assay. The <i>N</i>-methyl analogue <b>4</b> was as potent as <b>3</b> but was 2× less selective against hERG. Compound <b>5</b> contained a 1-methylquinolin-4(1<i>H</i>)-one moiety and showed no serum shift in cellular potency and no hERG activity. However, its enzymatic and cellular potency was reduced as well. Removing the methoxy group of the 2-methoxyquinoline moiety in <b>2</b> led to 3-quinoline derivative <b>6</b>, which was 3× to 5× weaker in both enzymatic activity against HDACs 1, 2, and 3, and cellular activity than <b>2</b>. Other quinoline analogues (<b>7</b>–<b>9</b>) were all potent against HDACs 1, 2, and 3, and <b>8</b> showed the best cellular activity among them. Interestingly, 6-quiloline analogue <b>7</b> was not active against hERG, but both 7-isoquinoline analogue (<b>6</b>) and 5-isoquinoline analogue (<b>8</b>) had their EC<sub>50</sub>’s against hERG in the low double-digit μM range. Analogues with fused-bicyclic heterocycles with two nitrogen atoms were also explored. Quinoxaline derivative <b>10</b>, cinnoline derivative <b>11</b>, and 1,8-naphthyridine derivative <b>12</b> were all 10× less potent than <b>7</b> against HDACs 1, 2, and 3. Analogues substituted with 3a,7a-dihydrobenzo[<i>d</i>]thiazole (<b>13</b>), 3a,7a-dihydrobenzo[<i>d</i>]oxazole (<b>14</b>), and 2-methyl-2<i>H</i>-indazole (<b>15</b>) were also prepared and they were all similar in enzymatic and cellular potency to <b>7</b>. 1-Methylquinolin-2(1<i>H</i>)-one group (<b>16</b>) and 2-methylisoquinolin-1(2<i>H</i>)-one group (<b>17</b>) were also incorporated. Both <b>16</b> and <b>17</b> showed single-digit nM IC<sub>50</sub>’s against HDACs 1, 2, and 3, and double-digit nM EC<sub>50</sub>’s in the cellular potency assay. Their serum shift in cellular potency was reduced to less than 1.5×. Both <b>16</b> and <b>17</b> showed hERG IC<sub>50</sub>’s greater than 60 μM. Nonfused bicyclic heterocycles (<b>18</b>–<b>21</b>) were also explored and their potency profile are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> as well. Although their IC<sub>50</sub>’s against HDACs 1, 2, and 3 were in the single-digit nM or sub-nM range, and their cellular potency EC<sub>50</sub>’s were in the double-digit EC<sub>50</sub>’s range, they showed single-digit μM EC<sub>50</sub>’s against hERG except <b>21</b> with hERG IC<sub>50</sub> as 21 μM.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. HDAC and hERG Activities of Compounds <b>3</b>–<b>21</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All reported potency values are the average of at least two independent measurements with standard deviation less than 3-fold of the reported mean.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">ND = not determined.</p></div></div><div></div></div><div class="NLM_p">Compound <b>7</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> stood out as it showed good enzymatic and cellular activity, no serum shift in cellular potency, and no hERG activity. Analogues of <b>7</b> were synthesized and their HDAC and hERG activities are provided in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Introduction of a methyl group next to the nitrogen of the quinoline led to <b>22</b>, which was 3× more potent in the latency reactivation assay than <b>7</b>. Encouraged by this data, ethyl (<b>23</b>), cyclopropyl (<b>24</b>), methoxy (<b>25</b>), and pyrrolidyl (<b>26</b>) analogues were also prepared. They all showed sub-nM IC<sub>50</sub>’s against HDACs 1, 2, 3, and double-digit nM EC<sub>50</sub>’s in cellular potency assay. However, their EC<sub>50</sub>’s against hERG were in the double-digit μM range. Oxazole (<b>27</b>) and pyrazole (<b>28</b>) moieties were also introduced to the same position, but both inhibitors had poor selectivity against hERG. Compound <b>22</b> was soaked into the crystal of HDAC 2 enzyme and the overlay of its X-ray structure with <b>2</b> was shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Both compounds overlaid with each other well. There should be space available for <b>22</b> to incorporate a methoxy group at the C-7 position of the quinoline. This was confirmed by the potency data of <b>29</b>, which contained a 7-methoxyquinoline moiety. Then, 7-methoxy-2-methylquinoline derivative <b>30</b> was prepared and indeed it showed good cellular potency with the serum shift as 1.2×. However, it still had moderate activity against hERG.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the X-ray structures of <b>2</b> (purple) and <b>22</b> (yellow) in the crystal of HDAC 2. Access codes for X-ray coordinates in RCSB Protein Data Bank (PDB) database are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ">6WBZ</a> (<b>2</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JS8">7JS8</a> (<b>22</b>). The authors will release the atomic coordinates upon article publication.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. HDAC and hERG Activities of Compounds <b>22</b>–<b>30</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All reported potency values are the average of at least two independent measurements with standard deviation less than 3-fold of the reported mean.</p></div></div><div></div></div><div class="NLM_p">Due to the good cellular potency of <b>30</b>, we followed up with its analogues that had different substitutions on nitrogen atom of the 6-azaspiro[2.5]octane moiety. Their potency profiles are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. The ethyl analogue <b>31</b> and isopropyl analogue <b>32</b> showed sub-nM IC<sub>50</sub>’s against HDACs 1, 2, and 3 as well as single-digit or double-digit nM EC<sub>50</sub>’s in cellular potency assay. They showed moderate to weak potency against HDACs 6 and 8 with IC<sub>50</sub>’s over 350 nM. Moreover, their EC<sub>50</sub>’s against hERG are greater than 40 μM. Compound <b>31</b> was the first compound showed a single-digit nM EC<sub>50</sub> value in the latency reactivation assay  in this series. The cyclopropylmethyl analogue <b>33</b> and cyclobutyl analogue <b>34</b> were both similar in potency to <b>31</b> and <b>32</b>, but their EC<sub>50</sub>’s against hERG were in the single-digit μM range. Comparing the cellular data of <b>29</b> and <b>30</b> with the data of their corresponding analogues without the 7-methoxy substitution in the quinoline moiety (<b>7</b> and <b>22</b>), the 7-methoxy substitution in the quinoline seemed to improve the potency in the HIV latency reactivation assay. Therefore, a methoxy group was introduced to a similar position of the heterocycles we explored in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The enzymatic and cellular EC<sub>50</sub>’s as well as hERG activity are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. The 2-ethyl-7-methoxyquinoline (<b>35</b>) and 2-cyclopropyl-7-methoxyquinoline (<b>36</b>–<b>37</b>) analogues showed single-digit or double-digit nM EC<sub>50</sub>’s in the cellular potency assay. The other methoxy substituted heterocycles (<b>38</b>–<b>41</b>) were less potent in the latency reactivation assay than <b>31</b>. We also explored other substitution at the 7-position of the quinoline. The 7-methoxy group of <b>31</b> was replaced with fluoro, chloro, methyl, and ethyl groups (<b>42</b>–<b>45</b>). All of these were less potent than <b>31</b> in the cellular assay and more active to hERG. However, they all showed good selectivity against HDACs 6 and 8.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. HDAC and hERG Activities of Compounds <b>31</b>–<b>45</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All reported potency values are the average of at least two independent measurements with standard deviation less than 3-fold of the reported mean. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">Varieties of heterocycles were explored in the imidazole series. Selected heterocycles were incorporated with the oxazole core as well and their HDAC and hERG activity data are provided in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The oxazole analogues were not as potent as the imidazole derivatives in both enzymatic and cellular assays. However, some compounds, such as <b>48</b> and <b>49</b>, still showed good enzymatic and cellular potency as well as reduced hERG activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. HDAC and hERG Activities of Compounds <b>46</b>–<b>56</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All reported potency values are the average of at least two independent measurements with standard deviation less than 3-fold of the reported mean.</p></div></div><div></div></div><div class="NLM_p">Compounds with good cellular potency and reduced hERG activity were screened in rat cassette PK studies. Compounds showed good clearance were tested in full rat and dog PK studies. The PK parameters are provided in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Imidazole analogues (<b>22</b>, <b>29</b>–<b>32</b>) all showed bioavailability lower than 10% with <b>7</b> have the highest value of 7.9%. Oxazole analogues (<b>48</b>, <b>49</b>, <b>51</b>, <b>52</b>, <b>54</b>, <b>56</b>) showed improved bioavailability than the imidazole analogues with values greater than 20% except <b>52</b>, which had a value of 6.9%. The improved PK exposure of oxazole analogues could be explained by their greater membrane permeability compared to the imidazole analogues. For example, the measured Papp value of <b>48</b> and <b>49</b> are 19 × 10<sup>–6</sup> cm/s and 16 × 10<sup>–6</sup> cm/s, respectively. However, the measured Papp value of <b>31</b> is only 2.8 × 10<sup>–6</sup> cm/s. Among the imidazole analogues, the PK profile of compound <b>31</b> is reasonable considering its single-digit nM EC<sub>50</sub> in the latency reactivation assay and reasonable <i>C</i><sub>max</sub> in both rat and dog PK studies. Among the oxazole analogues, compound <b>48</b> showed the best PK profile with bioavailability of 78% in rat and 42% in dog.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Profiles of Compounds <b>22</b>, <b>29</b>–<b>32</b>, <b>48</b>, <b>49</b>, <b>51</b>, <b>52</b>, <b>54</b>, and <b>56</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IV</th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">PO</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mpk)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/Kg)</th><th class="colsep0 rowsep0" align="center" char=".">dose (mpk)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>24h</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>F</i>%</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">0.0040</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="left">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">9.5</td><td class="colsep0 rowsep0" align="left">61</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.060</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">0.0010</td><td class="colsep0 rowsep0" align="left">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">33</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.98</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">0.0089</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.097</td><td class="colsep0 rowsep0" align="char" char=".">0.0032</td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.0090</td><td class="colsep0 rowsep0" align="char" char=".">0.0010</td><td class="colsep0 rowsep0" align="left">0.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="left">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">0.0072</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.0092</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.063</td><td class="colsep0 rowsep0" align="char" char=".">0.0010</td><td class="colsep0 rowsep0" align="left">6.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td><td class="colsep0 rowsep0" align="char" char=".">0.0036</td><td class="colsep0 rowsep0" align="left">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">6.5</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.60</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.0022</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">0.0012</td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">6.0</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.072</td><td class="colsep0 rowsep0" align="char" char=".">0.0033</td><td class="colsep0 rowsep0" align="left">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.070</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.0020</td><td class="colsep0 rowsep0" align="left">11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Male Wistar Han rats or Beagle dogs were used. Compound was dosed IV in 60% PEG200 and PO in 10% Tween.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15110" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15110" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Extensive structure–activity relationship (SAR) studies have been done on the different heterocyclic substitutions on the imidazole or oxazole moieties as well as different alkyl substitution on the 6-azaspiro[2.5]octane moiety. Novel HDAC inhibitors have been identified with improved enzymatic activity against HDACs 1, 2, and 3, cellular potency in the latency reactivation assay, and minimized serum shift in cellular potency between 0.1 or 5% NHS. Many of these HDAC inhibitors have reduced hERG activity as well. Compound <b>48</b> stands out as it meets all of the set requirements for moving into further development. Its serum shift between cell EC<sub>50</sub>’s at 0.1% or 5% NHS was reduced to 1.2×. The ratio of its hERG IC<sub>50</sub> over cell EC<sub>50</sub> at 5% NHS is 740×. The ratio of its HDAC 6 IC<sub>50</sub> over HDAC 2 IC<sub>50</sub> is 350×. The PK profile of <b>48</b> also meets our requirement. Its unbound <i>C</i><sub>max</sub> in rat PK study at 10 mpk is 120 nM, which is 2.6× over its cell EC<sub>50</sub> at 5% NHS. Its unbound <i>C</i><sub>24h</sub> is 1.3 nM, which covers its IC<sub>50</sub>’s against HDACs 1, 2, and 3. Compound <b>31</b> is another HDAC inhibitor of high interest due to its excellent selectivity over hERG and the fact that it meets majority of the requirement. Its serum shift was reduced to 1.7×, which is only slightly above 1.5×. Its selectively over hERG IC<sub>50</sub> is 4200×, which far exceeds the 500× set requirement. Its HDAC 2 selectivity over HDAC 6 is 880×. The PK profile of <b>31</b> marginally meets the requirements. Its unbound <i>C</i><sub>max</sub> in rat PK study at 10 mpk is 3 nM, which is 0.3× over its cell EC<sub>50</sub> at 5% NHS. Its unbound <i>C</i><sub>24h</sub> is 0.09 nM, which can cover its IC<sub>50</sub>’s against HDACs 1 and 3, but not HDAC 2. Compounds <b>31</b> and <b>48</b> have been identified as advanced leads and are being evaluated in safety studies and biological models for HIV latency reactivation. The <i>in vitro</i> target engagement and histone acetylation studies have been published recently.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The <i>in vivo</i> histone acetylation studies in rats will be published in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02005" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02005" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> were prepared in similar chemistry, which was exemplified by the preparation of <b>31</b> outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<named-content content-type="anchor" rid="sch2" type="simple"></named-content><a class="ref internalNav" href="#sch3" aria-label="3">3</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> describes the preparation of (<i>S</i>)-6-methyl-6-azaspiro[2.5]octane-1-carboxylic acid (<b>60a</b>) and (<i>S</i>)-6-ethyl-6-azaspiro[2.5]octane-1-carboxylic acid (<b>60b</b>). Compound <b>57</b> was prepared based on the procedures published.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The Boc group was removed, and the methyl group (<b>59a</b>) or ethyl group (<b>59b</b>) was introduced by reductive amination. The benzyl group was removed to give acid intermediates <b>60a</b> and <b>60b</b> respectively. 7-Methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (<b>64</b>) was prepared by the chemistry outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Ring closure of 4-bromo-3-methoxyaniline and (<i>E</i>)-but-2-enal gave 6-bromo-7-methoxy-2-methylquinoline (<b>63</b>) in moderate yield. Boronic ester <b>64</b> was obtained from <b>63</b> via the Suzuki coupling reaction with bis(pinacolato)diboron. With intermediates <b>60b</b> and <b>64</b> in hand, compound <b>31</b> was prepared based on the chemistry outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Treatment of <b>65</b> with 2 equiv of <i>n</i>-BuLi generated a dianion intermediate, which was converted to a monoanion intermediate by the addition of one equivalent of water. Addition of bromine to the mono-anion intermediate gave dibromide <b>66</b>. Lithium-halogen exchange with <i>n</i>-BuLi to generate the imidazole anion, which added to (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> to give <b>67</b>. Deprotection of the amine and ketone under acidic condition afforded intermediate <b>68</b>, which coupled with <b>60b</b> to give the common intermediates <b>69</b>. Coupling reaction between <b>69</b> and <b>64</b> gave <b>70</b>, which afforded <b>31</b> after the SEM group was removed. Compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> were prepared by the same chemistry outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a> with or without adjustment of the synthetic sequence. The boronic ester intermediates used for preparation of compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> were either purchased or prepared from the corresponding bromides using the same chemistry of step 2 in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. For any bromides that were not commercially available, their preparations are described in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>60a</b> and <b>60b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) trifluoroacetic acid (TFA), dichloromethane (DCM), 25 °C, 4 h; (ii) <b>59a</b>: formaldehyde, MeOH, 25 °C, 2 h, then NaBH(AcO)<sub>3</sub>, 1 h, 99% for two steps; <b>59b</b>: acetaldehyde, MeOH, 30 °C, 32 h, then NaBH(AcO)<sub>3</sub>, 30 °C, 16 h, 91% for two steps; (iii) <b>60a</b>: H<sub>2</sub> (15 psi), Pd/C (10%), MeOH, 24 °C, 1.5 h, 96%; <b>60b</b>: H<sub>2</sub> (15 psi), Pd/C (10%), MeOH, 18 °C, 2 h, 99%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Intermediate <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HCl, water, 110 °C, 2 h, 54%; (ii) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf), KOAc, 1,4-dioxane, 80 °C, 12 h, 71%.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compound <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi (2 equiv), THF, −78 °C, 10 min; H<sub>2</sub>O (1 equiv), −78 to −50 °C, 1 h; −78 °C, Br<sub>2</sub> (1.1 equiv), 30 min, 29%; (ii) <i>n</i>-BuLi, THF, −78 °C, then (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide, 54%; (iii) HCl, 25 °C, 8 h, 72%; (iv) <b>60b</b>, HATU, Et<sub>3</sub>N, DMF, 25 °C, 2 h; (v) <b>69</b>, <b>64</b>, PdCl<sub>2</sub>(DTBPF), K<sub>3</sub>PO<sub>4,</sub> THF, 70 °C, 2 h, 86%; (vi) TFA, rt, 2 h, 96%.</p></p></figure><div class="NLM_p">The preparation of oxazole analogues in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> was exemplified by the preparation of <b>48</b> as outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The oxazole anion generated by the treatment of oxazole with <i>n</i>-BuLi added to (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide to give <b>71</b>. Deprotonation of <b>71</b> with <i>t</i>-BuLi followed by the addition of CBr<sub>4</sub> afforded <b>72</b>. Treatment of <b>72</b> under acidic condition gave amine <b>73</b>, which coupled with <b>60a</b> to give common intermediate <b>74</b>. Compound <b>48</b> was obtained by the Suzuki coupling reaction of <b>74</b> with <b>64</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, BH<sub>3</sub>·THF, (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide, THF, −78 °C, 53%; (ii) <i>t</i>-BuLi, CBr<sub>4</sub>, THF, −78 °C, 51%, (iii) HCl, MeOH, 98%; (iv) <b>60a</b>, HATU, Et<sub>3</sub>N, DMF, 25 °C, 2 h; (v) <b>74</b>, <b>64</b>, PdCl<sub>2</sub>(DTBPF), K<sub>3</sub>PO<sub>4,</sub> THF, 70 °C, 2 h, 46%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chemicals purchased from commercial suppliers were used as received unless specified. Silica gel column chromatography was carried out on ISCO CombiFlash Companion. Prepacked silica gel cartridges were used. Thin-layer chromatography (TLC) visualization was performed under 254 nm ultraviolet light. Reversed-phase preparative high-performance liquid chromatography (HPLC) purifications were done on a Gilson 215 Liquid Handler with Unpoint software, typically with a Sun Fire Prep C18 OBD 5 am 19 × 50 mm column. The following method was typically used, run time: 15 min. flow rate: 14 mL/min. Mobile phase: 10 to 90% CH<sub>3</sub>CN/H<sub>2</sub>O, with 0.1% TFA. UV detection at 254 or 210 nm was typically used. SFC separations were normally done on a TharSFC instrumentation. Columns and separation conditions were specified in each separation. Nuclear magnetic resonance spectra were obtained on a Varian 400 MHz or Bruker 400 MHz spectrometers. Spectra were taken at ambient temperature. Chemical shifts were assigned using residual solvent signal as internal standard and are reported in parts per million (ppm). Resonance patterns are reported using the following notations: br (broad), s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). The purity of all final compounds was determined to be >95% according to the liquid chromatography–mass spectrometry (LCMS) data obtained on Agilent 1200 Series HPLC equipped with DAD and 6110 single quadrupole MSD and ELSD with Agilent TC-C18, 50 × 2.1 mm, 5 μm for acid methods, Waters X-Bridge ShieldRP18, 50 × 2.1 mm 5 μm for basic methods.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Human HDAC Enzymatic and HIV Latency Assay Procedure</h3><div class="NLM_p last">The procedures for human HDAC enzyme inhibitor Fluor-de-Lys assay and HIV latency reactivation model with 2C4 cell assay have been published in separated papers.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> All reported potency values are the average of at least two independent measurements with standard deviation less than 3-fold of the reported mean. hERG data were obtained based on the published method.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Procedure for Crystal Soaking of <b>22</b> with HDAC 2 Protein</h3><div class="NLM_p last">Crystallization of Human HDAC 2 protein (Proteros, Cat. No. PR-0105) was performed by hanging drop vapor diffusion with seeding at 293 K. Drops contained equal volumes of protein and crystallization buffer containing 25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Hepes pH 7.5. Crystal soaking solutions contained compound <b>22</b> at a concentration of 4 mM with crystallization buffer. HDAC 2 crystals were harvested and transferred to the soaking solution and incubated for 24 h prior to flash freezing in liquid nitrogen. Diffraction data were processed with AutoProc (Global Phasing), and structures were refined using AutoBuster with ligand geometry restraints derived from Grade. Compound <b>2</b> was soaked with HDAC 2 protein in the same method. The X-ray structures of <b>2</b> and <b>22</b> in the crystal of HDAC 2 have been deposited in RCSB Protein Data Bank (PDB) database. Their access codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ">6WBZ</a> (<b>2</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JS8">7JS8</a> (<b>22</b>), respectively. The authors will release the atomic coordinates upon article publication.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Rat Cassette PK Screening Generic Procedure</h3><div class="NLM_p last">Plasma pharmacokinetic parameters for clearance, volume of distribution, half-life, and mean residence time (MRT) were determined in rats from IV cassette administration studies. Two male rats typically weighing 225–260 grams, were fasted overnight prior to dosing. Compounds were prepared for IV dosing by addition to a vehicle, depending on the dose used. For a typical preparation, 1 mg per mL (IV) of up to five test compounds were added to vehicle composed of 20% dimethyl sulfoxide (DMSO), 60% poly(ethylene glycol) 400 (PEG400), and 20% water. IV formulation was administered to two rats via precannulated jugular vein. Blood was collected by precannulated artery, typically at predose, 2, 8, 15, 30 min, 1, 2, 4, 6, and 8 h postdose. Samples were collected in K2EDTA tubes, stored on ice, and centrifuged. Plasma was transferred to a micro titer plate and stored at −70 °C until analysis. Plasma samples were extracted using protein precipitation and analyzed by liquid chromatography separation followed by mass spec detection (LCMS/MS), using a standard curve for each compound. Plasma pharmacokinetic parameters were calculated by noncompartmental methods.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Rat PK Screening Generic Procedure</h3><div class="NLM_p last">Plasma pharmacokinetic parameters for clearance, volume of distribution, half-life, and oral bioavailability were determined in rats from oral administration and IV administration studies. Four male rats, typically weighing 225–260 g, were fasted overnight prior to dosing. Compounds were prepared for oral and IV dosing by addition to a vehicle, depending on the dose used. For a typical preparation, 1 mg per mL (IV) or 1.5 mg per mL (oral) of test compound was added to vehicle composed of 20% dimethyl sulfoxide (DMSO), 60% poly(ethylene glycol) 400 (PEG400), and 20% water. IV formulation was administered to two rats via precannulated jugular vein, and oral dosing was administered to two rats via oral gavage. Blood was collected by precannulated artery, typically at predose, 2, 8, 15, 30 min, 1, 2, 4, 6, 8, and 24 h postdose for IV, and at predose, 15, 30 min, 1, 2, 4, 6, 8, and 24 h for oral dosing. Samples were collected in K2EDTA tubes, stored on ice, and centrifuged. Plasma was transferred to a micro titer plate and stored at −70 °C until analysis. Plasma samples were extracted using protein precipitation and analyzed by liquid chromatography separation followed by mass spec detection (LCMS/MS), using a standard curve for each compound. Plasma pharmacokinetic parameters were calculated for IV and oral dosing data by noncompartmental methods. Oral bioavailability was determined as the ratio of the dose-normalized plasma area under the curve (AUC) following oral dosing vs IV dosing.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Dog PK Screening Generic Procedure</h3><div class="NLM_p last">Plasma pharmacokinetic parameters for clearance, volume of distribution, half-life, mean residence time (MRT), and oral bioavailability were determined in dogs from oral administration and IV administration studies. Four male dogs, typically weighing 8–12 kg, were fasted overnight prior to dosing. Compounds were prepared for oral and IV dosing by addition to a vehicle, depending on the dose used. For a typical preparation, 1 mg per mL (IV) or 1.5 mg per mL (oral) of test compound was added to vehicle composed of 20% dimethyl sulfoxide (DMSO), 60% poly(ethylene glycol) 400 (PEG400), and 20% water. IV formulation was administered to two dogs via the saphenous or cephalic vein, and oral dosing was administered to two dogs via oral gavage. Blood was collected by the cephalic or jugular vein, typically at predose, 2, 8, 15, 30 min, 1, 2, 4, 6, 8, and 24 h postdose for IV, and at predose, 15, 30 min, 1, 2, 4, 6, 8, and 24 h for oral dosing. Samples were collected in K2EDTA tubes, stored on ice, and centrifuged. Plasma was transferred to a micro titer plate and stored at −70 °C until analysis. Plasma samples were extracted using protein precipitation and analyzed by liquid chromatography separation followed by mass spec detection (LCMS/MS), using a standard curve for each compound. Plasma pharmacokinetic parameters were calculated for IV and oral dosing data by noncompartmental methods. Oral bioavailability was determined as the ratio of the dose-normalized plasma area under the curve (AUC) following oral dosing vs IV dosing.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-((<i>S</i>)-1-(5-(2-Hydroxyquinolin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>3</b>)</h3><div class="NLM_p last">To a 4 mL vial with pressure release cap was added <i>N</i>-((<i>S</i>)-1-(5-(2-methoxyquinolin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (150 mg, 0.282 mmol), HCl (23.17 μL, 0.282 mmol), water (1411 μL), and THF (1411 μL). The reaction mixture was stirred at 25 °C for 16 h. The product was purified by C18 chromatography (30 g, CH<sub>3</sub>CN in water with 0.1% TFA: 0–90%) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-hydroxyquinolin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide, 2TFA (<b>3</b>, the second peak, 13.1 mg, 6.23%), LCMS (ESI) calcd for C<sub>30</sub>H<sub>39</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 518.3, found: 518.4, <i>R<sub>t</sub></i> = 0.76 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.73, 8.57 (s and s, 1H), 8.14–8.11 (m, 1H), 7.80–7.76 (m, 1H), 7.69–7.53 (m, 1H), 7.50–7.37 (m, 1H), 7.33–7.32 (m, 1H), 5.15–5.13 (m, 1H), 3.62–3.38 (m, 2H), 3.38–3.19 (m, 2H), 3.80 (m, 1H), 2.57–2.31 (m, 4H), 2.31–2.20 (m, 1H), 2.20–1.74 (m, 6H), 1.70–1.47 (m, 3H), 1.39–1.18 (m, 6H), 1.09–0.99 (m, 4H).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(1-methyl-4-oxo-1,4-dihydroquinolin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>4</b>)</h3><div class="NLM_p last">1-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2(1<i>H</i>)-one was prepared from 3-bromo-1-methylquinolin-2(1<i>H</i>)-one based on the same method as <b>64</b>. Compound <b>4</b> was prepared based on the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 532.3, found: 532.44, <i>R<sub>t</sub></i> = 0.88 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.49 (brs, 1H), 7.82 (brs, 1H), 7.72–7.71 (m, 1H), 7.60–7.57 (m, 3H), 7.33–7.31 (m, 1H), 6.97 (s, 1H), 5.19–5.03 (m, 1H), 3.81 (s, 3H), 2.46–2.25 (m, 6H), 2.15–1.84 (m, 3H), 1.66–1.31 (m, 11H), 1.28–0.96 (m, 6H), 0.83–0.78 (m, 3H).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(1-methyl-4-oxo-1,4-dihydroquinolin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>5</b>)</h3><div class="NLM_p last">Br<sub>2</sub> (1.5 mL, 30.3 mmol) was added to a mixture of quinolin-4(1<i>H</i>)-one (4 g, 27.6 mmol) in AcOH (50 mL) at 25 °C, and the mixture was stirred at room temperature (rt) for 2 h. The mixture was filtered off. The filter cake was washed with NH<sub>4</sub>OH and dried under vacuum to get 3-bromoquinolin-4(1<i>H</i>)-one as a white solid (5.4 g, 21.69 mmol, 79%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47 (s, 1H), 8.14 (d, <i>J</i> = 7.9 Hz, 1H), 7.68 (t, 1H), 7.61 (d, 1H), 7.38 (t, 1H). NaH (1.446 g, 36.2 mmol) was added to a mixture of 3-bromoquinolin-4(1<i>H</i>)-one (5.4 g, 24.10 mmol) in THF (60 mL) at 0 °C. The mixture was stirred at 0 °C for 10 min, and MeI (2.69 mL, 43.0 mmol) was added. After the mixture was stirred at rt for 1.5 h the mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (50 mL). The solid was filtered, and the filter cake was dried under vacuum to get 3-bromo-1-methylquinolin-4(1<i>H</i>)-one as a white solid (4.1 g, 15.50 mmol, 64%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.26–8.20 (m, 1H), 7.84–7.77 (m, 1H), 7.75–7.69 (m, 1H), 7.52–7.45 (m, 1H), 3.88 (s, 1H). (1-Methyl-4-oxo-1,4-dihydroquinolin-3-yl)boronic acid was prepared based on the same method as <b>64</b>. Compound <b>5</b> was prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 532.3, found: 532.3, <i>R<sub>t</sub></i> = 2.077 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.77–8.67 (m, 1H), 8.49–8.39 (m, 1H), 7.93–7.76 (m, 3H), 7.62–7.53 (m, 1H), 5.22–5.07 (m, 1H), 4.05 (s, 3H), 3.58–3.39 (m, 2H), 3.25–2.99 (m, 2H), 2.86 (s, 3H), 2.68–2.56 (m, 1H), 2.47 (s, 4H), 2.37–2.15 (m, 1H), 2.13–1.75 (m, 5H), 1.67–1.45 (m, 3H), 1.44–1.14 (m, 5H), 1.13–0.92 (m, 3H).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(quinolin-3-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>6</b>)</h3><div class="NLM_p last">Prepared by the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>30</sub>H<sub>39</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 502.3, found: 502.4, <i>R<sub>t</sub></i> = 0.77 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.27–9.24 (m, 1H), 8.75 (s, 1H), 8.07–7.97 (m, 2H), 7.91 (s, 1H), 7.81 (s, 1H), 7,68–7.51 (m, 1H), 5.09–5.05 (m, 1H), 3.50–3.42 (m, 2H), 3.34–3.02 (m, 2H), 2.65–2.47 (m, 4H), 2.25–2.19 (m, 1H), 2.02–1.81 (m, 5H), 1.54–1.39 (m, 11H), 0.98–0.71 (m, 4H).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(quinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>7</b>)</h3><div class="NLM_p last">Prepared by the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>30</sub>H<sub>39</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 502.3, found: 502.5, <i>R<sub>t</sub></i> = 0.67 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.79–8.78 (m, 1H), 8.37–8.35 (m, 1H), 8.26 (brs, 1H), 8.18 (brs, 1H), 8.03–8.01 (m, 1H), 7.55–7.52 (m, 3H), 6.99 (s, 1H), 5.03 (m, 1H), 2,68–2.59 (m, 3H), 2.48–2.36 (m, 4H), 2.22 (s, 3H), 1.98–1.87 (m, 3H), 1.70–1.29 (m, 10H), 1.13–0.82 (m, 6H).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(isoquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>8</b>)</h3><div class="NLM_p last">Prepared by the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 516.3, found: 516.3, <i>R<sub>t</sub></i> = 0.68 min. <sup>1</sup>H NMR 1H (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.73 (brs, 1H), 8.70–8.67 (m, 1H), 8.61 (brs, 1H), 8.57–8.55 (m, 1H), 8.42–8.38 (m, 3H), 8.24–8.23 (m, 2H), 5.15–5.11 (m, 1H), 3.57–3.54 (m, 2H), 3.19–2.98 (m, 4H), 2.48–2.44 (m, 4H), 2.44–2.42 (m, 1H), 2.08–2.07 (m, 2H), 1.95–1.86 (m, 2H), 1.59–1.52 (m, 4H), 1.38–1.20 (m, 9H), 1.03–0.97 (m, 3H).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(isoquinolin-7-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>9</b>)</h3><div class="NLM_p last">Prepared by the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 516.3, found: 516.4, <i>R<sub>t</sub></i> = 0.75 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.12 (brs, 1H), 8.87–8.81 (m, 1H), 8.54–8.51 (m, 1H), 8.31–8.28 (m, 1H), 8.20–8.12 (m, 2H), 7.89–7.87 (m, 1H), 5.12–5.10 (m, 1H), 3.58–3.55 (m, 2H), 3.19–2.90 (m, 3H), 2.48–2.42 (m, 4H), 2.30–2.10 (m, 1H), 1.96–1.82 (m, 4H), 1.60–1.53 (m, 4H), 1.38–1.33 (m, 7H), 1.23–1.18 (m, 3H), 1.08–0.97 (m, 3H).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(quinoxalin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>10</b>)</h3><div class="NLM_p last">6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline was prepared from 6-bromoquinoxaline based on the same method as <b>64</b>. <b>10</b> was prepared based on the same method as <b>31</b>. White solid. LCMS (ESI) calcd for C<sub>29</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 503.3, found: 503.3, <i>R<sub>t</sub></i> = 0.865 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.78 (d, <i>J</i> = 17.2 Hz, 2H), 7.98–8.19 (m, 2H), 7.40 (s, 1H), 6.75 (d, <i>J</i> = 7.5 Hz, 1H), 4.98 (d, <i>J</i> = 7.1 Hz, 1H), 2.24–2.48 (m, 8H), 2.17 (brs, 3H), 1.93–2.11 (m, 2H), 1.52–1.80 (m, 4H), 1.37 (dd, <i>J</i> = 7.1, 18.3 Hz, 7H), 1.19 (brs, 1H), 1.03 (t, <i>J</i> = 7.3 Hz, 3H), 0.83 (dd, <i>J</i> = 4.3, 7.2 Hz, 1H).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(Cinnolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>11</b>)</h3><div class="NLM_p">See Scheme S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. <i>t</i>-BuOK (0.510 g, 4.55 mmol) was added to a solution of (bromomethyl)triphenylphosphonium bromide (1.98 g, 4.55 mmol) in THF (30 mL) at −78 °C. The mixture was stirred at −78 °C for 1 h and 2,5-dibromobenzaldehyde (1 g, 3.79 mmol) was added. The reaction was gradually warmed up to rt and stirred at rt for another 12 h. Aqueous NH<sub>4</sub>Cl (saturated, 10 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–50%) to give (<i>Z</i>)-1,4-dibromo-2-(2-bromovinyl)benzene (0.9 g, 49%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.90 (d, <i>J</i> = 1.8 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 7.34–7.28 (m, 1H), 7.12 (s, 1H), 6.64 (d, <i>J</i> = 8.2 Hz, 1H).</div><div class="NLM_p">Step 2. Diethyl hydrazine-1,2-dicarboxylate (0.517 g, 2.93 mmol) was added to a mixture of copper(I) iodide (0.0280 g, 0.147 mmol), K<sub>2</sub>CO<sub>3</sub> (0.507 g, 3.67 mmol), <i>N</i>1,<i>N</i>2-dimethylethane-1,2-diamine (0.0260 g, 0.293 mmol), and (<i>Z</i>)-1,4-dibromo-2-(2-bromovinyl)benzene (0.500 g, 1.47 mmol) in 1,4-dioxane (5 mL) and water (1 mL). The mixture was degassed under vacuum and refilled with N<sub>2</sub> three times. After the mixture was stirred at 90 °C for 10 h, it was cooled down and filtered. The filter cake was washed with EtOAc (50 mL). The filtrate was concentrated to dryness. The crude product was purified by silica gel column chromatography eluting with EtOAc in petroleum ether (0–20%) to give diethyl 6-bromocinnoline-1,2-dicarboxylate (150 mg, 23%) as a yellow solid. LCMS (ESI) calcd for C<sub>14</sub>H<sub>15</sub>BrN<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 355.0, 357.0, found: 354.9, 356.9, <i>R<sub>t</sub></i> = 1.192 min.</div><div class="NLM_p">Step 3. Diethyl 6-bromocinnoline-1,2-dicarboxylate (150 mg, 0.422 mmol) was added to a mixture of Pd(dppf)Cl<sub>2</sub> (30.9 mg, 0.0420 mmol), potassium acetate (104 mg, 1.06 mmol), and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (139 mg, 0.549 mmol) in 1,4-dioxane (5 mL) and water (1 mL). The mixture was degassed under vacuum and refilled with N<sub>2</sub> three times. The mixture was stirred to 90 °C for 10 h and was cooled down. It was filtered, and the filter cake was washed with EtOAc (50 mL). The filtrate was concentrated to dryness. The crude product was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–50%) to give diethyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cinnoline-1,2-dicarboxylate (130 mg, 61%) as a yellow solid. LCMS (ESI) calcd for C<sub>20</sub>H<sub>27</sub>BN<sub>2</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 403.2, found: 403.2, <i>R<sub>t</sub></i> = 1.255 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74–7.66 (m, 1H), 7.59–7.52 (m, 1H), 7.47–7.37 (m, 1H), 7.29 7.20 (m, 1H), 6.22–6.01 (m, 1H), 4.39–4.06 (m, 4H), 1.32 (s, 12H), 1.26–1.21 (m, 9H).</div><div class="NLM_p">Step 4. A mixture of diethyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cinnoline-1,2-dicarboxylate (130 mg, 0.323 mmol), (<i>R</i>)-<i>N</i>-((<i>S</i>)-1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-2-methylpropane-2-sulfinamide (225 mg, 0.388 mmol), K<sub>3</sub>PO<sub>4</sub> (206 mg, 0.970 mmol), and Pd(DTBPF)Cl<sub>2</sub> (21.0 mg, 0.0320 mmol) in THF (10 mL) and water (1 mL) was degassed under vacuum and refilled with N<sub>2</sub> three times. The mixture was stirred at 80 °C for 12 h and was concentrated to dryness. The crude product was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–100%) to give diethyl 6-(2-((<i>S</i>)-1-((<i>R</i>)-1,1-dimethylethylsulfinamido)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)cinnoline-1,2-dicarboxylate (120 mg, 46%) as a yellow solid. LCMS (ESI) calcd for C<sub>38</sub>H<sub>61</sub>N<sub>5</sub>O<sub>8</sub>SSi [M + H]<sup>+</sup>: 776.4, found: 776.3, <i>R<sub>t</sub></i> = 1.267 min.</div><div class="NLM_p">Step 5. A mixture of diethyl 6-(2-((<i>S</i>)-1-((<i>R</i>)-1,1-dimethylethylsulfinamido)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)cinnoline-1,2-dicarboxylate (120 mg, 0.155 mmol) and NaOH (0.2 mL, 1.000 mmol) in EtOH (2 mL) was heated to 70 °C for 12 h in air. The mixture was cooled down, diluted with DCM (20 mL), washed with water (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure to give the (<i>R</i>)-<i>N</i>-((<i>S</i>)-1-(5-(cinnolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-2-methylpropane-2-sulfinamide (100 mg) as a brown oil. It was used in the next step without further purification. LCMS (ESI) calcd for C<sub>32</sub>H<sub>51</sub>N<sub>5</sub>O<sub>4</sub>SSi [M + H]<sup>+</sup>: 630.3, found: 630.3, <i>R<sub>t</sub></i> = 1.209 min.</div><div class="NLM_p">Step 6. TFA (2 mL, 26.0 mmol) was added to a stirred mixture of (<i>R</i>)-<i>N</i>-((<i>S</i>)-1-(5-(cinnolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-2-methylpropane-2-sulfinamide (100 mg, 0.159 mmol) in DCM (2 mL) at 16 °C, and the mixture was stirred at 16 °C for 1 h. The solvent was evaporated under reduced pressure to give (<i>S</i>)-9-amino-9-(5-(cinnolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (100 mg) as a brown oil. It was used in the next step without further purification. LCMS (ESI) calcd for C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>O [M + H]<sup>+</sup>: 352.2, found: 352.1, <i>R<sub>t</sub></i> = 0.778 min.</div><div class="NLM_p last">Step 7. (<i>S</i>)-9-amino-9-(5-(cinnolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (100 mg, 0.285 mmol) was added to a mixture of HATU (130 mg, 0.341 mmol), (<i>S</i>)-6-methyl-6-azaspiro[2.5]octane-1-carboxylic acid (53 mg, 0.313 mmol), and DIEA (0.1 mL, 0.573 mmol) in DCM (3 mL), and the mixture was stirred at 16 °C for 2 h. The residue was purified by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.1% TFA), then by chiral SFC eluting with 35% EtOH with 0.05% DEA in CO<sub>2</sub> on Chiralcel AS column to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(cinnolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>11</b>, 10 mg, 6.7%) as a yellow solid. LCMS (ESI) calcd for C<sub>29</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 503.3, found: 503.3, <i>R<sub>t</sub></i> = 0.788 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.28–9.14 (m, 1H), 8.44–8.23 (m, 3H), 8.20–8.08 (m, 1H), 7.77–7.66 (m, 1H), 5.06–4.95 (m, 1H), 3.13–2.98 (m, 2H), 2.71–2.64 (m, 1H), 2.61–2.49 (m, 2H), 2.49–2.38 (m, 4H), 2.01–1.92 (m, 2H), 1.81–1.71 (m, 3H), 1.62–1.49 (m, 3H), 1.38–1.24 (m, 8H), 1.20–1.12 (m, 1H), 1.01–0.93 (m, 3H).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(1,8-Naphthyridin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>12</b>)</h3><div class="NLM_p last">3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,8-naphthyridine was prepared from 3-bromo-1,8-naphthyridine based on the same method as <b>64</b>. <b>12</b> was prepared based on the same method as <b>31</b>. Yellow solid. LCMS (ESI) calcd for C<sub>29</sub>H<sub>38</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 503.3, found: 503.3, <i>R<sub>t</sub></i> = 1.958 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.67–9.89 (m, 1H), 9.36–9.49 (m, 2H), 9.23–9.35 (m, 1H), 8.19–8.39 (m, 2H), 5.03–5.17 (m, 1H), 3.38–3.71 (m, 2H), 3.02–3.17 (m, 1H), 2.89–3.00 (m, 2H), 2.82–2.88 (m, 1H), 2.39–2.53 (m, 4H), 2.02–2.32 (m, 3H), 1.74–2.00 (m, 3H), 1.51–1.64 (m, 3H), 1.24–1.48 (m, 5H), 1.12–1.21 (m, 1H), 1.04–1.10 (m, 1H), 0.95–1.03 (m, 3H).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(Benzo[<i>d</i>]thiazol-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>13</b>)</h3><div class="NLM_p last">6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>d</i>]thiazole was prepared from 6-bromobenzo[<i>d</i>]thiazole based on the same method as <b>64</b>. <b>13</b> was prepared based on the same method as <b>31</b>. LC/MS: calcd for C<sub>28</sub>H<sub>37</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>: 508.3, found: 508.2 [M + H<sup>+</sup>], <i>R<sub>t</sub></i> = 0.802 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.45–9.54 (m, 1H), 8.51–8.73 (m, 1H), 8.16–8.25 (m, 1H), 7.91–8.09 (m, 2H), 5.02–5.11 (m, 1H), 3.58–3.72 (m, 1H), 3.39–3.55 (m, 1H), 2.98–3.25 (m, 1H), 2.74–2.96 (m, 4H), 2.46–2.47 (m, 4H), 1.76–2.30 (m, 5H), 1.47–1.68 (m, 3H), 1.24–1.45 (m, 5H), 1.11–1.23 (m, 1H), 1.10–0.98 (m, 4H).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(Benzo[<i>d</i>]oxazol-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>14</b>)</h3><div class="NLM_p last">6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[<i>d</i>]oxazole was prepared from 6-bromobenzo[<i>d</i>]oxazole based on the same method as <b>64</b>. White solid. LC/MS: MS (ESI) <i>m</i>/<i>z</i>: 246.1 [M + H<sup>+</sup>], <i>R<sub>t</sub></i> = 1.122 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (s, 1H), 8.04 (s, 1H), 7.74–7.86 (m, 2H), 1.37 (s, 12H). <b>14</b> was prepared based on the same method as <b>31</b>. Yellow oil. LC/MS: calcd for C<sub>28</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 492.3, found: 492.3, <i>R<sub>t</sub></i> = 0.792 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.45 (s, 1H), 7.97–8.07 (m, 1H), 7.66–7.83 (m, 2H), 7.39–7.47 (m, 1H), 4.97–5.03 (m, 1H), 2.28–2.72 (m, 9H), 2.22 (brs, 4H), 1.87–2.02 (m, 3H), 1.23–1.73 (m, 7H), 1.08–1.13 (m, 1H), 0.98–0.96 (m, 4H), 0.79–0.87 (m, 1H).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(2-methyl-2<i>H</i>-indazol-5-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>15</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>29</sub>H<sub>40</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 505.3, found: 505.1, <i>R<sub>t</sub></i> = 2.25 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.18 (s, 1H), 7.98 (s, 1H), 7.66–7.60 (m, 2H), 7.30 (s, 1H), 5.03–5.00 (m, 1H), 4.20 (s, 3H), 2.65 (brs, 2H), 2.46–2.40 (m, 6H), 2.43 (s, 3H), 1.98–1.91 (m, 3H), 1.72–1.62 (m, 6H), 1.43–1.29 (m, 4H), 1.14–1.12 (m, 1H), 0.99–0.97 (m, 3H), 0.87–0.84 (m, 1H).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>16</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 532.3, found: 532.3, <i>R<sub>t</sub></i> = 2.724 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.18 (brs, 1H), 7.95 (brs, 1H), 7.75 (brs, 1H), 7.47 (brs, 2H), 6.78–6.75 (m, 1H), 5.18 (brs, 1H), 3.73 (s, 3H), 3.66–3.33 (m, 2H), 3.07–2.63 (m, 4H), 2.44–2.40 (m, 6H), 2.10–2.00 (m, 4H), 1.35–1.22 (m, 7H), 1.05–0.93 (m, 6H).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(2-methyl-1-oxo-1,2-dihydroisoquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>17</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 532.3, found: 532.4, <i>R<sub>t</sub></i> = 0.922 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.41–8.39 (m, 1H), 8.11–8.01 (m, 2H), 7.90–7.84 (m, 1H),7.47–7.45 (m, 1H), 6.74–6.69 (m, 1H), 5.11–5.10 (m, 1H), 3.64 (s, 3H), 3.51–3.49 (m, 2H), 3.32-3-31 (m, 1H), 3.20–3.00 (m, 1H), 2.48–2.44 (m, 4H), 2.30–2.04 (m, 4H), 1.94–1.82 (m, 3H), 1.60–1.56 (m, 3H), 1.38–1.22 (m, 6H), 1.01–0.98 (m, 4H).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(2-oxo-6-phenyl-1,2-dihydropyridin-3-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>18</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>33</sub>H<sub>43</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 558.3, found: 558.5, <i>R<sub>t</sub></i> = 0.85 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.22–8.15 (m, 1H), 8.04–8.02 (m, 1H), 7.73 (brs, 2H), 7.55–7.54 (m, 3H), 6.80–6.78 (m, 1H), 5.13–5.11 (m, 1H), 3.56–3.38 (m, 3H), 3.30–3.03 (m, 4H), 2.48–2.42 (m, 4H), 2.36–1.81 (m, 5H), 1.59–1.21 (m, 11H), 1.07–0.96 (m, 4H).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(4-(pyridin-4-yl)phenyl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>19</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>32</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 528.3, found: 528.5, <i>R<sub>t</sub></i> = 0.66 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.57–8.56 (m, 2H), 7.85 (brs, 2H), 7.79–7.74 (m, 2H),7.73–7.72 (m, 2H), 7.43 (s, 1H), 5.04–5.01 (m, 1H), 2.47–2.42 (m, 6H), 2.30 (brs, 1H), 2.25 (s, 3H), 1.98–1.93 (m, 3H), 1.67–1.60 (m, 6H), 1.42–1.33 (m, 5H), 1.12–1.10 (m, 1H), 1.00-098 (m, 3H), 0.83–0.81 (m, 1H).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(4-(pyridin-3-yl)phenyl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>20</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>32</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 528.3, found: 528.5, <i>R<sub>t</sub></i> = 0.66 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (s, 1H), 8.51–8.50 (m, 1H), 8.13–8.10 (m, 1H), 7.85–7.83 (m, 2H), 7.70–7.68 (m, 2H), 7.53–7.50 (m, 1H), 7.41 (s, 1H), 5.04–5.01 (m, 1H), 2.46–2.42 (m, 7H), 2.22 (s, 3H), 1.98–1.92 (m, 3H), 1.68–1.58 (m, 6H), 1.36–1.34 (m, 5H), 1.13–1.11 (m, 1H), 1.01–0.98 (m, 3H), 0.84–0.83 (m, 1H).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(4-(pyrazin-2-yl)phenyl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>21</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>40</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 529.3, found: 529.5, <i>R<sub>t</sub></i> = 0.83 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.84–8.81 (m, 2H), 8.41–8.39 (m, 2H), 7.83–7.78 (m, 2H), 7.45 (s, 1H), 7.33–7.31 (m, 1H), 5.02–4.99 (m, 1H), 2.85 (brs, 2H), 2.65–2.64 (m, 1H), 2.45–2.41 (m, 8H), 1.98–1.81 (m, 3H), 1.75–1.71 (m, 4H), 1.69–1.67 (m, 2H), 1.44–1.35 (m, 4H), 1.15–1.13 (m, 1H), 0.99–0.97 (m, 3H), 0.89–0.87 (m, 1H).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>22</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. HRMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 516.3260, found 516.3338. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.22–8.18 (m, 2H), 8.10–8.08 (m, 1H), 7.94–7.92 (m, 1H), 7.51 (s, 1H), 7.42–7.40 (m, 1H), 5.04–5.02 (m, 1H), 2.71 (s, 3H), 2.61 (brs, 2H), 2.46–2.41 (m, 5H), 2.23 (s, 3H), 2.02–1.92 (m, 2H), 1.70–1.55 (m, 6H), 1.38–1.33 (m, 6H), 1.14–1.12 (m, 1H), 1.00–0.97 (m, 3H), 0.86–0.84 (m, 1H).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-Ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>23</b>)</h3><div class="NLM_p">See Scheme S2 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. <i>n</i>-BuLi (6.6 mL, 16.50 mmol) was added to a mixture of 6-bromo-2-chloroquinoline (2.0 g, 8.25 mmol) and triisopropyl borate (4 mL, 17.23 mmol) in THF (20 mL) at −78 °C, and the mixture was stirred at rt for 12 h. Hydrochloric acid (1 M, 8.0 mL, 8.0 mmol) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The combined organic fractions were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was recrystallized from petroleum ether (15 mL). The solid was collected and dried <i>in vacuo</i> to give (2-chloroquinolin-6-yl)boronic acid (1.7 g, 94%) as a light-gray solid. LCMS (ESI) calcd for C<sub>9</sub>H<sub>7</sub>BClNO<sub>2</sub> [M + H]<sup>+</sup>: 208.0, found: 208.0, <i>R<sub>t</sub></i> = 0.998 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42–8.50 (m, 1H), 8.37 (s, 2H), 8.16 (d, <i>J</i> = 8.2 Hz, 1H), 7.90 (d, <i>J</i> = 8.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.6 Hz, 1H).</div><div class="NLM_p">Step 2. PdCl<sub>2</sub>(DTBPF) (5.0 mg, 7.7 μmol) and potassium phosphate (197 mg, 0.928 mmol) were added to a mixture of (<i>S</i>)-<i>tert</i>-butyl (1-(5-(2-chloroquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamate (150 mg, 0.309 mmol) and potassium trifluoro(vinyl)borate (83 mg, 0.619 mmol) in THF (2 mL) and water (0.2 mL). The mixture was stirred at 85 °C for 8 h, cooled down, diluted with EtOAc (8 mL), washed with brine (3 × 10 mL), dried over Na<sub><sub>2</sub></sub>SO<sub><sub>4</sub></sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–100%) to give (<i>S</i>)-<i>tert</i>-butyl (7-oxo-1-(5-(2-vinylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)carbamate (100 mg, 68%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.05 (brs, 1H), 8.22 (brs, 1H), 8.12 (brs, 1H), 8.04 (brs, 2H), 7.59 (d, <i>J</i> = 8.6 Hz, 1H), 7.33–7.38 (m, 1H), 7.03 (dd, <i>J</i> = 11.0, 17.6 Hz, 1H), 6.27 (d, <i>J</i> = 17.6 Hz, 1H), 5.65 (d, <i>J</i> = 11.0 Hz, 1H), 5.16 (brs, 1H), 4.68 (brs, 1H), 2.37–2.47 (m, 4H), 2.21 (brs, 1H), 1.98 (brs, 1H), 1.60 (brs, 4H), 1.47 (s, 9H), 1.35–1.42 (m, 2H), 1.05 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p">Step 3. [1,1-Bis(di-<i>tert</i>-butylphosphino)ferrocene]palladium(II) dichloride (5.0 mg, 7.7 μmol) and potassium phosphate (197 mg, 0.928 mmol) was added to a stirred mixture of (<i>S</i>)-<i>tert</i>-butyl (1-(5-(2-chloroquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamate (150 mg, 0.309 mmol), and potassium trifluoro(vinyl)borate (83.0 mg, 0.619 mmol) in THF (2 mL) and water (0.2 mL) at rt (20 °C), and the mixture was stirred at 85 °C for 8 h. TLC showed starting material was consumed and a new product was formed. The mixture was cooled down, diluted with EtOAc (8 mL), washed with brine (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–100%) to give (<i>S</i>)-<i>tert</i>-butyl (7-oxo-1-(5-(2-vinylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)carbamate (100 mg, 0.210 mmol, 67.8%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.05 (br. s., 1H), 8.22 (br. s., 1H), 8.12 (br. s., 1H), 8.04 (br. s., 2H), 7.59 (d, <i>J</i> = 8.61 Hz, 1H), 7.33–7.38 (m, 1H), 7.03 (dd, <i>J</i> = 10.96, 17.61 Hz, 1H), 6.27 (d, <i>J</i> = 17.61 Hz, 1H), 5.65 (d, <i>J</i> = 10.96 Hz, 1H), 5.16 (br. s., 1H), 4.68 (br. s., 1H), 2.37–2.47 (m, 4H), 2.21 (br. s., 1H), 1.98 (br. s., 1H), 1.60 (br. s., 4H), 1.47 (s, 9H), 1.35–1.42 (m, 2H), 1.05 (t, <i>J</i> = 7.24 Hz, 3H).</div><div class="NLM_p">Step 4. 10% Pd–C (10 mg, 0.094 mmol) was added to a stirred mixture of (<i>S</i>)-<i>tert</i>-butyl (7-oxo-1-(5-(2-vinylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)carbamate (150 mg, 0.315 mmol) in EtOH (1 mL) at rt, and the mixture was stirred at rt for 2 h under H<sub>2</sub> balloon. The mixture was filtered, and the filter cake was washed with MeOH (3 × 10 mL). The filtrate was concentrated to dryness. The residue was purified by silica gel column flash chromatography, eluting with EtOAc in petroleum ether (0–100%) to give (<i>S</i>)-<i>tert</i>-butyl (1-(5-(2-ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamate (100 mg, 66%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.03 (brs, 1H), 8.21 (brs, 1H), 8.09 (d, <i>J</i> = 7.7 Hz, 1H), 8.02 (brs, 2H), 7.34 (s, 1H), 7.30 (d, <i>J</i> = 8.4 Hz, 1H), 5.15 (brs, 1H), 4.68 (brs, 1H), 3.00 (q, <i>J</i> = 7.8 Hz, 2H), 2.39–2.44 (m, 4H), 2.21 (brs, 1H), 1.98 (brs, 1H), 1.57–1.61 (m, 3H), 1.47 (s, 9H), 1.41 (t, <i>J</i> = 7.6 Hz, 5H), 1.05 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p">Step 5. TFA (0.5 mL, 6.49 mmol) was added to a stirred mixture of (<i>S</i>)-<i>tert</i>-butyl (1-(5-(2-ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamate (40 mg, 0.084 mmol) in DCM (2.5 mL) at 20 °C, and the mixture was stirred at rt for 1 h. The mixture was concentrated to give (<i>S</i>)-9-amino-9-(5-(2-ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (32 mg of crude) as a yellow oil. LCMS (ESI) calcd for C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 379.2, found: 0.759, <i>R<sub>t</sub></i> = 379.2 min.</div><div class="NLM_p last">Step 6. (<i>S</i>)-9-amino-9-(5-(2-ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (79 mg, 0.209 mmol) was added to a stirred mixture of Et<sub>3</sub>N (0.090 mL, 0.646 mmol), HATU (79 mg, 0.209 mmol), (<i>S</i>)-6-methyl-6-azaspiro[2.5]octane-1-carboxylic acid (53 mg, 0.313 mmol) in DMF (1 mL) at rt, and the mixture was stirred at rt for 1 h. The residue was purified by preparative HPLC (reversed-phase C-18 column), eluting with acetonitrile in water (10–90% with 0.05% NH<sub>3</sub>·H<sub>2</sub>O) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-ethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>23</b>, 60 mg, 52%) as a white solid. LCMS (ESI) calcd for C<sub>32</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 530.3, found: 530.3, <i>R<sub>t</sub></i> = 1.443 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–8.24 (m, 4H), 7.27–7.36 (m, 2H), 6.60 (brs, 1H), 4.89–5.01 (m, 1H), 3.00 (q, <i>J</i> = 7.8 Hz, 2H), 2.25–2.59 (m, 7H), 2.15–2.22 (m, 3H), 2.03 (d, <i>J</i> = 7.8 Hz, 4H), 1.63–1.85 (m, 3H), 1.53–1.62 (m, 2H), 1.28–1.52 (m, 8H), 1.21 (d, <i>J</i> = 4.7 Hz, 1H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H), 0.84 (dd, <i>J</i> = 4.3, 7.4 Hz, 1H).</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-Cyclopropylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>24</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>33</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 542.3, found: 542.2, <i>R<sub>t</sub></i> = 1.651 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.86–8.80 (m, 1H), 8.69–8.58 (m, 1H), 8.45–8.42 (m, 1H), 8.39–8.37 (m, 1H), 8.25–8.23 (m, 1H), 8.10–8.08 (m, 1H), 5.10–5.08 (m, 1H), 3.50–3.23 (m, 3H), 3.23–3.06 (m, 2H), 2.88–2.85 (m, 1H), 2.48–2.43 (m, 5H), 2.25–2.11 (m, 3H), 1.92–1.87 (m, 3H), 1.59–1.57 (m, 5H), 1.39–1.20 (m, 4H), 1.20–1.10 (m, 4H), 0.99–0.97 (m, 4H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-Methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>25</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 532.3, found: 532.5, <i>R<sub>t</sub></i> = 0.89 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.11–8.09 (m, 2H), 7.99–7.97 (m, 1H), 7.82–7.80 (m, 1H), 7.42 (s, 1H), 6.95–6.93 (m, 1H), 5.04–5.01 (m, 1H), 4.05 (s, 3H),2.61 (brs, 2H), 2.46–2.42 (m, 5H), 2.24 (s, 3H), 1.98–1.91 (m, 2H), 1.71–1.54 (m, 6H), 1.44–1.29 (m, 6H), 1.14–1.12 (m, 1H), 1.00–0.97 (m, 3H), 0.86–0.84 (m, 1H).</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(2-(pyrrolidin-1-yl)quinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>26</b>)</h3><div class="NLM_p">See Scheme S3 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. A solution of 6-bromo-2-chloroquinoline (1.00 g, 4.12 mmol) and pyrrolidine (0.88 g, 12.4 mmol) in DMF (10 mL) was stirred at 100 °C for 3 h. The reaction mixture was evaporated <i>in vacuo</i>, diluted with water (100 mL), and extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (80 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica column chromatography eluting with EtOAc in petroleum ether (6.6%) to afford 6-bromo-2-(pyrrolidin-1-yl)quinoline (1.09 g, 96%) as a light-yellow solid. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 279.0, <i>R<sub>t</sub></i> = 0.877 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74 (d, <i>J</i> = 9.0 Hz, 1H), 7.71 (s, 1H), 7.56 (s, 2H), 6.73 (d, <i>J</i> = 9.4 Hz, 1H), 3.61 (brs, 4H), 2.05 (t, <i>J</i> = 6.5 Hz, 4H).</div><div class="NLM_p">Step 2. A mixture of 6-bromo-2-(pyrrolidin-1-yl)quinoline (1.06 g, 3.82 mmol), bis(pinacolato)diboron (1.94 g, 7.63 mmol), potassium acetate (0.75 g, 7.63 mmol), and Pd(dppf)Cl<sub>2</sub> (0.28 g, 0.38 mmol) in 1,4-dioxane (30 mL) was stirred at 70 °C under N<sub>2</sub> for 8 h. The reaction mixture was cooled down and filtered through celite. The filtrate was diluted with water (150 mL) and extracted with EtOAc (3 × 80 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4,</sub> filtered, and concentrated. The residue was purified by silica column chromatography eluting with EtOAc in petroleum ether (20%) to afford 2-(pyrrolidin-1-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (0.56 g, 46%) as a light-yellow solid. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 325.2, <i>R<sub>t</sub></i> = 1.020 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <i>δ</i> 8.06 (s, 1H), 7.85 (dd, <i>J</i> = 16.0, 8.6 Hz, 2H), 7.64 (d, <i>J</i> = 7.0 Hz, 1H), 6.68 (d, <i>J</i> = 9.0 Hz, 1H), 3.61 (brs, 4H), 2.02 (t, <i>J</i> = 6.3 Hz, 4H), 1.35 (s, 12H).</div><div class="NLM_p">Step 3. A mixture of 2-(pyrrolidin-1-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) quinoline (0.18 g, 0.56 mmol), (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (0.27 g, 0.46 mmol), potassium phosphate monohydrate (0.27 g, 1.16 mmol), and Pd(dppf)Cl<sub>2</sub> (0.03 g, 0.05 mmol) in THF/H<sub>2</sub>O (6.4 mL/1.6 mL) was stirred at 70 °C under N<sub>2</sub> atmosphere for 12 h. The reaction mixture was cooled and filtered through celite. The resulting filtrate was diluted with water (120 mL) and extracted with EtOAc (60 mL × 2). The organic layers were combined, washed with brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by prep-TLC (SiO<sub>2</sub>, DCM/MeOH = 6:1) to afford (<i>S</i>)-6-methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(2-(pyrrolidin-1-yl)quinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (0.32 g, 40%) as a light-yellow solid. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 701.5, <i>R<sub>t</sub></i> = 1.060 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) <i>δ</i> 7.93 (s, 1H), 7.86 (m, 2H), 7.66–7.76 (m, 1H), 7.18 (s, 1H), 6.91 (brs, 1H), 6.73 (d, <i>J</i> = 9.3 Hz, 1H), 5.70 (d, <i>J</i> = 11.0 Hz, 1H), 5.00–5.21 (m, 2H), 3.64 (d, <i>J</i> = 4.8 Hz, 4H), 3.49–3.60 (m, 2H), 2.73 (brs, 1H), 2.53 (brs, 1H), 2.33–2.45 (m, 4H), 1.91–2.25 (m, 11H), 1.52–1.67 (m, 3H), 1.39–1.49 (m, 2H), 1.33 (brs, 3H), 1.18–1.28 (m, 3H), 1.03 (t, <i>J</i> = 7.3 Hz, 3H), 0.80–0.99 (m, 4H), 0.01 (s, 9H).</div><div class="NLM_p last">Step 4. A solution of (<i>S</i>)-6-methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(2-(pyrrolidin-1-yl)quinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (129 mg, 0.184 mmol) in TFA (5 mL) was stirred at 20 °C for 2 h. The reaction mixture was concentrated and purified by C18 prep-HPLC eluting with acetonitrile in water (7–37%, with 0.1% TFA). The collected product was concentrated, and 1 M HCl (0.8 mL) was added into the residue, which was lyophilized to afford (<i>S</i>)-6-methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(2-(pyrrolidin-1-yl)quinolin-6-yl)-1<i>H</i>-imidazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide hydrochloride (<b>26</b>, 72 mg, 64%) as light-yellow powder. LCMS (ESI) calcd for C<sub>34</sub>H<sub>46</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 571.4, found: 571.3, <i>R<sub>t</sub></i> = 0.847 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.45–8.43 (m, 1 H), 8.40–8.37 (m, 1 H), 8.30–8.20 (m, 1H), 8.08–8.04 (m, 1 H), 7.96 (d, <i>J</i> = 7.6 Hz, 1 H), 7.32 (d, <i>J</i> = 10.0 Hz, 1H), 5.07–5.02 (m, 1 H), 3.85–3.82 (m, 4H), 3.54–3.52 (m, 1 H), 3.51–3.48 (m, 2H), 3.34–2.95 (m, 2H), 2.85 (s, 3 H), 2.55–2.48 (m, 4H), 2.60–2.00 (m, 7H), 1.95–1.55 (m, 3H), 1.53–1.49 (m, 3H), 1.48–1.44 (m, 4H), 1.40–1.35 (m, 1H), 1.15–0.88 (m, 3H).</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-1-(5-(2-(oxazol-2-yl)quinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>27</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>33</sub>H<sub>40</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 569.3, found: 569.3, <i>R<sub>t</sub></i> = 2.157 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.53 (dd, <i>J</i> = 8.9, 13.3 Hz, 1H), 8.37–8.47 (m, 1H), 8.26–8.37 (m, 2H), 8.13–8.26 (m, 2H), 8.03 (s, 1H), 7.51 (s, 1H), 5.09 (m, 1H), 3.41–3.59 (m, 2H), 3.24 (d, <i>J</i> = 10.1 Hz, 1H), 3.02–3.13 (m, 1H), 2.83 (d, <i>J</i> = 19.6 Hz, 3H), 2.61 (brs, 1H), 2.43–2.51 (m, 3H), 2.28 (brs, 1H), 2.09 (brs, 2H), 1.79–1.97 (m, 3H), 1.49–1.66 (m, 3H), 1.16–1.43 (m, 5H), 0.78–1.10 (m, 4H).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-(1<i>H</i>-Pyrazol-1-yl)quinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>28</b>)</h3><div class="NLM_p">See Scheme S4 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. A mixture of 6-bromo-2-chloroquinoline (1.00 g, 4.12 mmol), 1<i>H</i>-pyrazole (0.84 g, 12.36 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (2.69 g, 8.24 mmol) in DMF (30 mL) was stirred at 100 °C for 17 h. The reaction mixture was evaporated <i>in vacuo</i>. To the residue was added water (150 mL) and the aqueous layer was extracted with EtOAc (3 × 60 mL). The organic layers were combined, washed with brine (80 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica column chromatography eluting with EtOAc in petroleum ether (6.6%) to afford 6-bromo-2-(1<i>H</i>-pyrazol-1-yl)quinoline (0.95 g, 84%) as a light-pink solid. LCMS (ESI) calcd for C<sub>12</sub>H<sub>8</sub>BrN<sub>3</sub> [M + H]<sup>+</sup>: 274.0, found: 273.9. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.53 (s, 1H), 7.74–7.82 (m, 2H), 7.83–7.91 (m, 1H), 7.98 (d, <i>J</i> = 1.96 Hz, 1H), 8.14–8.28 (m, 2H), 8.77 (d, <i>J</i> = 1.96 Hz, 1H).</div><div class="NLM_p">Step 2. Potassium acetate (1164 mg, 11.86 mmol) was added to the mixture of PdCl<sub>2</sub>(dppf) (400 mg, 0.547 mmol), 6-bromo-2-(1<i>H</i>-pyrazol-1-yl)quinoline (1300 mg, 4.74 mmol) and BPD (2200 mg, 8.66 mmol) in 1,4-dioxane (30 mL). The reaction mixture was stirred at 70 °C under N<sub>2</sub> for 8 h, filtered, and concentrated <i>in vacuo</i>. The residue was purified by silica column eluting with EtOAc in petroleum ether (20%) to afford 2-(1<i>H</i>-pyrazol-1-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (1.6 g, 89%) as a light-yellow solid. LCMS (ESI) calcd for C<sub>18</sub>H<sub>20</sub>BN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 322.2, found: 322.0.</div><div class="NLM_p last">Step 3. Compound <b>28</b> was prepared based on the same method as <b>31</b>. Calcd for C<sub>33</sub>H<sub>41</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 568.3, found: 568.3, <i>R<sub>t</sub></i> = 0.879 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.83 (s, 1H), 8.50–8.52 (m, 2H), 8.17–8.36 (m, 2H), 8.11 (s, 1H), 8.01 (d, <i>J</i> = 10 Hz, 1H), 7.85 (s, 1H), 6.63 (s, 1H), 5.04–5.08 (m, 1H), 3.64–3.66 (m, 1H), 3.45–3.48 (m, 2H), 3.10–3.31 (m, 2H), 2.43–2.50 (m, 4H), 1.92–2.47 (m, 6H), 1.57–1.60 (m, 3H), 1.20–1.40 (m, 5H), 0.99–1.20 (m, 6H).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>29</b>)</h3><div class="NLM_p">See Scheme S5 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. A solution of H<sub>2</sub>SO<sub>4</sub> (5.3 mL, 99 mmol) in water (6 mL) was added to 3-nitrobenzenesulfonic acid (5.1 g, 25.1 mmol) and propane-1,2,3-triol (6.3 mL, 86 mmol) to give a thick gray suspension. The suspension was heated to 110 °C and 4-bromo-3-methoxyaniline (5.0 g, 24.75 mmol) was added. Additional amount of water (6 mL), propane-1,2,3-triol (6 mL), and H<sub>2</sub>SO<sub>4</sub> (6 mL) were added, and the reaction temperature was further increased to 140 °C. After 5 h, the mixture became a homogeneous dark-brown solution. The mixture was cooled to rt, poured into ice, and the pH was adjusted to between 8 and 9 by addition of aq. NaOH (20%). The aqueous layer was extracted with EtOAc (3 × 20 mL), and the combined organic layers were washed with brine (2 × 30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–70%) to give 6-bromo-7-methoxyquinoline (2.95 g, 12.4 mmol, 50%) as a yellow solid. LCMS (ESI) calcd for C<sub>10</sub>H<sub>8</sub>BrNO [M + H]<sup>+</sup>: 238.0, found: 237.9, <i>R<sub>t</sub></i> = 1.031 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.86 (d, <i>J</i> = 2.7 Hz, 1H), 7.98–8.09 (m, 2H), 7.47 (s, 1H), 7.31 (dd, <i>J</i> = 4.3, 8.22 Hz, 1H), 4.06 (s, 3H).</div><div class="NLM_p">Step 2. PdCl<sub>2</sub>(dppf) (123 mg, 0.168 mmol) was added to a stirred mixture of BPD (450 mg, 1.77 mmol), potassium acetate (495 mg, 5.04 mmol), and 6-bromo-7-methoxyquinoline (400 mg, 1.68 mmol) in 1,4-dioxane (5 mL), stirred at 75 °C for 4 h, and cooled down to rt. It was diluted with EtOAc (10 mL), washed with brine (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (10–50%) to give (7-methoxyquinolin-6-yl)boronic acid (230 mg, 1.13 mmol, 67%) as a brown oil. LCMS (ESI) calcd for C<sub>10</sub>H<sub>10</sub>BNO<sub>3</sub> [M + H]<sup>+</sup>: 204.1, found: 204.0, <i>R<sub>t</sub></i> = 0.810 min.</div><div class="NLM_p">Step 3. PdCl<sub>2</sub>(DTBPF) (35 mg, 0.054 mmol) was added to a stirred mixture of K<sub>3</sub>PO<sub>4</sub> (314 mg, 1.47 mmol), (7-methoxyquinolin-6-yl)boronic acid (100 mg, 0.493 mmol), (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (288 mg, 0.493 mmol) in THF (1 mL) and water (0.5 mL), stirred at 70 °C for 4 h under N<sub>2</sub>, and cooled down to rt. It was diluted with EtOAc (10 mL), washed with water (3 × 10 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with MeOH in DCM (0–30%) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (120 mg, 0.181 mmol, 37%) as a yellow oil. LCMS (ESI) calcd for C<sub>37</sub>H<sub>55</sub>N<sub>5</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 662.4, found: 662.5, <i>R<sub>t</sub></i> = 1.087 min.</div><div class="NLM_p last">Step 4. (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (110 mg, 0.166 mmol) was added to TFA (2 mL) and stirred at rt for 2 h. The TFA was removed, and the residue was purified by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.05% NH<sub>3</sub>·H<sub>2</sub>O) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (60 mg) as a white solid. 2,3-Dihydroxysuccinic acid (17 mg, 0.113 mmol) in MeCN (2 mL) was added to a solution of (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (60 mg) in MeCN (1 mL). MeCN was removed to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide 2,3-dihydroxysuccinate (<b>29</b>, 76 mg, 0.110 mmol, 66%) as a yellow solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>3</sub>·C<sub>4</sub>H<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 532.3, found: 532.3, <i>R<sub>t</sub></i> = 1.911 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.73 (d, <i>J</i> = 3.3 Hz, 1H), 8.40 (s, 1H), 8.31 (d, <i>J</i> = 7.9 Hz, 1H), 7.66 (s, 1H), 7.38–7.50 (m, 2H), 5.05 (t, <i>J</i> = 7.5 Hz, 1H), 4.44 (s, 2H), 4.11 (s, 3H), 3.31–3.34 (m, 4H), 3.02–3.03 (m, 1H), 2.70 (brs, 3H), 2.37–2.50 (m, 4H), 1.73–2.06 (m, 6H), 1.31–1.65 (m, 7H), 1.20 (brs, 1H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>30</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>31</b>. HRMS (ESI) calcd for C<sub>32</sub>H<sub>43</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 546.3366, found: 546.3439, <i>R<sub>t</sub></i> = 1.900 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.94–9.08 (m, 1H), 8.89 and 8.67 (s, s, 1H), 8.11 and 8.06 (s, s, 1H), 7.83 (dd, <i>J</i> = 2.20, 8.38 Hz, 1H), 7.68 (s, 1H), 5.07–5.14 (m, 1H), 4.25 (d, <i>J</i> = 4.19 Hz, 3H), 3.40–3.55 (m, 2H), 3.39–3.66 (m, 1H), 3.02–3.26 (m, 1H), 3.00 (s, 3H), 2.81–2.93 (m, 3H), 2.41–2.53 (m, 4H), 1.75–2.31 (m, 6H), 1.21–1.64 (m, 8H), 1.12–1.64 (m, 1H), 0.95–1.10 (m, 3H).</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(4-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>31</b>)</h3><div class="NLM_p last">TFA (4 mL, 51.9 mmol) was added to a solution of (<i>S</i>)-6-ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (250 mg, 0.362 mmol) at rt, and the mixture was stirred at rt for 2 h. All of the volatiles were removed by an evaporator to give (<i>S</i>)-6-ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide as a brown oil (240 mg, 96%) HRMS (ESI) calcd for C<sub>33</sub>H<sub>45</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 560.3522, found: 560.3597. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.09–8.93 (m, 1H), 8.91–8.54 (m, 1H), 8.22–7.98 (m, 1H), 7.95–7.77 (m, 1H), 7.75–7.46 (m, 1H), 5.22–5.03 (m, 1H), 4.25 (s, 3H), 3.70–3.42 (m, 2H), 3.20–3.11 (m, 1H), 3.09–2.89 (m, 4H), 2.82–2.61 (m, 1H), 2.46 (m, 4H), 2.29–1.74 (m, 6H), 1.57 (m, 3H), 1.43–1.23 (m, 6H), 1.20–1.08 (m, 3H), 1.06–0.90 (m, 4H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 213.0, 175.7, 171.2, 158.8, 158.1, 149.5, 147.0, 137.0, 131.7, 124.9, 122.4, 121.7, 120.3, 119.9, 105.0, 72.9, 55.0, 51.5, 51.4, 51.2, 41.4, 35.1, 33.4, 32.3, 28.3, 26.2, 25.5, 25.0, 24.3, 23.2, 23.0, 16.7, 8.1, 6.7.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>S</i>)-6-Isopropyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>32</b>)</h3><div class="NLM_p last">Acetone (1 mL, 0.188 mmol) was added to (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (100 mg, 0.188 mmol) at rt (15 °C), and the mixture was stirred at 15 °C for 4 h. NaBH(OAc)<sub>3</sub> (355 mg, 1.881 mmol) was added, and the mixture was stirred at 15 °C for 18 h. The residue was purified by preparative reversed-phase HPLC eluting with acetonitrile/water with 0.05% NH<sub>3</sub>·H<sub>2</sub>O to give (<i>S</i>)-6-isopropyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide as a colorless solid (60 mg, 0.079 mmol, 42.3%). The solid was dissolved in MeOH (2 mL) and <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (16 mg, 0.107 mmol) was added. The mixture was concentrated to give (<i>S</i>)-6-isopropyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide 2,3-dihydroxysuccinate (40 mg, 0.047 mmol, 44.9%) as a colorless solid. HRMS (ESI) calcd for C<sub>34</sub>H<sub>47</sub>N<sub>5</sub>O<sub>3</sub>·C<sub>4</sub>H<sub>6</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 574.3679, found 574.3744. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.35 (brs, 1H), 8.22 (d, <i>J</i> = 8.22 Hz, 1H), 7.61–7.66 (m, 1H), 7.42 (s, 1H), 7.32 (d, <i>J</i> = 8.41 Hz, 1H), 5.09 (brs, 1H), 4.45 (s, 3H), 4.08 (s, 3H), 3.28–3.30 (m, 10H), 3.28–3.28 (m, 2H), 3.02 (brs, 1H), 2.70 (s, 3H), 2.37–2.48 (m, 4H), 2.13–2.29 (m, 1H), 1.99 (brs, 2H), 1.72–1.92 (m, 2H), 1.55 (d, <i>J</i> = 7.04 Hz, 2H), 1.25–1.40 (m, 5H), 0.94–0.98 (m, 1H), 0.96 (t, <i>J</i> = 7.24 Hz, 5H).</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (1<i>S</i>)-6-(Cyclopropylmethyl)-<i>N</i>-{(1<i>S</i>)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl]-7-oxononyl}-6-azaspiro[2.5]octane-1-carboxamide (<b>33</b>)</h3><div class="NLM_p last">Cyclopropanecarbaldehyde (25 mg, 0.357 mmol) was added to a solution of (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide 2,2,2-trifluoroacetate (125 mg, 0.194 mmol) in MeOH (2 mL), and the mixture was stirred at rt for 1 h. NaBH(OAc)<sub>3</sub> (123 mg, 0.581 mmol) was added, and the mixture was stirred at rt for 24 h. Water (5 mL) was added, and the mixture was extracted with ethyl acetate (3 × 5 mL). The organic layers were combined and washed with saturated aqueous NaHCO<sub>3</sub> (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by preparative reversed-phase HPLC eluting with acetonitrile/water with 0.05% NH<sub>3</sub>·H<sub>2</sub>O to give (<i>S</i>)-6-(cyclopropylmethyl)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide as a white solid (50 mg, 43%). The solid was dissolved in acetonitrile (2 mL) and <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (10 mg, 0.067 mmol) was added. The mixture was dried by lyophilization to give (<i>S</i>)-6-(cyclopropylmethyl)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-dihydroxysuccinate as a white solid. LCMS (ESI) calcd for C<sub>35</sub>H<sub>47</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 586.4, found: 586.1. 1H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.40 (brs, 1H), 8.23 (d, <i>J</i> = 8.2 Hz, 1H), 7.65 (s, 1H), 7.43 (s, 1H), 7.34 (d, J =8.2 Hz, 1H), 5.07 (t, <i>J</i> = 7.6 Hz, 1H), 4.45 (s, 2H), 4.10 (s, 3H), 3.50 (brs, 3H), 3.13 (brs, 2H), 2.71 (s, 4H), 2.38–2.50 (m, 4H), 1.73–2.35 (m, 6H), 1.08–1.68 (m, 9H), 0.98 (t, <i>J</i> = 7.2 Hz, 4H), 0.72 (brs, 1H), 0.43 (brs, 2H), −0.03 (brs, 2H).</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (1<i>S</i>)-6-Cyclobutyl-<i>N</i>-{(1<i>S</i>)-1-[5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl]-7-oxononyl}-6-azaspiro[2.5]octane-1-carboxamide (<b>34</b>)</h3><div class="NLM_p last">A mixture of cyclobutanone (25 mg, 0.357 mmol) and (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide 2,2,2-trifluoroacetate (125 mg, 0.194 mmol) in MeOH (2 mL) was stirred at rt for 1 h. NaBH(OAc)<sub>3</sub> (123 mg, 0.581 mmol) was added, and the mixture was stirred at rt for 24 h. Water (5 mL) was added, and the aqueous layer was extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with aqueous NaHCO<sub>3</sub> (saturated, 1 × 5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by preparative reversed-phase HPLC eluting with acetonitrile/water with 0.05% NH<sub>3</sub>·H<sub>2</sub>O to give (<i>S</i>)-6-cyclobutyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (40 mg, 33%) as a white solid. The solid was dissolved in acetonitrile (2 mL) and <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (11 mg, 0.073 mmol) was added. The mixture was dried by lyophilization to give (<i>S</i>)-6-cyclobutyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-dihydroxysuccinate as a white solid. LCMS (ESI) calcd for C<sub>35</sub>H<sub>47</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 586.4, found: 586.1, <i>R<sub>t</sub></i> = 1.666 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.45–8.59 (m, 1H), 8.25–8.36 (m, 1H), 7.63–7.77 (m, 1H), 7.45 (s, 1H), 7.32–7.41 (m, 1H), 5.01–5.16 (m, 1H), 4.48 (s, 2H), 4.11 (s, 3H), 2.88–3.10 (m, 2H), 2.72 (s, 3H), 2.44 (d, <i>J</i> = 6.7 Hz, 5H), 1.67–2.35 (m, 11H), 1.16–1.64 (m, 10H), 0.96–0.99 (m, 5H).</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>S</i>)-6-(Cyclopropylmethyl)-<i>N</i>-((<i>S</i>)-1-(4-(2-ethyl-7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>35</b>)</h3><div class="NLM_p last">6-Bromo-2-ethyl-7-methoxyquinoline was prepared from 4-bromo-3-methoxyaniline and (<i>E</i>)-pent-2-enal based on the same method as <b>63</b>. Compound <b>35</b> was prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>36</sub>H<sub>49</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 600.3, found: 600.2, <i>R<sub>t</sub></i> = 1.654 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.37 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 1H), 7.61 (s, 1H), 7.44 (s, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 5.06–5.01 (m, 1H), 4.43 (s, 2H), 4.08 (s, 3H), 3.53–3.46 (m, 1H), 3.12–3.10 (m, 2H), 2.99–2.97 (m, 3H), 2.45–2.43 (m, 2H), 2.42–2.39 (m, 6H), 2.25–2.10 (m, 2H), 2.00–1.79 (m, 5H), 1.57–1.54 (m, 3H), 1.39–1.35 (m, 9H), 0.98–0.94 (m, 4H), 0.68–0.67 (m, 1H), 0.40–0.30 (m, 2H), −0.07 (m, 1H).</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>S</i>)-6-(Cyclopropylmethyl)-<i>N</i>-((<i>S</i>)-1-(4-(2-ethyl-7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>36</b>)</h3><div class="NLM_p">See Scheme S6 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. AgNO<sub>3</sub> (43 mg, 0.253 mmol), cyclopropanecarboxylic acid (37 mg, 0.430 mmol) and 6-bromo-7-methoxyquinoline (100 mg, 0.420 mmol) were added to a solution of H<sub>2</sub>SO<sub>4</sub> (0.05 mL, 0.938 mmol) in water (3 mL) at 20 °C, and the mixture was warmed up to 70 °C and stirred at 70 °C for 6 h. (NH<sub>4</sub>)<sub>2</sub>S<sub>2</sub>O<sub>8</sub> (288 mg, 1.260 mmol) in water (2 mL) was added dropwise, and the mixture was stirred at 70 °C for 12 h, cooled down to rt, and diluted with EtOAc (10 mL). It was washed with water (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc /petroleum ether (0–60%) to give 6-bromo-2-cyclopropyl-7-methoxyquinoline as a colorless oil (10 mg, 8.6%). LCMS (ESI) calcd for C<sub>13</sub>H<sub>12</sub>BrNO [M + H]<sup>+</sup>: 278.0, found: 278.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (s, 1H), 7.85 (d, <i>J</i> = 8.4 Hz, 1H), 7.34 (s, 1H), 7.07 (d, <i>J</i> = 8.4 Hz, 1H), 4.03 (s, 3H), 2.16–2.26 (m, 1H), 1.09–1.15 (m, 3H), 0.85 (dd, <i>J</i> = 5.7, 19.85 Hz, 1H).</div><div class="NLM_p">Step 2. PdCl<sub>2</sub>(dppf) (30 mg, 0.041 mmol) was added to a mixture of BPD (110 mg, 0.433 mmol) and 6-bromo-2-cyclopropyl-7-methoxyquinoline (100 mg, 0.360 mmol) in 1,4-dioxane (1 mL) at rt and was stirred at 80 °C for 4 h under N<sub>2</sub>. The mixture was cooled down to rt, diluted with EtOAc (10 mL), washed with brine (3 × 10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–70%) to give (2-cyclopropyl-7-methoxyquinolin-6-yl)boronic acid (40 mg, 46%) as a colorless oil. LCMS (ESI) calcd for C<sub>13</sub>H<sub>14</sub>BNO<sub>3</sub> [M + H]<sup>+</sup>: 244.1, found: 244.1.</div><div class="NLM_p last">Step 3. Compound <b>36</b> was prepared based on the same procedure as <b>31</b>. LCMS (ESI) calcd for C37H49N5O3 [M + H]<sup>+</sup>: 612.3, found: 612.1, <i>R<sub>t</sub></i> = 1.694 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.33 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.62 (s, 1H), 7.42 (s, 1H), 7.13 (d, <i>J</i> = 8.8 Hz, 1H), 5.05 (t, <i>J</i> = 7.3 Hz, 1H), 4.45 (s, 2H), 4.08 (s, 3H), 3.48–3.46 (m, 2H), 3.14–3.12 (m, 2H), 2.69–2.68 (m, 2H), 2.46–2.44 (m, 4H), 2.27–2.26 (m, 2H), 2.02–2.01 (m, 2H), 1.59–1.57 (m, 3H), 1.52–1.51 (m, 3H), 1.36–1.35 (m, 4H), 1.16–1.14 (m, 6H), 0.99–0.97 (m, 4H), 0.68–0.67 (m, 1H), 0.43–0.05 (m, 3H).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-Cyclopropyl-7-methoxyquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>37</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>36</b> as yellow solid. LCMS (ESI) calcd for C<sub>34</sub>H<sub>45</sub>N<sub>5</sub>O<sub>3</sub>·ClH [M + H]<sup>+</sup>: 572.4, found: 572.4, <i>R<sub>t</sub></i> = 2.002 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.59–8.93 (m, 2H), 8.06 (d, <i>J</i> = 18.1 Hz, 1H), 7.70 (s, 1H), 7.46 (dd, <i>J</i> = 2.2, 8.6 Hz, 1H), 5.09 (brs, 1H), 4.24 (d, <i>J</i> = 4.2 Hz, 3H), 3.40–3.68 (m, 3H), 2.99–3.25 (m, 2H), 2.82–2.94 (m, 4H), 2.52–2.63 (m, 1H), 2.41–2.52 (m, 4H), 2.05–2.20 (m, 2H), 1.88–1.96 (m, 2H), 1.27–1.68 (m, 11H), 1.13–1.22 (m, 1H), 0.94–1.09 (m, 3H), 0.80 (t, <i>J</i> = 7.5 Hz, 1H).</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>38</b>)</h3><div class="NLM_p last">6-Bromo-7-methoxy-1-methylquinolin-2(1<i>H</i>)-one was prepared based on published procedure.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Compound <b>38</b> was prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>33</sub>H<sub>45</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 576.3, found: 576.2, <i>R<sub>t</sub></i> = 2.110 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.38 (brs, 0.5H), 8.09 (brs, 0.5H), 8.00–7.90 (m, 1H), 7.88–7.75 (m, 1H), 7.18 (brs, 1H), 6.63 (d, <i>J</i> = 9.4 Hz, 1H), 5.07 (brs, 1H), 4.15 (d, <i>J</i> = 4.1 Hz, 3H), 3.80 (brs, 3H), 3.62–3.40 (m, 2H), 3.23–3.11 (m, 3H), 3.07–2.89 (m, 1H), 2.72–2.56 (m, 2H), 2.26–1.97 (m, 2H), 1.96–1.70 (m, 4H), 1.56 (m, 3H), 1.42–1.21 (m, 7H), 1.18–1.09 (m, 3H), 1.06–0.85 (m, 4H).</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(5-methoxy-2-methyl-2<i>H</i>-indazol-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>39</b>)</h3><div class="NLM_p">See Scheme S7 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. Trimethyloxonium tertafluoroborate (0.782 g, 5.28 mmol) was added to a solution of 6-bromo-5-methoxy-1<i>H</i>-indazole (1.00 g, 4.40 mmol) in EtOAc (20 mL) and stirred at rt for 2 h. Water (50 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine (2 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (20%) to give 6-bromo-5-methoxy-2-methyl-2<i>H</i>-indazole as an orange solid (800 mg, 72%). LCMS (ESI) calcd for C<sub>9</sub>H<sub>9</sub>BrN<sub>2</sub>O [M + H]<sup>+</sup>: 241.0, found: 242.9. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (s, 1H), 7.90 (s, 1H), 7.19 (s, 1H), 4.11 (s, 3H), 3.83 (s, 3H).</div><div class="NLM_p">Step 2. Potassium acetate (855 mg, 8.71 mmol) and BPD (1475 mg, 5.81 mmol) were added to a stirred mixture of 6-bromo-5-methoxy-2-methyl-2<i>H</i>-indazole (700 mg, 2.90 mmol) in 1,4-dioxane (10 mL) at rt under N<sub>2</sub>, followed by addition of PdCl<sub>2</sub>(dppf) (212 mg, 0.290 mmol). The mixture was stirred at 80 °C for 18 h and filtered. The filter cake was washed with EtOAc (40 mL), and the filtrate was concentrated under vacuum. It was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (25%) to give 5-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2<i>H</i>-indazole (920 mg, 56%) as a red solid. LCMS (ESI) calcd for C<sub>15</sub>H<sub>21</sub>BN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 289.1, found: 289.1.</div><div class="NLM_p last">Step 3. Compound <b>39</b> was prepared based on the same procedure as <b>31</b>. Red solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>44</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 549.3, found: 549.2. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.34 (d, <i>J</i> = 4.2 Hz, 1H), 8.18 (s, 0.5H), 8.00 (s, 0.5H), 7.88 (d, <i>J</i> = 12 Hz, 1H), 7.36 (s, 1H), 5.12–5.05 (m, 1H), 4.27 (d, <i>J</i> = 3.2 Hz, 3H), 4.00 (d, <i>J</i> = 2.9 Hz, 3H), 3.60–3.33 (m, 2H), 3.28–3.14 (m, 2H), 3.08–2.91 (m, 1H), 2.73–2.58 (m, 1H), 2.51–2.38 (m, 5H), 2.25–1.86 (m, 7H), 1.63–1.47 (m, 3H), 1.43–1.28 (m, 6H), 1.23–1.14 (m, 3H), 1.07–0.96 (m, 4H).</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinoxalin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>40</b>)</h3><div class="NLM_p last"><i>n</i>-BuLi (1 mL, 2.500 mmol) was added to a solution of 6-bromo-7-methoxyquinoxaline (500 mg, 2.091 mmol) in THF (10 mL) at −78 °C. The mixture was stirred at −78 °C for 1 h. Triisopropyl borate (787 mg, 4.18 mmol) in THF (5 mL) was added at −78 °C, and the mixture was stirred at −78 °C for 2 h. The mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (5 mL) and extracted with EtOAc (10 mL). The organic layer was washed with 10% EtOAc in petroleum ether and filtered to give (7-methoxyquinoxalin-6-yl)boronic acid as a white solid (40 mg, 0.098 mmol, 4.7%). LCMS (ESI) calcd for C<sub>9</sub>H<sub>9</sub>BN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 205.0, found: 205.1, <i>R<sub>t</sub></i> = 0.288 min. Compound <b>40</b> was prepared based on the same method as <b>31</b>. Yellow solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>42</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 547.3, found: 547.1, <i>R<sub>t</sub></i> = 2.151 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.74–8.88 (m, 2H), 8.39–8.63 (m, 1H), 7.91–8.02 (m, 1H), 7.56–7.66 (m, 1H), 5.03–5.15 (m, 1H), 4.12–4.20 (m, 3H), 3.51–3.61 (m, 1H), 2.91–3.25 (m, 4H), 2.39–2.50 (m, 4H), 2.16–2.36 (m, 1H), 1.97–2.15 (m, 2H), 1.80–1.94 (m, 3H), 1.46–1.64 (m, 3H), 1.08–1.43 (m, 10H), 0.91–1.07 (m, 4H).</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-Methoxy-1,7-naphthyridin-3-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>41</b>)</h3><div class="NLM_p last">LDA (1.873 mL, 3.75 mmol) was added to a solution of 2-methoxy-1,7-naphthyridine (400 mg, 2.497 mmol) and triisopropyl borate (939 mg, 4.99 mmol) in THF (3 mL) at −78 °C, and the mixture was stirred at −78 °C for 3 h and 18 °C for 10 h. The reaction was quenched with saturated aqueous NH<sub>4</sub>Cl (10 mL) and extracted with EtOAc (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The product was purified by flash silica gel chromatography (20 g, MeOH/DCM: 0–10%) to give (2-methoxy-1,7-naphthyridin-3-yl)boronic acid as a white solid (100 mg, 20%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.17–9.10 (m, 1H), 8.45–8.39 (m, 1H), 8.30–8.23 (m, 1H), 7.85–7.79 (m, 1H), 4.12 (s, 1H). LCMS (ESI) calcd for C<sub>9</sub>H<sub>9</sub>BN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 205.1, found: 205.1. Compound <b>41</b> was prepared based on the same method as <b>31</b>. LCMS (ESI) calcd for C<sub>30</sub>H<sub>40</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 533.3, found: 533.3, <i>R<sub>t</sub></i> = 1.980 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.09 (s, 1H), 8.80–8.72 (m, 1H), 8.42–8.37 (m, 1H), 7.83–7.78 (m, 1H), 7.77 (s, 1H), 5.08–4.99 (m, 1H), 4.25 (s, 3H), 2.57–2.40 (m, 7H), 2.35–2.25 (m, 1H), 2.19–2.11 (m, 3H), 2.06–1.94 (m, 2H), 1.70–1.52 (m, 7H), 1.50–1.29 (m, 6H), 1.02–0.94 (m, 3H).</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (1<i>S</i>)-<i>N</i>-{(1<i>S</i>)-1-[5-(7-Fluoro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl]-7-oxononyl}-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>42</b>)</h3><div class="NLM_p last">4-Bromo-3-fluoroaniline (500 mg, 2.63 mmol) was added to a solution of <i>p</i>-chloranil (0.776 g, 3.16 mmol) in butanol (5.0 mL) and HCl (37%, 5 mL, 60.9 mmol) at rt, and the temperature was increased to 120 °C. (<i>E</i>)-but-2-enal (9.31 mL, 113 mmol) in BuOH (0.3 mL) was added dropwise. The mixture was stirred at 120 °C for 40 min. After cooling to rt, it was diluted with H<sub>2</sub>O (10 mL) and extracted with EtOAc (3 × 10 mL). The aqueous layer was neutralized with NaOH (37%) to pH> 9 and extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by preparative reversed-phase HPLC eluting with acetonitrile/water with 0.225% HCOOH to give 6-bromo-7-fluoro-2-methylquinoline as a white solid (200 mg, 32%). <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.67 (d, <i>J</i> = 8.6 Hz, 1H), 8.54 (d, <i>J</i> = 7.0 Hz, 1H), 7.85 (d, <i>J</i> = 9.0 Hz, 1H), 7.76 (d, <i>J</i> = 8.6 Hz, 1H), 2.89 (s, 3H). LCMS (ESI) calcd for C<sub>10</sub>H<sub>7</sub>BrFN [M + H]<sup>+</sup>: 240.0, found: 240.0. Compound <b>42</b> was prepared based on the same method as <b>31</b>. White solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>40</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 534.3, found: 534.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 (brs, 1H), 8.07 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (d, <i>J</i> = 12.9 Hz, 1H), 7.47 (d, <i>J</i> = 3.9 Hz, 1H), 7.24 (d, <i>J</i> = 8.6 Hz, 1H), 6.54 (d, <i>J</i> = 7.4 Hz, 1H), 4.97 (q, <i>J</i> = 7.4 Hz, 1H), 2.72 (s, 3H), 2.35–2.49 (m, 5H), 2.20–2.34 (m, 3H), 2.17 (s, 3H), 2.04 (d, <i>J</i> = 7.8 Hz, 3H), 1.59 (td, <i>J</i> = 7.2, 14.48 Hz, 4H), 1.30–1.51 (m, 6H), 1.21 (d, <i>J</i> = 4.3 Hz, 1H), 1.03 (t, <i>J</i> = 7.4 Hz, 3H), 0.83 (dd, <i>J</i> = 4.3, 7.43 Hz, 1H).</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>43</b>)</h3><div class="NLM_p">See Scheme S8 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. (<i>E</i>)-but-2-enal (2.03 g, 29.1 mmol) was added dropwise to a stirred mixture of 4-bromo-3-chloroaniline (4.00 g, 19.4 mmol) and conc. HCl (12.7 mL, 155 mmol) in water (4.0 mL) at 110 °C, and the mixture was stirred at 110 °C for 2 h. Then, the mixture was neutralized with NH<sub>4</sub>OH till pH = 7. The organic phase was extracted with DCM (3 × 50 mL). The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by preparative C-18 HPLC eluting with acetonitrile in water (10–90% with 0.1% TFA) to give 6-bromo-7-chloro-2-methylquinoline (1492 mg, 5.82 mmol, 30.0%) as a white solid and 6-bromo-5-chloro-2-methylquinoline (1577 mg, 6.15 mmol, 31.7%) as a white solid.</div><div class="NLM_p">Step 2. PdCl<sub>2</sub>(dppf) (61 mg, 0.084 mmol) was added to a stirred mixture of KOAc (494 mg, 5.03 mmol), BPD (724 mg, 2.85 mmol), and 6-bromo-7-chloro-2-methylquinoline (430 mg, 1.68 mmol) in dioxane (10 mL), and the mixture was stirred at 70 °C for 1 h under N<sub>2</sub>. The solvent was evaporated under reduced pressure. The residue was purified by silica gel, eluting with EtOAc in petroleum ether (50%) to give 7-chloro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (500 mg, 1.65 mmol, 98%) as a black solid. LCMS (ESI) calcd for C<sub>16</sub>H<sub>19</sub>BClNO<sub>2</sub> [M + H]<sup>+</sup>: 304.1, found: 304.1, <i>R<sub>t</sub></i> = 1.041 min.</div><div class="NLM_p">Step 3. PdCl<sub>2</sub>(DTBPF) (52 mg, 0.081 mmol) was added to a mixture of (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (600 mg, 0.896 mmol), 7-chloro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (408 mg, 1.344 mmol), and K<sub>3</sub>PO<sub>4</sub> (570 mg, 2.69 mmol) in 1,4-dioxane (12.0 mL) and water (0.5 mL). Then, the mixture was stirred at 70 °C under N<sub>2</sub> for 4 h. The reaction mixture was cooled to 26 °C and filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (20–50%) to give (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (550 mg, 0.718 mmol, 80%) as a yellow oil. LCMS (ESI) calcd for C<sub>41</sub>H<sub>60</sub>ClN<sub>5</sub>O5Si [M + H]<sup>+</sup>: 766.4, found: 766.5, <i>R<sub>t</sub></i> = 1.318 min.</div><div class="NLM_p">Step 4. (<i>S</i>)-<i>tert</i>-butyl-1-(((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (200 mg, 0.261 mmol) was added to TFA (1 mL, 0.261 mmol), and the mixture was stirred at 20 °C for 2 h. The mixture was concentrated to dryness to give crude (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (140 mg, 0.261 mmol), which was used without further purification. LCMS (ESI) calcd for C<sub>30</sub>H<sub>38</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 536.3, found: 536.3, <i>R<sub>t</sub></i> = 0.832 min.</div><div class="NLM_p last">Step 5. Formaldehyde (1 mL, 12.32 mmol) was added to a mixture of (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (140 mg, 0.261 mmol) in MeOH (3 mL), and the mixture was stirred at 20 °C for 2 h. NaBH(OAc)<sub>3</sub> (247 mg, 1.2 mmol) was added, and the mixture was stirred at 20 °C for 3 h. The reaction mixture was concentrated, and the residue was purified by preparative C18 HPLC eluting with acetonitrile in water (10–90%, with 0.05% NH<sub>3</sub>·H<sub>2</sub>O) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (75 mg, 0.136 mmol, 52.2%) as a white solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>40</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 550.3, found: 550.4, <i>R<sub>t</sub></i> = 0.863 min. <span class="smallcaps smallerCapital">l</span>-Tartaric acid (17 mg, 0.12 mmol) was added to (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (65 mg, 0.12 mmol) in water (2 mL) at 16 °C, and the mixture was stirred at the same temperature for 15 min. The mixture was lyophilized to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide 2<i>R</i>,3<i>R</i>-dihydroxysuccinate (<b>43</b>, 80 mg, 0.11 mmol) as a yellow oil. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.25–8.31 (m, 2H), 8.05 (s, 1H), 7.58–7.62 (m, 1H), 7.43–7.49 (m, 1H), 5.03–5.054 (m, 1H), 4.42 (s, 2H), 3.02–3.12 (m, 1H), 2.72 (s, 6H), 2.39–2.50 (m, 4H), 1.75–2.08 (m, 6H), 1.31–1.63 (m, 8H), 1.27–1.32 (m, 2H), 1.17–1.24 (m, 1H), 0.99 (t, <i>J</i> = 7.3 Hz, 4H).</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2,7-Dimethylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>44</b>)</h3><div class="NLM_p last">Prepared based on the same method of <b>31</b>. LCMS (ESI) calcd for C<sub>32</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 530.3, found: 530.2, <i>R<sub>t</sub></i> = 1.945 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.23 (d, <i>J</i> = 8.6 Hz, 1H), 8.04 (s, 1H), 7.83 (s, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H), 7.29 (s, 1H), 5.03 (t, <i>J</i> = 7.0 Hz, 1H), 4.42 (s, 2H), 3.42–4.13 (m, 1H), 2.98–3.22 (m, 2H), 2.63–2.95 (m, 6H), 2.60 (s, 3H), 2.41–2.49 (m, 4H), 2.08–2.34 (m, 1H), 1.74–2.07 (m, 6H), 1.53–1.62 (m, 2H), 1.28–1.50 (m, 5H), 1.19 (brs, 1H), 0.95–1.02 (m, 4H).</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (1<i>S</i>)-<i>N</i>-{(1<i>S</i>)-1-[5-(7-Ethyl-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl]-7-oxononyl}-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>45</b>)</h3><div class="NLM_p">See Scheme S9 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. PdCl<sub>2</sub>(DTBPF) (52 mg, 0.081 mmol) was added to a mixture of (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (600 mg, 0.896 mmol), 7-chloro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (408 mg, 1.34 mmol), and K<sub>3</sub>PO<sub>4</sub> (570 mg, 2.69 mmol) in dioxane (12.0 mL) and water (0.5 mL). After the mixture was stirred at 70 °C under N<sub>2</sub> for 4 h, it was cooled to rt and filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (10–50%) to give (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (550 mg, 80%) as a yellow oil. LCMS (ESI) calcd for C<sub>41</sub>H<sub>60</sub>ClN<sub>5</sub>O<sub>5</sub>Si [M + H]<sup>+</sup>: 766.4, found: 766.5.</div><div class="NLM_p">Step 2. PdCl<sub>2</sub>(DTBPF) (33 mg, 0.051 mmol) was added to a mixture of (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(7-chloro-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (203 mg, 0.265 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (210 mg, 1.364 mmol), and K<sub>3</sub>PO<sub>4</sub> (189 mg, 0.890 mmol) in THF (3 mL) and water (0.3 mL), and the mixture was stirred at 80 °C for 6 h. To the mixture was added another batch of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (200 mg), K<sub>3</sub>PO<sub>4</sub> (190 mg), PdCl<sub>2</sub>(DTBPF) (30 mg), bubbled with N<sub>2</sub>, and stirred at 80 °C for 9 h. To the mixture was added one more batch of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (180 mg), K<sub>3</sub>PO<sub>4</sub> (190 mg), PdCl<sub>2</sub>(DTBPF) (33 mg), and bubbled with N<sub>2</sub>, and stirred at 80 °C for another 20 h. The mixture was diluted with water (30 mL), extracted with DCM (3 × 15 mL). The combined organic layers were washed with brine (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with MeOH in DCM (0–10%). The product obtained was purified one more time by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.1% TFA) to give (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(2-methyl-7-vinylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (70 mg, 32%) as a yellow oil. LCMS (ESI) calcd for C<sub>43</sub>H<sub>63</sub>N<sub>5</sub>O<sub>5</sub>Si [M + H]<sup>+</sup>: 758.5, found: 758.4.</div><div class="NLM_p">Step 3. 10% Pd–C (80 mg, 0.075 mmol) was added to a mixture of (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(2-methyl-7-vinylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (70 mg, 0.092 mmol) in MeOH (15 mL), and the mixture was stirred at rt for 2 h under H<sub>2</sub> (15 psi). The mixture was filtered, and the filter cake was washed with MeOH (30 mL). The filtrate was concentrated to give (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (65 mg, 93%) as a yellow oil, which was used in the next step without further purification. LCMS (ESI) calcd for C<sub>43</sub>H<sub>65</sub>N<sub>5</sub>O<sub>5</sub>Si [M + H]<sup>+</sup>: 760.5, found: 760.5.</div><div class="NLM_p">Step 4. TFA (4.0 mL, 52 mmol) was added to (<i>S</i>)-<i>tert</i>-butyl 1-(((<i>S</i>)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)carbamoyl)-6-azaspiro[2.5]octane-6-carboxylate (65 mg, 0.086 mmol), and the mixture was stirred at rt for 3 h. TFA was removed under reduced pressure to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (45 mg) as a yellow oil, which was used in the next step without further purification. LCMS (ESI) calcd for C<sub>32</sub>H<sub>43</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 530.3, found: 530.4.</div><div class="NLM_p last">Step 5. A mixture of (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (45 mg, 0.085 mmol) and formaldehyde (0.5 mL, 6.72 mmol) in MeOH (2 mL) was stirred at rt for 8 h. Then, NaBH(OAc)<sub>3</sub> (103 mg, 0.486 mmol) was added portion-wise. After the mixture was stirred at rt for another 1 h, it was diluted with DMF (3 mL) and purified by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.1% TFA). The obtained product (20 mg) was purified one more time by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.05% NH<sub>3</sub>·H<sub>2</sub>O) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-ethyl-2-methylquinolin-6-yl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>45</b>, 11 mg, 24%) as a yellow oil. LCMS (ESI) calcd for C<sub>33</sub>H<sub>45</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 544.4, found: 544.4. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.19 (d, <i>J</i> = 8.22 Hz, 1H), 7.92 (brs, 1H), 7.85 (s, 1H), 7.37 (d, <i>J</i> = 8.61 Hz, 1H), 7.15 (brs, 1H), 5.02 (t, <i>J</i> = 7.63 Hz, 1H), 2.97–2.99 (m, 2H), 2.71 (s, 3H), 2.40–2.56 (m, 7H), 2.34 (brs, 1H), 2.17 (s, 3H), 1.88–2.05 (m, 2H), 1.67 (brs, 2H), 1.51–1.62 (m, 4H), 1.29–1.41 (m, 5H), 1.24 (t, <i>J</i> = 7.63 Hz, 3H), 1.11 (t, <i>J</i> = 4.89 Hz, 1H), 0.99 (t, <i>J</i> = 7.24 Hz, 3H), 0.82 (dd, <i>J</i> = 4.50, 8.02 Hz, 1H).</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Methoxyquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>46</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. Yellow solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>40</sub>N<sub>4</sub>O<sub>4</sub>·ClH [M + H]<sup>+</sup>: 533.3, found: 533.1, <i>R<sub>t</sub></i> = 2.118 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.20–9.27 (m, 1H), 9.19–9.36 (m, 1H), 9.09 (d, <i>J</i> = 5.3 Hz, 1H), 7.97 (dd, <i>J</i> = 5.7, 8.16 Hz, 1H), 7.80 (d, <i>J</i> = 8.8 Hz, 1H), 7.72 (d, <i>J</i> = 2.2 Hz, 1H), 5.17 (d, <i>J</i> = 6.6 Hz, 1H), 4.29 (s, 3H), 3.44–3.60 (m, 2H), 3.00–3.17 (m, 2H), 2.89 (d, <i>J</i> = 17.4 Hz, 3H), 2.42–2.52 (m, 4H), 2.32 (m, 2H), 1.86–2.09 (m, 5H), 1.46–1.65 (m, 3H), 1.31–1.46 (m, 4H), 1.18–1.31 (m, 1H), 0.96–1.03 (m, 3H).</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(2-methoxy-1,7-naphthyridin-3-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (2<i>R</i>,3<i>S</i>)-2,3-dihydroxysuccinate (<b>47</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. Yellow solid. LCMS (ESI) calcd for C<sub>31</sub>H<sub>41</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 548.3, found: 548.1, <i>R<sub>t</sub></i> = 2.201 min. 1H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.14 (s, 1H), 8.61 (s, 1H), 8.46 (d, <i>J</i> = 5.29 Hz, 1H), 7.90 (d, <i>J</i> = 5.51 Hz, 1H), 7.76 (s, 1H), 5.10–5.24 (m, 1H), 4.45 (s, 2H), 4.28 (s, 3H), 3.11–3.23 (m, 2H), 2.38–2.53 (m, 5H), 2.03–2.15 (m, 1H), 1.88–2.00 (m, 3H), 1.77–1.87 (m, 1H), 1.11–1.68 (m, 14H), 0.99 (t, <i>J</i> = 7.39 Hz, 4H), 0.88–1.08 (m, 1H).</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>48</b>)</h3><div class="NLM_p last">To a 10 mL vial was added a solution of (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-bromooxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (150 mg, 0.330 mmol), 7-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (119 mg, 0.396 mmol), potassium phosphate (210 mg, 0.990 mmol), and PdCl<sub>2</sub>(DTBPF) (22 mg, 0.034 mmol). The vial was degassed and refilled with nitrogen three times. Dioxane (2 mL) and water (0.05 mL) were sealed in a 10 mL vial with nitrogen, and the reaction mixture was stirred at 70 °C for 2 h. The reaction mixture was concentrated to dryness and the product. After it was cooled down, the solvents was removed under reduced pressure and the product was purified by preparative reversed-phase HPLC eluting with acetonitrile/water with 0.1% TFA to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide as a yellow solid (80 mg, 0.128 mmol, 38.8%). HRMS (ESI) calcd for C<sub>32</sub>H<sub>42</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 547.3206, found 547.3288. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.96–9.07 (m, 1H), 8.58–8.69 (m, 1H), 7.78 (dd, <i>J</i> = 7.7, 12.57 Hz, 2H), 7.65 (d, <i>J</i> = 2.9 Hz, 1H), 5.15 (t, <i>J</i> = 6.2 Hz, 1H), 4.26 (s, 3H), 3.42–3.60 (m, 2H), 2.99 (s, 3H), 2.88 (d, <i>J</i> = 13.45 Hz, 3H), 2.40–2.52 (m, 4H), 2.25–2.38 (m, 1H), 1.83–2.13 (m, 5H), 1.17–1.65 (m, 10H), 0.95–1.08 (m, 4H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 212.9, 175.4, 171.4, 164.1, 159.9, 157.1, 147.7, 147.3, 137.1, 126.2, 124.3, 121.5, 120.6, 118.1, 105.5, 72.7, 55.1, 53.9, 53.6, 42.4, 41.4, 35.1, 32.7, 32.5, 28.3, 26.1, 25.3, 25.1, 24.1, 23.2, 17.0, 6.7.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>49</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. HRMS (ESI) calcd for C<sub>33</sub>H<sub>44</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 561.3363, found 561.3435. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.26–8.24 (m, 2H), 7.58 (s, 1H), 7.43 (s,1H), 7.35–7.32 (m, 1H), 5.18–5.14 (m, 1H), 4.40 (s, 2H), 4.11 (s, 3H), 3.11–3.09 (m, 2H), 2.70 (s, 3H), 2.48–2.41 (m, 4H), 1.97–1.93 (m, 5H), 1.85–1.80 (m, 1H), 1.60–1.38 (m, 11H), 1.23 (brs, 4H), 1.00–0.96 (m, 4H).</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>50</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. Yellow solid. LCMS (ESI) calcd for C<sub>33</sub>H<sub>44</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 577.7, found: 577.7, <i>R<sub>t</sub></i> = 1.008 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.08–8.16 (m, 1H), 8.02 (dd, <i>J</i> = 2.31, 9.37 Hz, 1H), 7.58 and 7.65 (s, s, 1H), 7.14 (s, 1H), 6.62 (d, <i>J</i> = 9.48 Hz, 1H), 5.11–5.21 (m, 1H), 4.15 (s, 3H), 3.79 (s, 3H), 3.47–3.57 (m, 1H), 2.95–3.26 (m, 4H), 2.41–2.52 (m, 4H), 1.79–2.13 (m, 6H), 1.22–1.62 (m, 12H), 0.94–1.08 (m, 4H).</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxyquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>51</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. Yellow oil. HRMS (ESI) calcd for C<sub>32</sub>H<sub>42</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 547.3206, found 547.3285. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 9.17–9.28 (m, 1H), 9.08 (d, J=4.19 Hz, 1H), 8.65–8.78 (m, 1H), 7.95 (m, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 5.10–5.17 (m, 1H), 4.29 (s, 3H), 3.38–3.69 (m, 2H), 2.93–3.31 (m, 5H), 2.46 (s, 4H), 2.23–2.37 (m, 1H), 1.81–2.17 (m, 5H), 1.17–1.66 (m, 11H), 0.95–1.15 (m, 3H),</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(7-Fluoro-2-methylquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-dihydroxysuccinate (<b>52</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. White solid. HRMS (ESI) calcd for C<sub>31</sub>H<sub>39</sub>FN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 535.3006, found 535.3090. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.35 (dd, <i>J</i> = 4.5, 7.8 Hz, 2H), 7.70 (d, <i>J</i> = 12.5 Hz, 1H), 7.55 (d, <i>J</i> = 4.1 Hz, 1H), 7.47 (d, <i>J</i> = 8.4 Hz, 1H), 5.14–5.21 (m, 1H), 4.48 (s, 2H), 3.49 (brs, 1H), 2.96–3.15 (m, 1H), 2.85 (s, 3H), 2.73 (s, 3H), 2.41–2.51 (m, 4H), 1.90–2.35 (m, 5H), 1.83 (t, <i>J</i> = 6.7 Hz, 1H), 1.34–1.66 (m, 7H), 1.15–1.32 (m, 2H), 0.99 (t, <i>J</i> = 7.3 Hz, 4H).</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>53</b>)</h3><div class="NLM_p">See Scheme S10 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. Tricyclohexylphosphine (121 mg, 0.432 mmol) and diacetoxypalladium (48 mg, 0.214 mmol) were added to a mixture of potassium phosphate tribasic (917 mg, 4.32 mmol), cyclopropylboronic acid (185 mg, 2.159 mmol), and 6-bromo-7-fluoro-2-iodoquinoline (760 mg, 2.159 mmol) in toluene (5 mL), and the mixture was stirred at 100 °C for 8 h. The mixture was cooled down, diluted with EtOAc (10 mL), washed with brine (3 × 15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (0–10%) to give 6-bromo-2-cyclopropyl-7-fluoroquinoline (300 mg, 1.13 mmol, 52%) as a yellow solid. LCMS (ESI) calcd for C<sub>12</sub>H<sub>9</sub>BrFN [M + H]<sup>+</sup>: 266.0, found: 267.7, <i>R<sub>t</sub></i> = 1.082 min.</div><div class="NLM_p">Step 2. <i>n</i>-BuLi (1.5 mL, 3.75 mmol) was added to a stirred mixture of triisopropyl borate (424 mg, 2.255 mmol) and 6-bromo-2-cyclopropyl-7-fluoroquinoline (300 mg, 1.127 mmol) in THF (2 mL) at −78 °C, and the mixture was gradually warmed up to rt and stirred at rt for 4 h. Aqueous ammonium chloride (20%, 10 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with MeOH in DCM (0–10%) to give (2-cyclopropyl-7-fluoroquinolin-6-yl)boronic acid (160 mg, 0.693 mmol, 61%) as a yellow oil. LCMS (ESI) calcd for C<sub>12</sub>H<sub>11</sub>BFNO<sub>2</sub> [M + H]<sup>+</sup>: 232.1, found: 231.7, <i>R<sub>t</sub></i> = 0.902 min.</div><div class="NLM_p last">Step 3. PdCl<sub>2</sub>(DTBPF) (40 mg, 0.061 mmol) was added to a mixture of K<sub>3</sub>PO<sub>4</sub> (358 mg, 1.69 mmol), (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-bromooxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (250 mg, 0.550 mmol), and (2-cyclopropyl-7-fluoroquinolin-6-yl)boronic acid (130 mg, 0.563 mmol) in THF (3 mL) and water (0.5 mL) at rt, and the mixture was stirred at 70 °C for 6 h. The mixture was concentrated to 3 mL and purified by preparative C18 HPLC eluting with acetonitrile in water (10–90% with 0.1% TFA) to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-cyclopropyl-7-fluoroquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (65 mg, 0.112 mmol, 20%) as a yellow solid. HCl (1 M in water, 2.3 mL, 0.230 mmol) was added to the above product in MeCN (2 mL) at rt. The product was lyophilized to give (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-(2-cyclopropyl-7-fluoroquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide hydrochloride (<b>53</b>, 60 mg, 0.096 mmol, 83%) as a yellow solid. LCMS (ESI) calcd for C<sub>33</sub>H<sub>41</sub>FN<sub>4</sub>O<sub>3</sub>·ClH [M + H]<sup>+</sup>: 561.3, found: 561.3, <i>R<sub>t</sub></i> = 2.042 min. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.97–9.04 (m, 1H), 8.63–8.75 (m, 1H), 7.99 (d, <i>J</i> = 11.0 Hz, 1H), 7.67 (dd, <i>J</i> = 4.1, 13.5 Hz, 1H), 7.57 (d, <i>J</i> = 8.6 Hz, 1H), 5.08–5.20 (m, 1H), 3.39–3.60 (m, 2H), 3.02–3.11 (m, 1H), 2.81–2.94 (m, 3H), 2.52–2.63 (m, 1H), 2.38–2.50 (m, 3H), 2.22–2.32 (m, 1H), 1.79–2.09 (m, 5H), 1.68 (d, <i>J</i> = 5.5 Hz, 2H), 1.15–1.62 (m, 11H), 0.88–1.12 (m, 4H), 0.78 (t, <i>J</i> = 7.2 Hz, 1H).</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(5-methoxy-2-methyl-2<i>H</i>-indazol-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>54</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>39</b> and <b>48</b>. White solid. HRMS (ESI) calcd for C<sub>31</sub>H<sub>43</sub>N<sub>5</sub>O<sub>4</sub>·ClH [M + H]<sup>+</sup>: 550.3115, found 550.3886. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.37 (brs, 1H), 8.00 (d, <i>J</i> = 10.1 Hz, 1H), 7.62 (d, <i>J</i> = 4.9 Hz, 1H), 7.33 (s, 1H), 5.17–5.11 (m, 1H), 4.28 (d, <i>J</i> = 3.1 Hz, 3H), 4.04–3.99 (m, 3H), 3.62–3.51 (m, 2H), 3.37–3.33 (m, 1H), 3.22–2.98 (m, 4H), 2.76 (d, <i>J</i> = 3.5 Hz, 1H), 2.50–2.40 (m, 3H), 2.37–2.19 (m, 1H), 2.09–1.91 (m, 6H), 1.89–1.79 (m, 1H), 1.61–1.53 (m, 4H), 1.51–1.25 (m, 6H), 1.23–1.17 (m, 2H), 1.07–0.96 (m, 4H).</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (<i>S</i>)-6-Methyl-<i>N</i>-((<i>S</i>)-7-oxo-1-(5-(4-(pyridin-3-yl)phenyl)oxazol-2-yl)nonyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>55</b>)</h3><div class="NLM_p last">Prepared based on the same method as <b>48</b>. LCMS (ESI) calcd for C<sub>32</sub>H<sub>40</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 529.3, found: 529.3, <i>R<sub>t</sub></i> = 2.161 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.87 (d, <i>J</i> = 1.6 Hz, 1H), 8.61 (d, <i>J</i> = 3.9 Hz, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.61–7.75 (m, 4H), 7.39 (dd, <i>J</i> = 5.1, 7.8 Hz, 1H), 7.28 (s, 1H), 6.91 (d, <i>J</i> = 7.8 Hz, 1H), 5.23–5.29 (m, 1H), 2.85–3.36 (m, 3H), 2.72 (s, 3H), 2.40 (tt, <i>J</i> = 3.6, 6.9 Hz, 3H), 1.80–2.10 (m, 6H), 1.53–1.69 (m, 4H), 1.23–1.48 (m, 6H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H), 0.95 (brs, 1H).</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(2-ethyl-7-methoxy-1-oxo-1,2-dihydroisoquinolin-6-yl)oxazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>56</b>)</h3><div class="NLM_p">See Scheme S11 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">Supporting Information</a> for the synthetic scheme.</div><div class="NLM_p">Step 1. HATU (3.61 g, 9.5 mmol) and TEA (1.042 g, 10.32 mmol) were added to a stirred mixture of 4-bromo-3-methoxybenzoic acid (2 g, 8.6 mmol) in DCM (20 mL) at rt, and the mixture was stirred at rt for 15 min. Then, 2,2-dimethoxyethan-1-amine (997 mg, 9.5 mmol) was added. The solution was stirred for 1 h. Then, the solvent was removed to give 4-bromo-<i>N</i>-(2,2-dimethoxyethyl)-3-methoxybenzamide (2.72 g crude) as a brown oil, which was used in the next step without further purification.</div><div class="NLM_p">Step 2. H<sub>2</sub>SO<sub>4</sub> (20 mL) was added slowly to stirring 4-bromo-<i>N</i>-(2,2-dimethoxyethyl)-3-methoxybenzamide (2.72 g crude, 8.6 mmol), and the mixture was stirred at rt for 2 h. The reaction was poured into ice water. The resulting precipitate was collected by filtration and the filter cake was washed with water (50 mL) and dried to afford 6-bromo-7-methoxyisoquinolin-1(2<i>H</i>)-one (1.52 g crude) as a yellow solid, which was used without further purification in the next step.</div><div class="NLM_p">Step 3. Iodoethane (1.4 g, 9.0 mmol) was added to a stirred mixture of 6-bromo-7-methoxyisoquinolin-1(2<i>H</i>)-one (1.52 g, 5.98 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (2.9 g, 8.97 mmol) in DMF (20 mL), and the mixture was stirred at rt for 2 h. The mixture was filtered, and the filter cake was washed with DMF (10 mL). The filtrate was poured into water (50 mL) and the precipitate was collected with filtration and the filter cake was washed with water (50 mL) and dried to give 6-bromo-2-ethyl-7-methoxyisoquinolin-1(2<i>H</i>)-one (1.6 g, crude), which was used in the next step without further purification. LCMS (ESI) calcd for C<sub>12</sub>H<sub>12</sub>BrNO<sub>2</sub> [M + H]<sup>+</sup>: 282.0, found: 284.0.</div><div class="NLM_p">Step 4. Potassium acetate (1.660 g, 17 mmol) and BPD (2.16 g, 8.51 mmol) were added to a mixture of 6-bromo-2-ethyl-7-methoxyisoquinolin-1(2<i>H</i>)-one (1.60 g, 5.67 mmol) in 1,4-dioxane (20 mL) at rt. The mixture was replaced with N<sub>2</sub> and PdCl<sub>2</sub>(dppf) (0.414 g, 0.567 mmol) was added. The mixture was stirred at 80 °C for 18 h. After it was cooled down, the mixture was filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether (30%) to give 2-ethyl-7-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1(2<i>H</i>)-one (0.92 g, 49%) as a yellow solid. LCMS (ESI) calcd for C<sub>18</sub>H<sub>24</sub>BNO<sub>4</sub> [M + H]+: 330.2, found: 330.2.</div><div class="NLM_p last">Step 5. Compound <b>56</b> was prepared based on the method as <b>48</b>. HRMS (ESI) calcd for C<sub>33</sub>H<sub>44</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 591.3468, found 591.3537. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.04 (s, 1H), 7.89 (s, 1H), 7.65 (s, 1H), 7.33 (d, <i>J</i> = 7.28 Hz, 1H), 6.77 (d, <i>J</i> = 7.72 Hz, 1H), 5.13–5.18 (m, 1H), 4.43 (s, 3H), 4.07–4.14 (m, 5H), 3.37–3.64 (m, 2H), 3.14 (m, 4H), 2.41–2.51 (m, 4H), 2.06 (brs, 1H), 1.88–1.89 (m, 2H), 1.80 (brs, 1H), 1.22–1.62 (m, 16H), 0.99 (t, <i>J</i> = 7.28 Hz, 4H).</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (<i>S</i>)-Benzyl 6-Azaspiro[2.5]octane-1-carboxylate (<b>58</b>)</h3><div class="NLM_p last">TFA (4.5 mL, 60.6 mmol) was added to a solution of (<i>S</i>)-1-benzyl 6-<i>tert</i>-butyl 6-azaspiro[2.5]octane-1,6-dicarboxylate (3.0 g, 8.68 mmol) in DCM (30 mL), and the mixture was stirred at rt for 4 h. The solvents were removed by an evaporator to give crude (<i>S</i>)-benzyl 6-azaspiro[2.5]octane-1-carboxylate (3.1 g), which was used directly for the next step without further purification. LCMS (ESI) calcd for C<sub>15</sub>H<sub>19</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 246.1, found: 246.1.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (<i>S</i>)-Benzyl 6-Methyl-6-azaspiro[2.5]octane-1-carboxylate (<b>59a</b>)</h3><div class="NLM_p last">Formaldehyde (18.77 g, 231 mmol) was added to a solution of (<i>S</i>)-benzyl 6-azaspiro[2.5]octane-1-carboxylate (9.9 g, 28.9 mmol) in MeOH (100 mL), and the mixture was stirred at rt for 2 h. Sodium triacetoxyhydroborate (18.39 g, 87 mmol) was added, and the mixture was stirred at rt for 1 h. The solvent was removed by an evaporator. Water (100 mL) was added, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column flash chromatography eluting with MeOH in DCM from 0 to 10% to give (<i>S</i>)-benzyl 6-methyl-6-azaspiro[2.5]octane-1-carboxylate as a yellow oil (7.5 g, 99% for two steps). LCMS (ESI) calcd for C<sub>16</sub>H<sub>21</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 260.3, found: 260.1.</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (<i>S</i>)-Benzyl 6-ethyl-6-azaspiro[2.5]octane-1-carboxylate (<b>59b</b>)</h3><div class="NLM_p last">Acetaldehyde (21 mL, 149 mmol) was added to a solution of (<i>S</i>)-benzyl 6-azaspiro[2.5]octane-1-carboxylate (6.2 g, 18.11 mmol) in MeOH (60 mL), and the mixture was stirred at 30 °C for 16 h. More acetaldehyde (4.0 mL) was added, and the mixture was stirred at 30 °C for another 16 h. Sodium triacetoxyhydroborate (11.52 g, 54.3 mmol) was added, and the mixture was stirred at 30 °C for 16 h. The solvent was removed by an evaporator. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (35 mL × 3). The combined organic layers were washed with saturated aqueous NaHCO<sub>3</sub> (35 mL × 2), brine (35 mL × 2), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel flash chromatography eluting with MeOH in DCM from 0 to 10% to give (<i>S</i>)-benzyl 6-ethyl-6-azaspiro[2.5]octane-1-carboxylate as a yellow oil (4.5 g, 91% for two steps). LCMS (ESI) calcd for C<sub>17</sub>H<sub>23</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 274.2, found: 274.1.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (<i>S</i>)-6-Methyl-6-azaspiro[2.5]octane-1-carboxylic acid (<b>60a</b>)</h3><div class="NLM_p last">To a 100 mL three-neck round-bottom flask was added (<i>S</i>)-benzyl 6-methyl-6-azaspiro[2.5]octane-1-carboxylate (7.5 g, 28.9 mmol) in MeOH (75 mL) and Pd/C (10%, wet, 520 mg, 0.489 mmol) under Ar. The suspension was degassed under vacuum and refilled with nitrogen three times. The mixture was stirred under H<sub>2</sub> (15 psi) at 24 °C for 90 min and filtered. The filter cake was washed with MeOH (20 mL × 2) and the filtrate was concentrated to give (<i>S</i>)-6-methyl-6-azaspiro[2.5]octane-1-carboxylic acid as a colorless oil (4.7 g, 96%). LCMS (ESI) calcd for C<sub>9</sub>H<sub>15</sub>NO<sub>2</sub> [M + H]<sup>+</sup>: 169.1, found: 246.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.88 (brs, 3H), 2.73 (brs, 1H), 2.50 (s, 3H), 1.77 (brs, 2H), 1.51 (m, 3H), 0.95 (m, 2H).</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (<i>S</i>)-6-Ethyl-6-azaspiro[2.5]octane-1-carboxylic acid (<b>60b</b>)</h3><div class="NLM_p last">To a solution of (<i>S</i>)-benzyl 6-ethyl-6-azaspiro[2.5]octane-1-carboxylate (4.5 g, 16.46 mmol) in MeOH (45 mL) was added Pd/C (10%, wet, 300 mg, 0.282 mmol) under Ar. The suspension was degassed under vacuum and refilled with N<sub>2</sub> three times. The mixture was then stirred under H<sub>2</sub> (15 psi) at 18 °C for 2 h and filtered. The filter cake was washed with MeOH (15 mL × 3). The filtrate was concentrated to give (<i>S</i>)-6-ethyl-6-azaspiro[2.5]octane-1-carboxylic acid as a colorless oil (3.0 g, 99%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.60–2.71 (m, 2H), 2.54–2.60 (m, 2H), 2.50 (brs, 2H), 1.65–1.78 (m, 2H), 1.48 (dd, <i>J</i> = 5.6, 7.4 Hz, 3H), 1.06 (t, <i>J</i> =7.2 Hz, 3H), 0.87–0.92 (m, 1H), 0.81–0.87 (m, 1H).</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 6-Bromo-7-methoxy-2-methylquinoline (<b>63</b>)</h3><div class="NLM_p last">A suspension of 4-bromo-3-methoxyaniline (15.00 g, 74.2 mmol) and concentrated HCl (52.5 mL, 639 mmol) in water (60 mL) was heated to 110 °C. (<i>E</i>)-but-2-enal (8.23 g, 117 mmol) was added dropwise into the above mixture over 30 min. The reaction mixture was stirred at 110 °C for 2 h and was cooled to rt. Aqueous ammonia (28%, 300 mL) was added, and the mixture was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column flash chromatography eluting with EtOAc in petroleum ether from 10 to 40% to give <b>63</b> as a pale brown solid (10.12 g, 40 mmol, 54%). LCMS (ESI) calcd for C<sub>11</sub>H<sub>10</sub>BrNO [M + H]<sup>+</sup>: 252.0, found: 251.9.</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 7-Methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (<b>64</b>)</h3><div class="NLM_p last">Pd(dppf)Cl<sub>2</sub> (85 mg, 0.116 mmol) was added to a solution of potassium acetate (405 mg, 4.13 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (786 mg, 3.09 mmol), and 6-bromo-7-methoxy-2-methylquinoline (520 mg, 2.063 mmol) in 1,4-dioxane (8 mL). The mixture was stirred at 80 °C for 12 h under nitrogen and concentrated. The residue was purified by silica gel column flash chromatography, eluting with 50% EtOAc in petroleum ether to give 7-methoxy-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (440 mg, 71%) as a brown gum. LCMS (ESI) calcd for C<sub>17</sub>H<sub>22</sub>BNO<sub>3</sub> [M + H]<sup>+</sup>: 300.2, found: 300.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.12 (s, 1H), 7.98 (d, <i>J</i> = 8.22 Hz, 1H), 7.34 (s, 1H), 7.14 (d, <i>J</i> = 8.22 Hz, 1H), 3.97 (s, 3H), 2.72 (s, 3H), 1.41 (s, 12H).</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 2,4-Dibromo-1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>66</b>)</h3><div class="NLM_p last">To a 10 L three-neck round-bottom flask was added a solution of 2,4,5-tribromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazole (420 g, 966 mmol) in tetrahydrofuran (4000 mL). It was cooled to −78 °C, and <i>n</i>-BuLi (2.49 M in hexane, 783 mL, 1950 mmol) was added dropwise with stirring. The mixture was stirred at −78 °C for 10 min. Water (17.4 g, 966.67 mmol) was added. The mixture was slowly warmed to −50 °C over 1 h and cooled back to −78 °C again. Br<sub>2</sub> (170 g, 1.06 mol) was added, and the reaction was stirred at −78 °C for another 30 min. The reaction was then quenched by the addition of 2 L of water. The resulting solution was extracted with ethyl acetate (2 L × 3), and the organic layers were combined. The resulting mixture was washed with brine (1 L). The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate in petroleum ether (1:30) to afford 2,4-dibromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazole (100 g, 29%) as a yellow solid. LCMS (ESI) calcd for C<sub>9</sub>H<sub>16</sub>Br<sub>2</sub>N<sub>2</sub>OSi [M + H]<sup>+</sup>:356.9, found: 256.9.</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (<i>R</i>)-<i>N</i>-((<i>S</i>)-1-(4-Bromo-1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-2-methylpropane-2-sulfinamide (<b>67</b>)</h3><div class="NLM_p last">To a 5 L three-neck round-bottom flask was added a solution of 2,4-dibromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazole (120 g, 336.96 mmol) in tetrahydrofuran (1200 mL). It was cooled to −78 °C and <i>n</i>-BuLi (138 g, 2.15 mol) was added dropwise, followed by (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide (102 g, 336.12 mmol). The solution was gradually warm up to -30 °C and stirred for 30 min. The reaction was quenched by the addition of 1 L of water. The resulting solution was extracted with ethyl acetate (1 L × 3), and the organic layers were combined, washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was purified by silica gel Prep-HPLC eluting with 50–70% CH<sub>3</sub>CN in water with 0.5% NH<sub>4</sub>HCO<sub>3</sub> to give 130 g product. The product was purified again by Chiral-Prep-HPLC (Prep SFC 350, column: CHIRALPAK 250 cm × 25 cm; mobile phase: 20% MeOH in CO<sub>2</sub>) to give (<i>R</i>)-<i>N</i>-[(1<i>S</i>)-1-(4-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl]-2-methylpropane-2-sulfinamide as a yellow oil (106 g, 54%). LCMS (ESI) calcd for C<sub>24</sub>H<sub>46</sub>BrN<sub>3</sub>O<sub>4</sub>SSi [M + H]<sup>+</sup>: 582.2, found: 582.1.</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (<i>S</i>)-9-Amino-9-(4-bromo-1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (<b>68</b>)</h3><div class="NLM_p last">To a 3 L three-neck round-bottom flask was added a solution of (<i>R</i>)-<i>N</i>-[(1<i>S</i>)-1-(4-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl]-2-methylpropane-2-sulfinamide (130 g, 223.87 mmol) in tetrahydrofuran (1300 mL). It was cooled to 0–5 °C, and hydrochloric acid (32%, 28 g, 246.3 mmol) was added dropwise. The solution was warmed up to rt and stirred for 8 h. It was diluted with 1000 mL of ice water and extracted with ethyl acetate (500 mL × 3). The combined organic layer was washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was purified by silica gel column eluting with EtOH/DCM (1/30). The product was dissolved in DCM (500 mL), and hydrochloric acid (16 g) in EtOAc (100 mL) was added. The mixture was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford (9<i>S</i>)-9-amino-9-(4-bromo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1<i>H</i>-imidazol-2-yl)nonan-3-one hydrochloride as a yellow oil (75.6 g, 72%). LCMS (ESI) calcd for C<sub>18</sub>H<sub>34</sub>BrN<sub>3</sub>O<sub>2</sub>Si [M + H]<sup>+</sup>: 432.2, found: 434.0. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.29 (brs, 3H), 7.51 (s, 1H), 5.54 (d, <i>J</i> = 11.1 Hz, 1H), 5.23 (d, <i>J</i> = 11.2 Hz, 1H), 4.40 (t, <i>J</i> = 6.9 Hz, 1H), 3.44 (m, 2H), 2.41- 2.26 (m, 4H), 1.84 (brs, 2H), 1.36 (m, 2H), 1.11 (m, 5H), 0.94- 0.68 (m, 5H), −0.06 (s, 9H).</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-Bromo-1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-ethyl-6-azaspiro[2.5]octane-1-carboxamide (<b>69</b>)</h3><div class="NLM_p last">HATU (0.967 g, 2.54 mmol) and Et<sub>3</sub>N (1.6 mL, 11.48 mmol) were added to a solution of (<i>S</i>)-6-ethyl-6-azaspiro[2.5]octane-1-carboxylic acid (0.466 g, 2.54 mmol) in DMF (15 mL) at rt and stirred for 15 min. (<i>S</i>)-9-amino-9-(5-bromo-1-((2- (trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)nonan-3-one (1.0 g, 2.3 mmol) was added and stirred at rt for 1 h. Water (10 mL) was added, and the aqueous layer was extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel flash chromatography eluting with MeOH in DCM from 1 to 10% to give <b>69</b> as a yellow oil (970 mg, 66%). LCMS (ESI) calcd for C<sub>28</sub>H<sub>49</sub>BrN<sub>4</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 597.3 and 599.3, found: 597.3 and 599.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.87 (s, 1H), 6.15–6.27 (m, 1H), 5.54–5.66 (m, 1H), 5.08–5.17 (m, 1H), 5.01–5.07 (m, 1H), 3.44–3.56 (m, 2H), 2.47–2.56 (m, 1H), 2.27–2.45 (m, 8H), 1.74–2.01 (m, 4H), 1.62–1.73 (m, 1H), 1.44–1.61 (m, 3H), 1.18–1.42 (m, 6H), 1.11–1.17 (m, 1H), 1.06 (s, 6H), 0.83–0.97 (m, 2H), 0.74–0.82 (m, 1H), 0.00 (s, 9H).</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (<i>S</i>)-6-Ethyl-<i>N</i>-((<i>S</i>)-1-(5-(7-methoxy-2-methylquinolin-6-yl)-1-((2-(Trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)-7-oxononyl)-6-azaspiro[2.5]octane-1-carboxamide (<b>70</b>)</h3><div class="NLM_p last">PdCl<sub>2</sub>(DTBPF) (27 mg, 0.041 mmol) was added to a mixture of <b>64a</b> (128 mg, 0.427 mmol), <b>69</b> (250 mg, 0.418 mmol), and K<sub>3</sub>PO<sub>4</sub> (266 mg, 1.255 mmol) in THF (3 mL) and water (0.3 mL) at rt under a nitrogen atmosphere. The mixture was stirred at 70 °C for 2 h and cooled down to rt. Water (15 mL) was added, and the aqueous layer was extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography eluting with MeOH in DCM from 0 to 10% to give <b>70</b> as a brown oil (250 mg, 86%). LCMS (ESI) calcd for C<sub>39</sub>H<sub>59</sub>N<sub>5</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 690.4, found: 690.4.</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> (<i>R</i>)-<i>N</i>-((<i>S</i>)-6-(2-Ethyl-1,3-dioxolan-2-yl)-1-(oxazol-2-yl) hexyl)-2-methylpropane-2-sulfinamide (<b>71</b>)</h3><div class="NLM_p last">BH<sub>3</sub>·THF (1.0 <i>M</i>, 1.8 mL, 1.800 mmol) was added to a solution of oxazole (148 mg, 2.142 mmol) in THF (5 mL), and the mixture was stirred at rt for 1 h under N<sub>2</sub> before it was cooled to −78 °C. <i>n</i>-BuLi (2.5 M in hexane, 0.7 mL, 1.750 mmol) was added. The mixture was stirred at −78 °C for 1 h. (<i>R</i>,<i>E</i>)-<i>N</i>-(6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene)-2-methylpropane-2-sulfinamide (500 mg, 1.648 mmol) in THF (1 mL) was added dropwise, and the mixture was stirred at −78 °C for 2 h. Saturated aqueous NH<sub>4</sub>Cl (0.2 mL) was added, and the aqueous layer was extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography eluting with MeOH in DCM from 0 to 10% to give <b>71</b> as a yellow oil (326 mg, 53%). LCMS (ESI) calcd for C<sub>18</sub>H<sub>32</sub>N<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: 373.2, found: 373.1.</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Preparation of (<i>R</i>)-<i>N</i>-((<i>S</i>)-1-(5-Bromooxazol-2-yl)-6-(2-ethyl-1,3-dioxolan-2-yl)hexyl)-2-methylpropane-2-sulfinamide (<b>72</b>)</h3><div class="NLM_p last"><i>t</i>-BuLi (1.3 M in hexane, 3.3 mL, 4.29 mmol) was added to a solution of <b>71</b> (400 mg, 1.074 mmol) in THF (4 mL) at −78 °C, and the mixture was stirred at −78 °C for 1 h under N<sub>2</sub>. CBr<sub>4</sub> (1068 mg, 3.22 mmol) in THF (0.5 mL) was added slowly, and the mixture was stirred at −78 °C for 1 h. Saturated aqueous NH<sub>4</sub>Cl (2 mL) was added, and the mixture was extracted with DCM (6 mL × 3). The combined organic layers were washed with brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography eluting with EtOAc in petroleum ether from 50 to 100% to give <b>72</b> as a brown oil (246 mg, 51%). LCMS (ESI) calcd for C<sub>18</sub>H<sub>31</sub>BrN<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup>: 451.1, found: 453.1.</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (<i>S</i>)-9-Amino-9-(5-bromooxazol-2-yl)nonan-3-one (<b>73</b>)</h3><div class="NLM_p last">HCl (4 M in MeOH, 0.1 mL, 0.4 mmol) was added to a solution of <b>72</b> (91 mg, 0.202 mmol) in MeOH (1 mL), and the mixture was stirred at rt for 5 min. Saturated aqueous NaHCO<sub>3</sub> (1 mL) was added, and the mixture was extracted with ethyl acetate (3 mL × 3). The combined organic layers were washed with brine (2 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>73</b> as a yellow oil (60 mg, 98%), which was used without further purification. LCMS (ESI) calcd for C<sub>12</sub>H<sub>19</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 303.1, found: 303.0.</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(5-Bromooxazol-2-yl)-7-oxononyl)-6-methyl-6-azaspiro[2.5]octane-1-carboxamide (<b>74</b>)</h3><div class="NLM_p last">Et<sub>3</sub>N (1.026 mL, 7.36 mmol) was added to a solution of <b>73</b> (500 mg, 1.472 mmol) in DMF (1 mL); then, this solution was added to <b>60a</b> (299 mg, 1.766 mmol) in DMF (1 mL). Then, T<sub>3</sub>P (1405 mg, 2.208 mmol) was added. The mixture was stirred at rt for 16 h and diluted with DCM (15 mL). It was washed with brine (15 mL × 3), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel column chromatography eluting with MeOH in DCM from 0 to 10% to give <b>74</b> as a light-yellow oil (500 mg, 1.076 mmol, 73.1%). LCMS (ESI) calcd for C<sub>21</sub>H<sub>32</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 454.2, found: 456.2, 470.2, <i>R<sub>t</sub></i> = 0.977 min.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02150" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02150?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02150</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Schemes S1–S11 for the synthesis of compounds <b>11</b>, <b>23</b>, <b>26</b>, <b>28</b>, <b>29</b>, <b>36</b>, <b>39</b>, <b>43</b>, <b>45</b>, <b>53</b>, and <b>56</b>; <sup>1</sup>H NMR spectra of compounds <b>3–56</b>; and <sup>13</sup>C NMR and LCMS spectra of compounds <b>31</b> and <b>48</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf">jm0c02150_si_001.pdf (3.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_002.csv">jm0c02150_si_002.csv (6.64 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02150" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wensheng Yu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#89feece7fae1ece7eea7f0fcc9e4ecfbeae2a7eae6e4"><span class="__cf_email__" data-cfemail="ee998b809d868b8089c0979bae838b9c8d85c08d8183">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Liu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dane Clausen</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Younong Yu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph L. Duffy</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Wang</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shouning Xu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin Deng</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takao Suzuki</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 288 Fute Zhong
Road, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine C. Chung</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert W. Myers</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel J. Klein</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James I. Fells</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Katharine Holloway</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Wu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guoxin Wu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bonnie J. Howell</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard J. O. Barnard</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 770 Sumneytown
Pike, West Point, Pennsylvania 19486, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Kozlowski</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co. Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are either current employees of Merck & Co., Inc. or employed at Merck & Co., Inc. during this work except S. X.; L.D.; and S.T. who are employees of a CRO company.<br /></br></div></li></ul></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22265" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22265" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This paper was published ASAP on April 2, 2021, with an error in the name of one author. The corrected version was reposted on April 6, 2021.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BPD</td><td class="NLM_def"><p class="first last">bis(pinacolato)diboron</p></td></tr><tr><td class="NLM_term"><i>c</i>-Pr</td><td class="NLM_def"><p class="first last">cyclopropyl</p></td></tr><tr><td class="NLM_term"><i>c</i>-Bu</td><td class="NLM_def"><p class="first last">cyclobutyl</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase (HDAC)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 28 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>Source: <a href="https://www.unaids.org/en/resources/fact-sheet" class="extLink">https://www.unaids.org/en/resources/fact-sheet</a> accessed at February 19th, <span class="NLM_year">2021</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Source%3A+https%3A%2F%2Fwww.unaids.org%2Fen%2Fresources%2Ffact-sheet+accessed+at+February+19th%2C+2021."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano-Sarabia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Prospects for treatment of latent HIV</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fclpt.2012.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=23212106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=46-56&author=K.+Bartonauthor=B.+Burchauthor=N.+Soriano-Sarabiaauthor=D.+M.+Margolis&title=Prospects+for+treatment+of+latent+HIV&doi=10.1038%2Fclpt.2012.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for Treatment of Latent HIV</span></div><div class="casAuthors">Barton, K. M.; Burch, B. D.; Soriano-Sarabia, N.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection.  However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely.  Currently, the soln. to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding no. of people infected worldwide.  ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability.  Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection.  Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART.  This review will discuss these strategies in detail and their potential for clin. development.  Clin. Pharmacol. & Therapeutics (2013); 93 1, 46-56. doi:10.1038/clpt.2012.202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzlcZDCjSkvLVg90H21EOLACvtfcHk0lgSH2SnHR3LXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP&md5=72364092e1bcf5634cd21be17a47786e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.202%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%26aulast%3DBurch%26aufirst%3DB.%26aulast%3DSoriano-Sarabia%26aufirst%3DN.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DProspects%2520for%2520treatment%2520of%2520latent%2520HIV%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fclpt.2012.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruc, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span> <span> </span><span class="NLM_article-title">Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiv218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1093%2Finfdis%2Fjiv218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=25877550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12ls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=1361-1365&author=A.+M.+Crooksauthor=R.+Batesonauthor=A.+B.+Copeauthor=N.+P.+Dahlauthor=M.+K.+Griggsauthor=J.+D.+Kurucauthor=C.+L.+Gayauthor=J.+J.+Eronauthor=D.+M.+Margolisauthor=R.+J.+Boschauthor=N.+M.+Archin&title=Precise+quantitation+of+the+latent+HIV-1+reservoir%3A+implications+for+eradication+strategies&doi=10.1093%2Finfdis%2Fjiv218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies</span></div><div class="casAuthors">Crooks, Amanda M.; Bateson, Rosalie; Cope, Anna B.; Dahl, Noelle P.; Griggs, Morgan K.; Kuruc, JoAnn D.; Gay, Cynthia L.; Eron, Joseph J.; Margolis, David M.; Bosch, Ronald J.; Archin, Nancie M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1361-1365</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The quant. viral outgrowth assay (QVOA) provides a precise minimal est. of the reservoir of resting CD4 T-cell infection (resting cell infection [RCI]).  However, the variability of RCI over time during antiretroviral therapy (ART), relevant to assess potential effects of latency-reversing agents or other interventions, has not been fully described.  We performed QVOA on resting CD4 T cells obtained via leukapheresis from 37 human immunodeficiency virus (HIV)-infected patients receiving stable suppressive ART for a period of 6 years.  Patients who started ART during acute (n = 17) or chronic (n = 20) HIV infection were studied once HIV RNA levels were <50 copies/mL for ≥6 mo.  Using random effects anal. of 160 RCI measurements, we found that RCI declined significantly over time (P < .001), with an estd. mean half-life of 3.6 years (95% confidence interval, 2.3-8.1 years), remarkably consistent with findings of prior studies.  There was no evidence of more rapid decay in acute vs. chronic HIV infection (P = .99) for patients suppressed ≥6 mo.  RCI was reliably estd. with longitudinal measurements generally showing <2-fold variation from the previous measure.  When QVOA is performed in this format, RCI decreases of >6-fold were rare.  We suggest that a 6-fold decline is a relevant threshold to reliably identify effects of antilatency interventions on RCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa8EBUam6ebVg90H21EOLACvtfcHk0lgSH2SnHR3LXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12ls7s%253D&md5=f6b7b69dd0b966ec157117200ede8bf3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiv218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiv218%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DA.%2BM.%26aulast%3DBateson%26aufirst%3DR.%26aulast%3DCope%26aufirst%3DA.%2BB.%26aulast%3DDahl%26aufirst%3DN.%2BP.%26aulast%3DGriggs%26aufirst%3DM.%2BK.%26aulast%3DKuruc%26aufirst%3DJ.%2BD.%26aulast%3DGay%26aufirst%3DC.%2BL.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26atitle%3DPrecise%2520quantitation%2520of%2520the%2520latent%2520HIV-1%2520reservoir%253A%2520implications%2520for%2520eradication%2520strategies%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D212%26spage%3D1361%26epage%3D1365%26doi%3D10.1093%2Finfdis%2Fjiv218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajdas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolick, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gange, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span> <span> </span><span class="NLM_article-title">Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1038/nm880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fnm880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=12754504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=727-728&author=J.+D.+Silicianoauthor=J.+Kajdasauthor=D.+Finziauthor=T.+C.+Quinnauthor=K.+Chadwickauthor=J.+B.+Margolickauthor=C.+Kovacsauthor=S.+J.+Gangeauthor=R.+F.+Siliciano&title=Long-term+follow-up+studies+confirm+the+stability+of+the+latent+reservoir+for+HIV-1+in+resting+CD4%2B+T+cells&doi=10.1038%2Fnm880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells</span></div><div class="casAuthors">Siliciano, Janet D.; Kajdas, Joleen; Finzi, Diana; Quinn, Thomas C.; Chadwick, Karen; Margolick, Joseph B.; Kovacs, Colin; Gange, Stephen J.; Siliciano, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-728</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Latent HIV-1 persists in resting memory CD4+ T cells, even in patients receiving highly active antiretroviral therapy (HAART).  It has been unclear how stable this latent reservoir is and whether its persistence reflects replenishment by low-level viremia.  Here we show that even in treated patients who have had no detectable viremia for as long as 7 yr, the reservoir decays so slowly (t1/2 = 44 mo) that eradication is unlikely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzVUrIkxch7Vg90H21EOLACvtfcHk0lgrha8GIpifzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7k%253D&md5=c5f963cda784002f8282d3aa3b2c67a3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm880%26sid%3Dliteratum%253Aachs%26aulast%3DSiliciano%26aufirst%3DJ.%2BD.%26aulast%3DKajdas%26aufirst%3DJ.%26aulast%3DFinzi%26aufirst%3DD.%26aulast%3DQuinn%26aufirst%3DT.%2BC.%26aulast%3DChadwick%26aufirst%3DK.%26aulast%3DMargolick%26aufirst%3DJ.%2BB.%26aulast%3DKovacs%26aufirst%3DC.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26atitle%3DLong-term%2520follow-up%2520studies%2520confirm%2520the%2520stability%2520of%2520the%2520latent%2520reservoir%2520for%2520HIV-1%2520in%2520resting%2520CD4%252B%2520T%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D727%26epage%3D728%26doi%3D10.1038%2Fnm880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S.</span></span> <span> </span><span class="NLM_article-title">“Shock and Kill”</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/487439a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2F487439a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=22836995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=439-440&author=S.+Deeks&title=%E2%80%9CShock+and+Kill%E2%80%9D&doi=10.1038%2F487439a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HIV Shock and kill</span></div><div class="casAuthors">Deeks, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">439-440</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antiretroviral therapies block HIV replication but they do not eliminate inactive viruses within cells.  A clin. trial shows that a drug can revive HIV in patients as a potential first step towards a cure.  See Letter p.482.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxs7bBcsLhO7Vg90H21EOLACvtfcHk0lgrha8GIpifzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtb%252FK&md5=1b87dca65bc344cb41d50738dd0b61ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F487439a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F487439a%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DS.%26atitle%3D%25E2%2580%259CShock%2520and%2520Kill%25E2%2580%259D%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D439%26epage%3D440%26doi%3D10.1038%2F487439a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darcis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessche, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lint, G. V.</span></span> <span> </span><span class="NLM_article-title">HIV latency: should we shock or lock</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.it.2016.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.it.2016.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=28073694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGhsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=217-228&author=G.+Darcisauthor=B.+V.+Driesscheauthor=G.+V.+Lint&title=HIV+latency%3A+should+we+shock+or+lock&doi=10.1016%2Fj.it.2016.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HIV Latency: Should We Shock or Lock?</span></div><div class="casAuthors">Darcis, Gilles; Van Driessche, Benoit; Van Lint, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-228</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combinatory antiretroviral therapy (cART) increases the survival and quality of life of HIV-1-infected patients.  However, interruption of therapy almost invariably leads to the re-emergence of detectable viral replication because HIV-1 persists in viral latent reservoirs.  Improved understanding of the mol. mechanisms involved in HIV-1 latency has paved the way for innovative strategies that attempt to purge latent virus.  In this article we discuss the results of the broadly explored 'shock and kill' strategy, and also highlight the major hurdles facing this approach.  Finally, we present recent innovative works suggesting that locking out latent proviruses could be a potential alternative therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7DyUCQiaq7Vg90H21EOLACvtfcHk0lgrha8GIpifzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGhsbnN&md5=31e923de60c14747b913fd9d370013f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DDarcis%26aufirst%3DG.%26aulast%3DDriessche%26aufirst%3DB.%2BV.%26aulast%3DLint%26aufirst%3DG.%2BV.%26atitle%3DHIV%2520latency%253A%2520should%2520we%2520shock%2520or%2520lock%26jtitle%3DTrends%2520Immunol.%26date%3D2017%26volume%3D38%26spage%3D217%26epage%3D228%26doi%3D10.1016%2Fj.it.2016.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunstein, M.</span></span> <span> </span><span class="NLM_article-title">Histone acetylation in chromatin structure and transcription</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1038/38664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2F38664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=9311776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=349-352&author=M.+Grunstein&title=Histone+acetylation+in+chromatin+structure+and+transcription&doi=10.1038%2F38664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetylation in chromatin structure and transcription</span></div><div class="casAuthors">Grunstein, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6649</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 75 refs.  The amino termini of histones extend from the nucleosomal core and are modified by acetyltransferase and deacetylases during the cell cycle.  These acetylation patterns may direct histone assembly and help regulate the unfolding and activity of genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv2Ds8rzh-rVg90H21EOLACvtfcHk0lgrha8GIpifzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D&md5=cdd287ff2d87e9c89944366b71aaf6d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F38664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F38664%26sid%3Dliteratum%253Aachs%26aulast%3DGrunstein%26aufirst%3DM.%26atitle%3DHistone%2520acetylation%2520in%2520chromatin%2520structure%2520and%2520transcription%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D349%26epage%3D352%26doi%3D10.1038%2F38664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pazin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadonaga, J. T.</span></span> <span> </span><span class="NLM_article-title">What’s up and down with histone deacetylation and transcription?</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80211-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS0092-8674%2800%2980211-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=9150131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK2sXjtFWisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=325-328&author=M.+J.+Pazinauthor=J.+T.+Kadonaga&title=What%E2%80%99s+up+and+down+with+histone+deacetylation+and+transcription%3F&doi=10.1016%2FS0092-8674%2800%2980211-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">What's up and down with histone deacetylation and transcription?</span></div><div class="casAuthors">Pazin, Michael J.; Kadonaga, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-328</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 20 refs., discussing sequence-specific transcriptional repressors that can recruit deacetylases to promoters, core histone deacetylation in relation to transcriptional repression, protein acetylation and regulation of transcription, and deacetylases involved in transcriptional activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtKwEWNsDbLLVg90H21EOLACvtfcHk0lhwI3uYfI_sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtFWisLY%253D&md5=e6752279cff1afa2efbd95e586da3455</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980211-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980211-1%26sid%3Dliteratum%253Aachs%26aulast%3DPazin%26aufirst%3DM.%2BJ.%26aulast%3DKadonaga%26aufirst%3DJ.%2BT.%26atitle%3DWhat%25E2%2580%2599s%2520up%2520and%2520down%2520with%2520histone%2520deacetylation%2520and%2520transcription%253F%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D325%26epage%3D328%26doi%3D10.1016%2FS0092-8674%2800%2980211-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span> <span> </span><span class="NLM_article-title">HDAC expression and clinical prognosis in human malignancies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.10.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.canlet.2008.10.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=19103471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=168-176&author=W.+Weichert&title=HDAC+expression+and+clinical+prognosis+in+human+malignancies&doi=10.1016%2Fj.canlet.2008.10.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC expression and clinical prognosis in human malignancies</span></div><div class="casAuthors">Weichert, Wilko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases are known to play a central role in the regulation of several cellular properties intimately interlinked with the development and progression of cancer.  Consequently, a multitude of histone deacetylase (HDAC) inhibitors have been developed and are currently tested as anticancer agents in a variety of solid and hematol. malignancies.  However, only recently research began to focus on the actual expression patterns of specific HDAC isoforms in neoplasias.  The majority of studies investigating this issue reported an enhanced expression of class I HDAC isoforms in solid human tumors, both on mRNA and protein level, when compared to the resp. tissue of origin.  In most studies, class I HDAC expression was high in locally advanced, dedifferentiated, strongly proliferating tumors.  In some but not all entities elevated class I HDAC expression was assocd. with compromised patient prognosis, however, an assocn. of elevated class I HDAC expression with improved prognosis has also be reported for selected tumor entities.  In contrast to class I isoforms, expression of class II HDACs has been found reduced in tumors and high expression of these isoforms in some entities predicted better patient outcome.  Since all of these data point to a potential biol. role of differences in HDAC expression in human tumors, future translational studies will focus on the question, whether HDAC expression patterns are predictive for response to treatment with histone deacetylase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox6AkybidOQbVg90H21EOLACvtfcHk0lhwI3uYfI_sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt70%253D&md5=cae20e78c0567e745f764d7aaaf1eeaf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.10.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.10.047%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26atitle%3DHDAC%2520expression%2520and%2520clinical%2520prognosis%2520in%2520human%2520malignancies%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.canlet.2008.10.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span> <span> </span><span class="NLM_article-title">Clinical use and applications of histone deacetylase inhibitors in multiple myeloma</span>. <i>Clin. Pharmacol.: Adv. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.2147/cpaa.s94021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.2147%2Fcpaa.s94021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=27226735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=35-44&author=S.+Kumarauthor=N.+Tandonauthor=V.+Ramakrishnan&title=Clinical+use+and+applications+of+histone+deacetylase+inhibitors+in+multiple+myeloma&doi=10.2147%2Fcpaa.s94021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use and applications of histone deacetylase inhibitors in multiple myeloma</span></div><div class="casAuthors">Tandon, Nidhi; Ramakrishnan, Vijay; Kumar, Shaji K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology: Advances and Applications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CPAAGX</span>;
        ISSN:<span class="NLM_cas:issn">1179-1438</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade.  Despite these advances, resistance to therapy leads to eventual relapse and fatal outcomes in the vast majority of patients.  Hence, there is an unmet need for new safe and efficacious therapies for continued improvement in outcomes.  Given the role of epigenetic aberrations in the pathogenesis and progression of MM and the success of histone deacetylase inhibitors (HDACi) in other malignancies, many HDACi have been tried in MM.  Various preclin. studies helped us to understand the antimyeloma activity of different HDACi in MM as a single agent or in combination with conventional, novel, and immune therapies.  The early clin. trials of HDACi depicted only modest single-agent activity, but recent studies have revealed encouraging clin. response rates in combination with other antimyeloma agents, esp. proteasome inhibitors.  This led to the approval of the combination of panobinostat and bortezomib for the treatment of relapsed/refractory MM patients with two prior lines of treatment by the US Food and Drug Administration.  However, it remains yet to be defined how we can incorporate HDACi in the current therapeutic paradigms for MM that will help to achieve longer disease control and significant survival benefits.  In addn., isoform-selective and/or class-selective HDAC inhibition to reduce unfavorable side effects needs further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQBrcNeZHgx7Vg90H21EOLACvtfcHk0lhwI3uYfI_sPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlertro%253D&md5=c5ad697e90297b2a2397737098dde73c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2Fcpaa.s94021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fcpaa.s94021%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTandon%26aufirst%3DN.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DClinical%2520use%2520and%2520applications%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520multiple%2520myeloma%26jtitle%3DClin.%2520Pharmacol.%253A%2520Adv.%2520Appl.%26date%3D2016%26volume%3D8%26spage%3D35%26epage%3D44%26doi%3D10.2147%2Fcpaa.s94021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberty, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruc, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strain, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1038/nature11286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fnature11286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=22837004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=482-485&author=N.+M.+Archinauthor=A.+L.+Libertyauthor=A.+D.+Kashubaauthor=S.+K.+Choudharyauthor=J.+D.+Kurucauthor=A.+M.+Crooksauthor=D.+C.+Parkerauthor=E.+M.+Andersonauthor=M.+F.+Kearneyauthor=M.+C.+Strainauthor=D.+D.+Richmanauthor=M.+G.+Hudgensauthor=R.+J.+Boschauthor=J.+M.+Coffinauthor=J.+J.+Eronauthor=D.+J.+Hazudaauthor=D.+M.+Margolis&title=Administration+of+vorinostat+disrupts+HIV-1+latency+in+patients+on+antiretroviral+therapy&doi=10.1038%2Fnature11286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy</span></div><div class="casAuthors">Archin, N. M.; Liberty, A. L.; Kashuba, A. D.; Choudhary, S. K.; Kuruc, J. D.; Crooks, A. M.; Parker, D. C.; Anderson, E. M.; Kearney, M. F.; Strain, M. C.; Richman, D. D.; Hudgens, M. G.; Bosch, R. J.; Coffin, J. M.; Eron, J. J.; Hazuda, D. J.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">482-485</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection.  Inducing the expression of latent genomes within resting CD4+ T cells is the primary strategy to clear this reservoir.  Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro, the utility of this approach has never been directly proven in a translational clin. study of HIV-infected patients.  Here we isolated the circulating resting CD4+ T cells of patients in whom viremia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir.  In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4+ cells (mean increase, 4.8-fold).  This demonstrates that a mol. mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK97t6JvwKNrVg90H21EOLACvtfcHk0limv6D3IE_o4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtrfP&md5=bfe1b9c441d7eeda40d46897a9801311</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature11286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11286%26sid%3Dliteratum%253Aachs%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DLiberty%26aufirst%3DA.%2BL.%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26aulast%3DChoudhary%26aufirst%3DS.%2BK.%26aulast%3DKuruc%26aufirst%3DJ.%2BD.%26aulast%3DCrooks%26aufirst%3DA.%2BM.%26aulast%3DParker%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DE.%2BM.%26aulast%3DKearney%26aufirst%3DM.%2BF.%26aulast%3DStrain%26aufirst%3DM.%2BC.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26aulast%3DHudgens%26aufirst%3DM.%2BG.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DCoffin%26aufirst%3DJ.%2BM.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DAdministration%2520of%2520vorinostat%2520disrupts%2520HIV-1%2520latency%2520in%2520patients%2520on%2520antiretroviral%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D482%26epage%3D485%26doi%3D10.1038%2Fnature11286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erikstrup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichterfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogaard, O. S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group clinical trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e13</span>– <span class="NLM_lpage">e21</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(14)70014-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS2352-3018%2814%2970014-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=26423811" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=e13-e21&author=T.+A.+Rasmussenauthor=M.+Tolstrupauthor=C.+R.+Brinkmannauthor=R.+Olesenauthor=C.+Erikstrupauthor=A.+Solomonauthor=A.+Winckelmannauthor=S.+Palmerauthor=C.+Dinarelloauthor=M.+Buzonauthor=M.+Lichterfeldauthor=S.+R.+Lewinauthor=L.+Ostergaardauthor=O.+S.+Sogaard&title=Panobinostat%2C+a+histone+deacetylase+inhibitor%2C+for+latent-virus+reactivation+in+HIV-infected+patients+on+suppressive+antiretroviral+therapy%3A+a+phase+1%2F2%2C+single+group+clinical+trial&doi=10.1016%2FS2352-3018%2814%2970014-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2814%2970014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252814%252970014-1%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DC.%2BR.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DErikstrup%26aufirst%3DC.%26aulast%3DSolomon%26aufirst%3DA.%26aulast%3DWinckelmann%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%26aulast%3DBuzon%26aufirst%3DM.%26aulast%3DLichterfeld%26aufirst%3DM.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26aulast%3DOstergaard%26aufirst%3DL.%26aulast%3DSogaard%26aufirst%3DO.%2BS.%26atitle%3DPanobinostat%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520for%2520latent-virus%2520reactivation%2520in%2520HIV-infected%2520patients%2520on%2520suppressive%2520antiretroviral%2520therapy%253A%2520a%2520phase%25201%252F2%252C%2520single%2520group%2520clinical%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2014%26volume%3D1%26spage%3De13%26epage%3De21%26doi%3D10.1016%2FS2352-3018%2814%2970014-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graversen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleimann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Cunningham, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantaleo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogsgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomont, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span> <span> </span><span class="NLM_article-title">The depsipeptide romidepsin reverses HIV-1 latency in vivo</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1005142</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1005142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1371%2Fjournal.ppat.1005142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=26379282" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=O.+S.+S%C3%B8gaardauthor=M.+E.+Graversenauthor=S.+Lethauthor=R.+Olesenauthor=C.+R.+Brinkmannauthor=S.+K.+Nissenauthor=A.+S.+Kjaerauthor=M.+H.+Schleimannauthor=P.+W.+Dentonauthor=W.+J.+Hey-Cunninghamauthor=K.+K.+Koelschauthor=G.+Pantaleoauthor=K.+Krogsgaardauthor=M.+Sommerfeltauthor=R.+Fromentinauthor=N.+Chomontauthor=T.+A.+Rasmussenauthor=L.+Astergaardauthor=M.+Tolstrup&title=The+depsipeptide+romidepsin+reverses+HIV-1+latency+in+vivo&doi=10.1371%2Fjournal.ppat.1005142"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005142%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B8gaard%26aufirst%3DO.%2BS.%26aulast%3DGraversen%26aufirst%3DM.%2BE.%26aulast%3DLeth%26aufirst%3DS.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DBrinkmann%26aufirst%3DC.%2BR.%26aulast%3DNissen%26aufirst%3DS.%2BK.%26aulast%3DKjaer%26aufirst%3DA.%2BS.%26aulast%3DSchleimann%26aufirst%3DM.%2BH.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DHey-Cunningham%26aufirst%3DW.%2BJ.%26aulast%3DKoelsch%26aufirst%3DK.%2BK.%26aulast%3DPantaleo%26aufirst%3DG.%26aulast%3DKrogsgaard%26aufirst%3DK.%26aulast%3DSommerfelt%26aufirst%3DM.%26aulast%3DFromentin%26aufirst%3DR.%26aulast%3DChomont%26aufirst%3DN.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DAstergaard%26aufirst%3DL.%26aulast%3DTolstrup%26aufirst%3DM.%26atitle%3DThe%2520depsipeptide%2520romidepsin%2520reverses%2520HIV-1%2520latency%2520in%2520vivo%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1005142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano-Sarabia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Prospects for treatment of latent HIV</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fclpt.2012.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=23212106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=46-56&author=K.+Bartonauthor=B.+Burchauthor=N.+Soriano-Sarabiaauthor=D.+M.+Margolis&title=Prospects+for+treatment+of+latent+HIV&doi=10.1038%2Fclpt.2012.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for Treatment of Latent HIV</span></div><div class="casAuthors">Barton, K. M.; Burch, B. D.; Soriano-Sarabia, N.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection.  However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely.  Currently, the soln. to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding no. of people infected worldwide.  ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability.  Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection.  Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART.  This review will discuss these strategies in detail and their potential for clin. development.  Clin. Pharmacol. & Therapeutics (2013); 93 1, 46-56. doi:10.1038/clpt.2012.202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzlcZDCjSkvLVg90H21EOLACvtfcHk0lgokRtMVY4dqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP&md5=72364092e1bcf5634cd21be17a47786e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.202%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%26aulast%3DBurch%26aufirst%3DB.%26aulast%3DSoriano-Sarabia%26aufirst%3DN.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DProspects%2520for%2520treatment%2520of%2520latent%2520HIV%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fclpt.2012.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleimann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Højen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graversen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjær, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mørk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfelt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogsgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, S. O.</span></span> <span> </span><span class="NLM_article-title">Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e463</span>– <span class="NLM_lpage">e472</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(16)30055-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS2352-3018%2816%2930055-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=27658863" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e463-e472&author=S.+Lethauthor=H.+M.+Schleimannauthor=K.+S.+Nissenauthor=F.+J.+H%C3%B8jenauthor=R.+Olesenauthor=E.+M.+Graversenauthor=S.+J%C3%B8rgensenauthor=S.+A.+Kj%C3%A6rauthor=W.+P.+Dentonauthor=A.+M%C3%B8rkauthor=A.+M.+Sommerfeltauthor=K.+Krogsgaardauthor=L.+%C3%98stergaardauthor=A.+T.+Rasmussenauthor=M.+Tolstrupauthor=S.+O.+S%C3%B8gaard&title=Combined+effect+of+Vacc-4x%2C+recombinant+human+granulocyte+macrophage+colony-stimulating+factor+vaccination%2C+and+romidepsin+on+the+HIV-1+reservoir+%28REDUC%29%3A+a+single-arm%2C+phase+1B%2F2A+trial&doi=10.1016%2FS2352-3018%2816%2930055-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2816%2930055-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252816%252930055-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeth%26aufirst%3DS.%26aulast%3DSchleimann%26aufirst%3DH.%2BM.%26aulast%3DNissen%26aufirst%3DK.%2BS.%26aulast%3DH%25C3%25B8jen%26aufirst%3DF.%2BJ.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DGraversen%26aufirst%3DE.%2BM.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DS.%26aulast%3DKj%25C3%25A6r%26aufirst%3DS.%2BA.%26aulast%3DDenton%26aufirst%3DW.%2BP.%26aulast%3DM%25C3%25B8rk%26aufirst%3DA.%26aulast%3DSommerfelt%26aufirst%3DA.%2BM.%26aulast%3DKrogsgaard%26aufirst%3DK.%26aulast%3D%25C3%2598stergaard%26aufirst%3DL.%26aulast%3DRasmussen%26aufirst%3DA.%2BT.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DS%25C3%25B8gaard%26aufirst%3DS.%2BO.%26atitle%3DCombined%2520effect%2520of%2520Vacc-4x%252C%2520recombinant%2520human%2520granulocyte%2520macrophage%2520colony-stimulating%2520factor%2520vaccination%252C%2520and%2520romidepsin%2520on%2520the%2520HIV-1%2520reservoir%2520%2528REDUC%2529%253A%2520a%2520single-arm%252C%2520phase%25201B%252F2A%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2016%26volume%3D3%26spage%3De463%26epage%3De472%26doi%3D10.1016%2FS2352-3018%2816%2930055-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stöhr, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorrell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loes, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopycinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frater, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)32990-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS0140-6736%2819%2932990-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32085823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsValt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=888-898&author=S.+Fidlerauthor=W.+St%C3%B6hrauthor=M.+Paceauthor=L.+Dorrellauthor=A.+Leverauthor=S.+Pettauthor=K.+S.+Loesauthor=J.+Foxauthor=A.+Clarkeauthor=M.+Nelsonauthor=J.+Thornhillauthor=M.+Khanauthor=A.+Funauthor=M.+Bandaraauthor=D.+Kellyauthor=J.+Kopycinskiauthor=T.+Hankeauthor=H.+Yangauthor=R.+Bennettauthor=M.+Johnsonauthor=B.+Howellauthor=R.+Barnardauthor=G.+Wuauthor=S.+Kayeauthor=M.+Willsauthor=A.+Babikerauthor=J.+Frater&title=Antiretroviral+therapy+alone+versus+antiretroviral+therapy+with+a+kick+and+kill+approach%2C+on+measures+of+the+HIV+reservoir+in+participants+with+recent+HIV+infection+%28the+RIVER+trial%29%3A+a+phase+2%2C+randomised+trial&doi=10.1016%2FS0140-6736%2819%2932990-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial</span></div><div class="casAuthors">Fidler, Sarah; Stohr, Wolfgang; Pace, Matt; Dorrell, Lucy; Lever, Andrew; Pett, Sarah; Kinloch-de Loes, Sabine; Fox, Julie; Clarke, Amanda; Nelson, Mark; Thornhill, John; Khan, Maryam; Fun, Axel; Bandara, Mikaila; Kelly, Damian; Kopycinski, Jakub; Hanke, Tomas; Yang, Hongbing; Bennett, Rachel; Johnson, Margaret; Howell, Bonnie; Barnard, Richard; Wu, Guoxin; Kaye, Steve; Wills, Mark; Babiker, Abdel; Frater, John</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10227</span>),
    <span class="NLM_cas:pages">888-898</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells.  Approaches that force HIV transcription from these cells, making them susceptible to killing-termed kick and kill regimens-have been explored as a strategy towards an HIV cure.  RIVER is the first randomised trial to det. the effect of ART-only vs. ART plus kick and kill on markers of the HIV reservoir.  This phase 2, open-label, multicentre, randomised, controlled trial was undertaken at six clin. sites in the UK.  Patients aged 18-60 years who were confirmed as HIV-pos. within a max. of the past 6 mo and started ART within 1 mo from confirmed diagnosis were randomly assigned by a computer generated randomisation list to receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and replication-deficient viral vector T-cell inducing vaccines encoding conserved HIV sequences ChAdV63.  HIVconsv-prime and MVA.  HIVconsv-boost (the kill; ART + V + V; intervention).  The primary endpoint was total HIV DNA isolated from peripheral blood CD4+ T-cells at weeks 16 and 18 after randomisation.  Anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, NCT02336074.  Between June 14, 2015 and Jul 11, 2017, 60 men with HIV were randomly assigned to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants completed the study, with no loss-to-follow-up.  Mean total HIV DNA at weeks 16 and 18 after randomisation was 3·02 log10 copies HIV DNA per 106 CD4+ T-cells in the ART-only group vs. 3·06 log10 copies HIV DNA per 106 CD4+ T-cells in ART + V + V group, with no statistically significant difference between the two groups (mean difference of 0·04 log10 copies HIV DNA per 106 CD4+ T-cells [95% CI -0·03 to 0·11; p=0·26]).  There were no intervention-related serious adverse events.  This kick and kill approach conferred no significant benefit compared with ART alone on measures of the HIV reservoir.  Although this does not disprove the efficacy kick and kill strategy, for future trials enhancement of both kick and kill agents will be required.  Medical Research Council (MR/L00528X/1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2dUe5cxGGWbVg90H21EOLACvtfcHk0liJA1U8mbLQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsValt7s%253D&md5=f8a9a837b92ca51b0e1f676a2d109bf9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2932990-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252932990-3%26sid%3Dliteratum%253Aachs%26aulast%3DFidler%26aufirst%3DS.%26aulast%3DSt%25C3%25B6hr%26aufirst%3DW.%26aulast%3DPace%26aufirst%3DM.%26aulast%3DDorrell%26aufirst%3DL.%26aulast%3DLever%26aufirst%3DA.%26aulast%3DPett%26aufirst%3DS.%26aulast%3DLoes%26aufirst%3DK.%2BS.%26aulast%3DFox%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DThornhill%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DFun%26aufirst%3DA.%26aulast%3DBandara%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DD.%26aulast%3DKopycinski%26aufirst%3DJ.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DBennett%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DHowell%26aufirst%3DB.%26aulast%3DBarnard%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DWills%26aufirst%3DM.%26aulast%3DBabiker%26aufirst%3DA.%26aulast%3DFrater%26aufirst%3DJ.%26atitle%3DAntiretroviral%2520therapy%2520alone%2520versus%2520antiretroviral%2520therapy%2520with%2520a%2520kick%2520and%2520kill%2520approach%252C%2520on%2520measures%2520of%2520the%2520HIV%2520reservoir%2520in%2520participants%2520with%2520recent%2520HIV%2520infection%2520%2528the%2520RIVER%2520trial%2529%253A%2520a%2520phase%25202%252C%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D888%26epage%3D898%26doi%3D10.1016%2FS0140-6736%2819%2932990-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marx-Blümel, L.</span>; <span class="NLM_string-name">Marx, C.</span>; <span class="NLM_string-name">Kühne, M.</span>; <span class="NLM_string-name">Sonnemann, J.</span></span> <span> </span><span class="NLM_article-title">Assessment of HDACi-induced cytotoxicity</span>. In  <i>Methods in Molecular Biology</i>; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">1510</span>, pp  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">45</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=23-45&author=L.+Marx-Bl%C3%BCmel&author=C.+Marx&author=M.+K%C3%BChne&author=J.+Sonnemann&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMarx-Bl%25C3%25BCmel%26aufirst%3DL.%26atitle%3DAssessment%2520of%2520HDACi-induced%2520cytotoxicity%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26pub%3DHumana%2520Press%26date%3D2017%26volume%3D1510%26spage%3D23%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llauger-Bufi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3453</span>– <span class="NLM_lpage">3456</span>, <span class="refDoi"> DOI: 10.1021/jm9004303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFWnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3453-3456&author=O.+Kinzelauthor=L.+Llauger-Bufiauthor=G.+Pescatoreauthor=M.+Rowleyauthor=C.+Schultz-Fademrechtauthor=E.+Monteagudoauthor=M.+Fonsiauthor=O.+G.+Pazauthor=F.+Fioreauthor=C.+Steink%C3%BChlerauthor=P.+Jones&title=Discovery+of+a+potent+class+I+selective+ketone+histone+deacetylase+inhibitor+with+antitumor+activity+in+vivo+and+optimized+pharmacokinetic+properties&doi=10.1021%2Fjm9004303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties</span></div><div class="casAuthors">Kinzel, Olaf; Llauger-Bufi, Laura; Pescatore, Giovanna; Rowley, Michael; Schultz-Fademrecht, Carsten; Monteagudo, Edith; Fonsi, Massimiliano; Gonzalez Paz, Odalys; Fiore, Fabrizio; Steinkuhler, Christian; Jones, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3453-3456</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of a potent, class I selective ketone HDAC inhibitor is shown.  It possesses optimized pharmacokinetic properties in preclin. species, has a clean off-target profile, and is neg. in a microbial mutagenicity (Ames) test.  In a mouse xenograft model it shows efficacy comparable to that of vorinostat at a 10-fold reduced dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHRRFS9TSYV7Vg90H21EOLACvtfcHk0liJA1U8mbLQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFWnsb0%253D&md5=8674adc0c3892942a1fc7b154cbc84b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm9004303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004303%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DLlauger-Bufi%26aufirst%3DL.%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DPaz%26aufirst%3DO.%2BG.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520class%2520I%2520selective%2520ketone%2520histone%2520deacetylase%2520inhibitor%2520with%2520antitumor%2520activity%2520in%2520vivo%2520and%2520optimized%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3453%26epage%3D3456%26doi%3D10.1021%2Fjm9004303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hokello, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">12291</span>– <span class="NLM_lpage">12303</span>, <span class="refDoi"> DOI: 10.1128/JVI.01383-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.01383-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=18829756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVymsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=12291-12303&author=R.+Pearsonauthor=Y.+K.+Kimauthor=J.+Hokelloauthor=K.+Lassenauthor=J.+Friedmanauthor=M.+Tyagiauthor=J.+Karn&title=Epigenetic+silencing+of+human+immunodeficiency+virus+%28HIV%29+transcription+by+formation+of+restrictive+chromatin+structures+at+the+viral+long+terminal+repeat+drives+the+progressive+entry+of+HIV+into+latency&doi=10.1128%2FJVI.01383-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency</span></div><div class="casAuthors">Pearson, Richard; Kim, Young Kyeung; Hokello, Joseph; Lassen, Kara; Friedman, Julia; Tyagi, Mudit; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12291-12303</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mol. mechanisms utilized by human immunodeficiency virus (HIV) to enter latency are poorly understood.  Following the infection of Jurkat T cells with lentiviral vectors that express Tat in cis, gene expression is progressively silenced.  Silencing is greatly enhanced when the lentiviral vectors carry an attenuated Tat gene with the H13L mutation.  Individual clones of lentivirus-infected cells showed a wide range of shutdown rates, with the majority showing a 50% silencing frequency between 30 to 80 days.  The silenced clones characteristically contained a small fraction (0 to 15%) of activated cells that continued to express d2EGFP.  When d2EGFP+ and d2EGFP- cell populations were isolated from the shutdown clones, they quickly reverted to the original distribution of inactive and active cells, suggesting that the d2EGFP+ cells arise from stochastic fluctuations in gene expression.  The detailed anal. of transcription initiation and elongation using chromatin immunopptn. (ChIP) assays confirms that Tat levels are restricted in the latently infected cells but gradually rise during proviral reactivation.  ChIP assays using clones of latently infected cells demonstrate that the latent proviruses carry high levels of deacetylated histones and trimethylated histones.  In contrast, the cellular genes IκBα and GAPDH had high levels of acetylated histones and no trimethylated histones.  The levels of trimethylated histone H3 and HP1-α assocd. with HIV proviruses fell rapidly after tumor necrosis factor alpha activation.  The progressive shutdown of HIV transcription following infection suggests that epigenetic mechanisms targeting chromatin structures selectively restrict HIV transcription initiation.  This decreases Tat prodn. below the levels that are required to sustain HIV gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf55wxe7XgyLVg90H21EOLACvtfcHk0lhgKqfUBFqGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVymsL%252FF&md5=e0d4a987dc7cf23512097146d83fb551</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FJVI.01383-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01383-08%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DY.%2BK.%26aulast%3DHokello%26aufirst%3DJ.%26aulast%3DLassen%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DTyagi%26aufirst%3DM.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEpigenetic%2520silencing%2520of%2520human%2520immunodeficiency%2520virus%2520%2528HIV%2529%2520transcription%2520by%2520formation%2520of%2520restrictive%2520chromatin%2520structures%2520at%2520the%2520viral%2520long%2520terminal%2520repeat%2520drives%2520the%2520progressive%2520entry%2520of%2520HIV%2520into%2520latency%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D12291%26epage%3D12303%26doi%3D10.1128%2FJVI.01383-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">6425</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1128/JVI.01519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.01519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=20410271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVehtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=6425-37&author=M.+Tyagiauthor=R.+J.+Pearsonauthor=J.+Karn&title=Establishment+of+HIV+latency+in+primary+CD4%2B+cells+is+due+to+epigenetic+transcriptional+silencing+and+P-TEFb+restriction&doi=10.1128%2FJVI.01519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction</span></div><div class="casAuthors">Tyagi, Mudit; Pearson, Richard John; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6425-6437</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The development of suitable exptl. systems for studying HIV latency in primary cells that permit detailed biochem. analyses and the screening of drugs is a crit. step in the effort to develop viral eradication strategies.  Primary CD4+ T cells were isolated from peripheral blood and amplified by antibodies to the T-cell receptor (TCR).  The cells were then infected by lentiviral vectors carrying fluorescent reporters and either the wild-type Tat gene or the attenuated H13L Tat gene.  After sorting for the pos. cells and reamplification, the infected cells were allowed to spontaneously enter latency by long-term cultivation on the H80 feeder cell line in the absence of TCR stimulation.  By 6 wk almost all of the cells lost fluorescent protein marker expression; however, more than 95% of these latently infected cells could be reactivated after stimulation of the TCR by α-CD3/CD28 antibodies.  Chromatin immunopptn. assays showed that, analogously to Jurkat T cells, latent proviruses in primary CD4+ T cells are enriched in heterochromatic markers, including high levels of CBF-1, histone deacetylases, and methylated histones.  Upon TCR activation, there was recruitment of NF-κB to the promoter and conversion of heterochromatin structures present on the latent provirus to active euchromatin structures contg. acetylated histones.  Surprisingly, latently infected primary cells cannot be induced by tumor necrosis factor alpha because of a restriction in P-TEFb levels, which can be overcome by activation of the TCR.  Thus, a combination of restrictive chromatin structures at the HIV long terminal repeat and limiting P-TEFb levels contribute to transcriptional silencing leading to latency in primary CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3awVy2TqQSbVg90H21EOLACvtfcHk0lhgKqfUBFqGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVehtbs%253D&md5=705996c4ce33a8615dbd38692496ddef</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.01519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01519-09%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DM.%26aulast%3DPearson%26aufirst%3DR.%2BJ.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEstablishment%2520of%2520HIV%2520latency%2520in%2520primary%2520CD4%252B%2520cells%2520is%2520due%2520to%2520epigenetic%2520transcriptional%2520silencing%2520and%2520P-TEFb%2520restriction%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D6425%26epage%3D37%26doi%3D10.1128%2FJVI.01519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9089</span>, <span class="refDoi"> DOI: 10.1128/JVI.00836-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.00836-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=21715480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=9078-9089&author=J.+Friedmanauthor=W.-K.+Choauthor=C.+K.+Chuauthor=K.+S.+Keedyauthor=N.+M.+Archinauthor=D.+M.+Margolisauthor=J.+Karn&title=Epigenetic+silencing+of+HIV-1+by+the+histone+H3+lysine+27+methyltransferase+enhancer+of+zeste+2&doi=10.1128%2FJVI.00836-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2</span></div><div class="casAuthors">Friedman, Julia; Cho, Won-Kyung; Chu, Chung K.; Keedy, Kara S.; Archin, Nancie M.; Margolis, David M.; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9078-9089</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Latent HIV proviruses are silenced as the result of deacetylation and methylation of histones located at the viral long terminal repeat (LTR).  Inhibition of histone deacetylases (HDACs) leads to the reemergence of HIV-1 from latency, but the contribution of histone lysine methyltransferases (HKMTs) to maintaining HIV latency remains uncertain.  Chromatin immunopptn. expts. using latently infected Jurkat T-cell lines demonstrated that the HKMT enhancer of Zeste 2 (EZH2) was present at high levels at the LTR of silenced HIV proviruses and was rapidly displaced following proviral reactivation.  Knockdown of EZH2, a key component of the Polycomb repressive complex 2 (PRC2) silencing machinery, and the enzyme which is required for tri-Me histone lysine 27 (H3K27me3) synthesis induced up to 40% of the latent HIV proviruses.  In contrast, there was less than 5% induction of latent proviruses following knockdown of SUV39H1, which is required for H3K9me3 synthesis.  Knockdown of EZH2 also sensitized latent proviruses to external stimuli, such as T-cell receptor stimulation, and slowed the reversion of reactivated proviruses to latency.  Similarly, cell populations that responded poorly to external stimuli carried HIV proviruses that were enriched in H3K27me3 and relatively depleted in H3K9me3.  Treating latently infected cells with the HKMT inhibitor 3-deazaneplanocin A, which targets EZH2, led to the reactivation of silenced proviruses, whereas chaetocin and BIX01294 showed only minimal reactivation activities.  These findings suggest that PRC2-mediated silencing is an important feature of HIV latency and that inhibitors of histone methylation may play a useful role in induction strategies designed to eradicate latent HIV pools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNJWzxW8Sf7Vg90H21EOLACvtfcHk0lhgKqfUBFqGXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKqtbbE&md5=a1236af4f0fe8a4dfb1857e4d884a5da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FJVI.00836-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00836-11%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DW.-K.%26aulast%3DChu%26aufirst%3DC.%2BK.%26aulast%3DKeedy%26aufirst%3DK.%2BS.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEpigenetic%2520silencing%2520of%2520HIV-1%2520by%2520the%2520histone%2520H3%2520lysine%252027%2520methyltransferase%2520enhancer%2520of%2520zeste%25202%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D9078%26epage%3D9089%26doi%3D10.1128%2FJVI.00836-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolkenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of ethyl ketone-based HDAC-1,2,3 selective inhibitors for HIV latency reactivation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127197</span>– <span class="NLM_lpage">127204</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.bmcl.2020.127197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32331932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127197-127204&author=W.+Yuauthor=J.+Liuauthor=Y.+Yuauthor=V.+Zhangauthor=C.+Clausenauthor=J.+Kellyauthor=S.+Wolkenbergauthor=D.+Beshoreauthor=J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Discovery+of+ethyl+ketone-based+HDAC-1%2C2%2C3+selective+inhibitors+for+HIV+latency+reactivation&doi=10.1016%2Fj.bmcl.2020.127197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation</span></div><div class="casAuthors">Yu, Wensheng; Liu, Jian; Yu, Younong; Zhang, Vivian; Clausen, Dane; Kelly, Joseph; Wolkenberg, Scott; Beshore, Douglas; Duffy, Joseph L.; Chang, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">127197</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of Et ketone based HDACs 1, 2, and 3 selective inhibitors have been identified with good enzymic and cellular activity and high selectivity over HDACs 6 and 8.  These inhibitors contain a spirobicyclic group in the amide region.  Compd. 13 stands out as a lead due to its good potency, high selectivity, and reasonable rat and dog PK.  Compds. 33 and 34 show good potency and rat PK profiles as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRDknBquRfbVg90H21EOLACvtfcHk0lhZcMTnTCFP3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D&md5=d0fb2e00f70938578cebc54129de8ce9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127197%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DClausen%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DWolkenberg%26aufirst%3DS.%26aulast%3DBeshore%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520ethyl%2520ketone-based%2520HDAC-1%252C2%252C3%2520selective%2520inhibitors%2520for%2520HIV%2520latency%2520reactivation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127197%26epage%3D127204%26doi%3D10.1016%2Fj.bmcl.2020.127197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span> <span> </span><span class="NLM_article-title">Role of hERG potassium channel assays in drug development</span>. <i>Channels</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.4161/chan.2.2.6004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.4161%2Fchan.2.2.6004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=18849661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=87-93&author=B.+Priestauthor=M.+I.+Bellauthor=M.+Garcia&title=Role+of+hERG+potassium+channel+assays+in+drug+development&doi=10.4161%2Fchan.2.2.6004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hERG potassium channel assays in drug development</span></div><div class="casAuthors">Priest Birgit T; Bell Ian M; Garcia Maria L</div><div class="citationInfo"><span class="NLM_cas:title">Channels (Austin, Tex.)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Numerous structurally and functionally unrelated drugs block the hERG potassium channel.  HERG channels are involved in cardiac action potential repolarization, and reduced function of hERG lengthens ventricular action potentials, prolongs the QT interval in an electrocardiogram, and increases the risk for potentially fatal ventricular arrhythmias.  In order to reduce the risk of investing resources in a drug candidate that fails preclinical safety studies because of QT prolongation, it is important to screen compounds for activity on hERG channels early in the lead optimization process.  A number of hERG assays are available, ranging from high throughput binding assays on stably expressed recombinant channels to very time consuming electrophysiological examinations in cardiac myocytes.  Depending on the number of compounds to be tested, binding assays or functional assays measuring membrane potential or Rb(+) flux, combined with electrophysiology on a few compounds, can be used to efficiently develop the structure-function relationship of hERG interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiaz7NnHSp2-98rul4nhSdfW6udTcc2eZbDkCFgY9Jw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFWmsg%253D%253D&md5=a848fd2107a9af7ebac875a32bc08486</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4161%2Fchan.2.2.6004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fchan.2.2.6004%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%26aulast%3DBell%26aufirst%3DM.%2BI.%26aulast%3DGarcia%26aufirst%3DM.%26atitle%3DRole%2520of%2520hERG%2520potassium%2520channel%2520assays%2520in%2520drug%2520development%26jtitle%3DChannels%26date%3D2008%26volume%3D2%26spage%3D87%26epage%3D93%26doi%3D10.4161%2Fchan.2.2.6004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newhard, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassaday, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadroni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R.</span></span> <span> </span><span class="NLM_article-title">In vitro pharmacokinetic/pharmacodynamic modeling of HIV latency reversal by novel HDAC inhibitors using an automated platform</span>. <i>SLAS Discovery</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="NLM_elocation-id">247255522098381</span> <span class="refDoi"> DOI: 10.1177/2472555220983810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1177%2F2472555220983810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=W.+Newhardauthor=M.+Patelauthor=J.+Cassadayauthor=J.+Ballardauthor=B.+Squadroniauthor=G.+Wuauthor=J.+Liuauthor=W.+Yuauthor=J.+Kozlowskiauthor=P.+Zuckauthor=B.+Howellauthor=D.+Hazudaauthor=R.+Vargoauthor=R.+Barnard&title=In+vitro+pharmacokinetic%2Fpharmacodynamic+modeling+of+HIV+latency+reversal+by+novel+HDAC+inhibitors+using+an+automated+platform&doi=10.1177%2F2472555220983810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F2472555220983810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555220983810%26sid%3Dliteratum%253Aachs%26aulast%3DNewhard%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DCassaday%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DSquadroni%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DHowell%26aufirst%3DB.%26aulast%3DHazuda%26aufirst%3DD.%26aulast%3DVargo%26aufirst%3DR.%26aulast%3DBarnard%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520of%2520HIV%2520latency%2520reversal%2520by%2520novel%2520HDAC%2520inhibitors%2520using%2520an%2520automated%2520platform%26jtitle%3DSLAS%2520Discovery%26date%3D2021%26doi%3D10.1177%2F2472555220983810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span>; <span class="NLM_string-name">Clausen, D. J.</span>; <span class="NLM_string-name">Yu, W.</span>; <span class="NLM_string-name">Kelly, J. M.</span>; <span class="NLM_string-name">Kim, H. M.</span>; <span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of imidazole derivatives as inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection</span>. PCT Int. Appl. <span class="NLM_patent">WO2020028150</span><span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+Liu&author=D.+J.+Clausen&author=W.+Yu&author=J.+M.+Kelly&author=H.+M.+Kim&author=J.+A.+Kozlowski&title=Preparation+of+imidazole+derivatives+as+inhibitors+of+histone+deacetylase+useful+for+the+treatment+or+prevention+of+HIV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520imidazole%2520derivatives%2520as%2520inhibitors%2520of%2520histone%2520deacetylase%2520useful%2520for%2520the%2520treatment%2520or%2520prevention%2520of%2520HIV%2520infection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127367</span>– <span class="NLM_lpage">127373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.bmcl.2020.127367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32738976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127367-127373&author=D.+J.+Clausenauthor=J.+Liuauthor=W.+Yuauthor=J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Development+of+a+selective+HDAC+inhibitor+aimed+at+reactivating+the+HIV+latent+reservoir&doi=10.1016%2Fj.bmcl.2020.127367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir</span></div><div class="casAuthors">Clausen, Dane J.; Liu, Jian; Yu, Wensheng; Duffy, Joseph L.; Chung, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">127367</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and SAR development of a trisubstituted imidazole HDAC inhibitor is described.  The compds. were synthesized with high diastereocontrol by leveraging Ellman sulfinyl imine chem.  Structural elucidation provided insight into binding mode and supported design rational.  Pharmacokinetic properties of lead compds. were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxEq8rSKpQLVg90H21EOLACvtfcHk0lja66imkoZlqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisrbP&md5=bb8221389e55066bd312eaeb11abb019</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127367%26sid%3Dliteratum%253Aachs%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520selective%2520HDAC%2520inhibitor%2520aimed%2520at%2520reactivating%2520the%2520HIV%2520latent%2520reservoir%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127367%26epage%3D127373%26doi%3D10.1016%2Fj.bmcl.2020.127367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J. O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, A. J.</span></span> <span> </span><span class="NLM_article-title">Selective class I HDAC inhibitors based on aryl ketone zinc binding induce HIV-1 protein for clearance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WmsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1476-1483&author=J.+Liuauthor=J.+Kellyauthor=W.+Yuauthor=D.+J.+Clausenauthor=Y.+Yuauthor=H.+Kimauthor=L.+J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=S.+Carrollauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=J.+O.+R.+Barnardauthor=A.+J.+Kozlowski&title=Selective+class+I+HDAC+inhibitors+based+on+aryl+ketone+zinc+binding+induce+HIV-1+protein+for+clearance&doi=10.1021%2Facsmedchemlett.0c00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance</span></div><div class="casAuthors">Liu, Jian; Kelly, Joseph; Yu, Wensheng; Clausen, Dane; Yu, Younong; Kim, Hyunjin; Duffy, Joseph L.; Chung, Christine C.; Myers, Robert W.; Carroll, Steve; Klein, Daniel J.; Fells, James; Holloway, M. Katharine; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1476-1483</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV persistence in latently infected, resting CD4+ T cells is broadly considered a barrier to eradicate HIV.  Activation of the provirus using latency-reversing agents (LRAs) followed by immune-mediated clearance to purge reservoirs has been touted as a promising therapeutic approach.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) control the acetylation level of lysine residues in histones to regulate the gene transcription.  Several clin. HDAC inhibitors had been examd. as LRAs, which induced HIV activation in vitro and in vivo.  Here we report the discovery of a series of selective and potent class I HDAC inhibitors based on aryl ketones as a zinc binding group, which reversed HIV latency using a Jurkat model of HIV latency in 2C4 cells.  The SAR led to the discovery of a highly selective class I HDAC inhibitor 10(I) with excellent potency.  HDACi 10 induces the HIV gag P24 protein in patient latent CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDghJJZQUEyLVg90H21EOLACvtfcHk0lja66imkoZlqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WmsrrL&md5=b0b1ae6c4d5a06eb9f74ab59fcb46a8e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00302%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DL.%2BJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DJ.%2BO.%2BR.%26aulast%3DKozlowski%26aufirst%3DA.%2BJ.%26atitle%3DSelective%2520class%2520I%2520HDAC%2520inhibitors%2520based%2520on%2520aryl%2520ketone%2520zinc%2520binding%2520induce%2520HIV-1%2520protein%2520for%2520clearance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1476%26epage%3D1483%26doi%3D10.1021%2Facsmedchemlett.0c00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, C. M.</span></span> <span> </span><span class="NLM_article-title">Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K<sup>+</sup> channel</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1161/01.RES.78.3.499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1161%2F01.RES.78.3.499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=8593709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK28XhtlWrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1996&pages=499-503&author=P.+S.+Spectorauthor=E.+M.+Curranauthor=T.+M.+Keatingauthor=C.+M.+Sanguinetti&title=Class+III+antiarrhythmic+drugs+block+HERG%2C+a+human+cardiac+delayed+rectifier+K%2B+channel&doi=10.1161%2F01.RES.78.3.499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel: open-channel block by methanesulfonanilides</span></div><div class="casAuthors">Spector, Peter S.; Curran, Mark E.; Keating, Mark T.; Sanguinetti, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The authors recently reported that mutations in HERG, a potassium channel gene, cause long QT syndrome.  Heterologous expression of HERG in Xenopus oocytes revealed that this channel had biophys. properties nearly identical to a cardiac delayed rectifier K+ current, IKr, but had dissimilar pharmacol. properties.  Class III antiarrhythmic drugs such as E-4031 and MK-499 are potent and specific blockers of IKr in cardiac myocytes.  The authors initial studies indicated that these compds. did not block HERG at a concn. of 1 μmol/L.  In the present study, the authors used std. two-microelectrode voltage-clamp techniques to further characterize the effects of these drugs on HERG channels expressed in oocytes.  Consistent with initial findings, 1 μmol/L MK-499 and E-4031 had no effect on HERG when oocytes were voltage clamped at a neg. potential and not pulsed during equilibration with the drug.  However, MK-499 did block HERG current if oocytes were repetitively pulsed, or clamped at a voltage pos. to the threshold potential for channel activation.  This finding is in contrast to previous studies that showed significant block of IKr in isolated myocytes by similar drugs, even in the absence of pulsing.  This apparent discrepancy may be due to differences in channel characteristics (HERG vs. guinea pig and mouse IKr), tissue (oocytes vs. myocytes), or specific drugs.  Under steady state conditions, block of HERG by MK-499 was half maximal at 123 nmol/L at a test potential of -20 mV.  MK-499 (150 nmol/L) did not affect the voltage dependence of activation and rectification nor the kinetics of activation and rectification nor the kinetics of activation and deactivation of HERG.  These data indicate that MK-499 preferentially blocks open HERG channels and further support the conclusion that HERG subunits form Ikr channels in cardiac myocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohpugjsvh4TrVg90H21EOLACvtfcHk0lill0_kbIva2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtlWrt7Y%253D&md5=34d25ece3016497241f378e0c3839735</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1161%2F01.RES.78.3.499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.78.3.499%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DP.%2BS.%26aulast%3DCurran%26aufirst%3DE.%2BM.%26aulast%3DKeating%26aufirst%3DT.%2BM.%26aulast%3DSanguinetti%26aufirst%3DC.%2BM.%26atitle%3DClass%2520III%2520antiarrhythmic%2520drugs%2520block%2520HERG%252C%2520a%2520human%2520cardiac%2520delayed%2520rectifier%2520K%252B%2520channel%26jtitle%3DCirc.%2520Res.%26date%3D1996%26volume%3D78%26spage%3D499%26epage%3D503%26doi%3D10.1161%2F01.RES.78.3.499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">James  Fells</span>, <span class="hlFld-ContribAuthor ">Dane  Clausen</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Klein</span>, <span class="hlFld-ContribAuthor ">C.  Christine Chung</span>, <span class="hlFld-ContribAuthor ">Robert W.  Myers</span>, <span class="hlFld-ContribAuthor ">Jin  Wu</span>, <span class="hlFld-ContribAuthor ">Guoxin  Wu</span>, <span class="hlFld-ContribAuthor ">Bonnie J.  Howell</span>, <span class="hlFld-ContribAuthor ">Richard J.O.  Barnard</span>, <span class="hlFld-ContribAuthor ">Joseph  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128168. <a href="https://doi.org/10.1016/j.bmcl.2021.128168" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128168%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bmacrocyclic%252BHDACs%252B1%25252C%252B2%25252C%252Band%252B3%252Bselective%252Binhibitors%252Bfor%252BHIV%252Blatency%252Breactivation%26aulast%3DYu%26aufirst%3DWensheng%26date%3D2021%26volume%3D47%26spage%3D128168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HDAC inhibitors <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of the X-ray structures of <b>2</b> (purple) and <b>22</b> (yellow) in the crystal of HDAC 2. Access codes for X-ray coordinates in RCSB Protein Data Bank (PDB) database are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ">6WBZ</a> (<b>2</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JS8">7JS8</a> (<b>22</b>). The authors will release the atomic coordinates upon article publication.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>60a</b> and <b>60b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) trifluoroacetic acid (TFA), dichloromethane (DCM), 25 °C, 4 h; (ii) <b>59a</b>: formaldehyde, MeOH, 25 °C, 2 h, then NaBH(AcO)<sub>3</sub>, 1 h, 99% for two steps; <b>59b</b>: acetaldehyde, MeOH, 30 °C, 32 h, then NaBH(AcO)<sub>3</sub>, 30 °C, 16 h, 91% for two steps; (iii) <b>60a</b>: H<sub>2</sub> (15 psi), Pd/C (10%), MeOH, 24 °C, 1.5 h, 96%; <b>60b</b>: H<sub>2</sub> (15 psi), Pd/C (10%), MeOH, 18 °C, 2 h, 99%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Intermediate <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HCl, water, 110 °C, 2 h, 54%; (ii) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf), KOAc, 1,4-dioxane, 80 °C, 12 h, 71%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compound <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi (2 equiv), THF, −78 °C, 10 min; H<sub>2</sub>O (1 equiv), −78 to −50 °C, 1 h; −78 °C, Br<sub>2</sub> (1.1 equiv), 30 min, 29%; (ii) <i>n</i>-BuLi, THF, −78 °C, then (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide, 54%; (iii) HCl, 25 °C, 8 h, 72%; (iv) <b>60b</b>, HATU, Et<sub>3</sub>N, DMF, 25 °C, 2 h; (v) <b>69</b>, <b>64</b>, PdCl<sub>2</sub>(DTBPF), K<sub>3</sub>PO<sub>4,</sub> THF, 70 °C, 2 h, 86%; (vi) TFA, rt, 2 h, 96%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/medium/jm0c02150_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compound <b>48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.0c02150/20210415/images/large/jm0c02150_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02150&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, BH<sub>3</sub>·THF, (<i>R</i>)-<i>N</i>-[(1<i>E</i>)-6-(2-ethyl-1,3-dioxolan-2-yl)hexylidene]-2-methylpropane-2-sulfinamide, THF, −78 °C, 53%; (ii) <i>t</i>-BuLi, CBr<sub>4</sub>, THF, −78 °C, 51%, (iii) HCl, MeOH, 98%; (iv) <b>60a</b>, HATU, Et<sub>3</sub>N, DMF, 25 °C, 2 h; (v) <b>74</b>, <b>64</b>, PdCl<sub>2</sub>(DTBPF), K<sub>3</sub>PO<sub>4,</sub> THF, 70 °C, 2 h, 46%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i95">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 28 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>Source: <a href="https://www.unaids.org/en/resources/fact-sheet" class="extLink">https://www.unaids.org/en/resources/fact-sheet</a> accessed at February 19th, <span class="NLM_year">2021</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Source%3A+https%3A%2F%2Fwww.unaids.org%2Fen%2Fresources%2Ffact-sheet+accessed+at+February+19th%2C+2021."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano-Sarabia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Prospects for treatment of latent HIV</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fclpt.2012.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=23212106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=46-56&author=K.+Bartonauthor=B.+Burchauthor=N.+Soriano-Sarabiaauthor=D.+M.+Margolis&title=Prospects+for+treatment+of+latent+HIV&doi=10.1038%2Fclpt.2012.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for Treatment of Latent HIV</span></div><div class="casAuthors">Barton, K. M.; Burch, B. D.; Soriano-Sarabia, N.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection.  However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely.  Currently, the soln. to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding no. of people infected worldwide.  ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability.  Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection.  Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART.  This review will discuss these strategies in detail and their potential for clin. development.  Clin. Pharmacol. & Therapeutics (2013); 93 1, 46-56. doi:10.1038/clpt.2012.202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzlcZDCjSkvLVg90H21EOLACvtfcHk0li0V021RmzUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP&md5=72364092e1bcf5634cd21be17a47786e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.202%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%26aulast%3DBurch%26aufirst%3DB.%26aulast%3DSoriano-Sarabia%26aufirst%3DN.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DProspects%2520for%2520treatment%2520of%2520latent%2520HIV%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fclpt.2012.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cope, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griggs, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruc, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span> <span> </span><span class="NLM_article-title">Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">1361</span>– <span class="NLM_lpage">1365</span>, <span class="refDoi"> DOI: 10.1093/infdis/jiv218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1093%2Finfdis%2Fjiv218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=25877550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12ls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2015&pages=1361-1365&author=A.+M.+Crooksauthor=R.+Batesonauthor=A.+B.+Copeauthor=N.+P.+Dahlauthor=M.+K.+Griggsauthor=J.+D.+Kurucauthor=C.+L.+Gayauthor=J.+J.+Eronauthor=D.+M.+Margolisauthor=R.+J.+Boschauthor=N.+M.+Archin&title=Precise+quantitation+of+the+latent+HIV-1+reservoir%3A+implications+for+eradication+strategies&doi=10.1093%2Finfdis%2Fjiv218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies</span></div><div class="casAuthors">Crooks, Amanda M.; Bateson, Rosalie; Cope, Anna B.; Dahl, Noelle P.; Griggs, Morgan K.; Kuruc, JoAnn D.; Gay, Cynthia L.; Eron, Joseph J.; Margolis, David M.; Bosch, Ronald J.; Archin, Nancie M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1361-1365</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The quant. viral outgrowth assay (QVOA) provides a precise minimal est. of the reservoir of resting CD4 T-cell infection (resting cell infection [RCI]).  However, the variability of RCI over time during antiretroviral therapy (ART), relevant to assess potential effects of latency-reversing agents or other interventions, has not been fully described.  We performed QVOA on resting CD4 T cells obtained via leukapheresis from 37 human immunodeficiency virus (HIV)-infected patients receiving stable suppressive ART for a period of 6 years.  Patients who started ART during acute (n = 17) or chronic (n = 20) HIV infection were studied once HIV RNA levels were <50 copies/mL for ≥6 mo.  Using random effects anal. of 160 RCI measurements, we found that RCI declined significantly over time (P < .001), with an estd. mean half-life of 3.6 years (95% confidence interval, 2.3-8.1 years), remarkably consistent with findings of prior studies.  There was no evidence of more rapid decay in acute vs. chronic HIV infection (P = .99) for patients suppressed ≥6 mo.  RCI was reliably estd. with longitudinal measurements generally showing <2-fold variation from the previous measure.  When QVOA is performed in this format, RCI decreases of >6-fold were rare.  We suggest that a 6-fold decline is a relevant threshold to reliably identify effects of antilatency interventions on RCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraa8EBUam6ebVg90H21EOLACvtfcHk0liPbR0rkiZaCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12ls7s%253D&md5=f6b7b69dd0b966ec157117200ede8bf3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiv218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiv218%26sid%3Dliteratum%253Aachs%26aulast%3DCrooks%26aufirst%3DA.%2BM.%26aulast%3DBateson%26aufirst%3DR.%26aulast%3DCope%26aufirst%3DA.%2BB.%26aulast%3DDahl%26aufirst%3DN.%2BP.%26aulast%3DGriggs%26aufirst%3DM.%2BK.%26aulast%3DKuruc%26aufirst%3DJ.%2BD.%26aulast%3DGay%26aufirst%3DC.%2BL.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26atitle%3DPrecise%2520quantitation%2520of%2520the%2520latent%2520HIV-1%2520reservoir%253A%2520implications%2520for%2520eradication%2520strategies%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D212%26spage%3D1361%26epage%3D1365%26doi%3D10.1093%2Finfdis%2Fjiv218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajdas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadwick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolick, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gange, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span> <span> </span><span class="NLM_article-title">Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1038/nm880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fnm880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=12754504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=727-728&author=J.+D.+Silicianoauthor=J.+Kajdasauthor=D.+Finziauthor=T.+C.+Quinnauthor=K.+Chadwickauthor=J.+B.+Margolickauthor=C.+Kovacsauthor=S.+J.+Gangeauthor=R.+F.+Siliciano&title=Long-term+follow-up+studies+confirm+the+stability+of+the+latent+reservoir+for+HIV-1+in+resting+CD4%2B+T+cells&doi=10.1038%2Fnm880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells</span></div><div class="casAuthors">Siliciano, Janet D.; Kajdas, Joleen; Finzi, Diana; Quinn, Thomas C.; Chadwick, Karen; Margolick, Joseph B.; Kovacs, Colin; Gange, Stephen J.; Siliciano, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">727-728</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Latent HIV-1 persists in resting memory CD4+ T cells, even in patients receiving highly active antiretroviral therapy (HAART).  It has been unclear how stable this latent reservoir is and whether its persistence reflects replenishment by low-level viremia.  Here we show that even in treated patients who have had no detectable viremia for as long as 7 yr, the reservoir decays so slowly (t1/2 = 44 mo) that eradication is unlikely.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZzVUrIkxch7Vg90H21EOLACvtfcHk0liPbR0rkiZaCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFOnu7k%253D&md5=c5f963cda784002f8282d3aa3b2c67a3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm880%26sid%3Dliteratum%253Aachs%26aulast%3DSiliciano%26aufirst%3DJ.%2BD.%26aulast%3DKajdas%26aufirst%3DJ.%26aulast%3DFinzi%26aufirst%3DD.%26aulast%3DQuinn%26aufirst%3DT.%2BC.%26aulast%3DChadwick%26aufirst%3DK.%26aulast%3DMargolick%26aufirst%3DJ.%2BB.%26aulast%3DKovacs%26aufirst%3DC.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26atitle%3DLong-term%2520follow-up%2520studies%2520confirm%2520the%2520stability%2520of%2520the%2520latent%2520reservoir%2520for%2520HIV-1%2520in%2520resting%2520CD4%252B%2520T%2520cells%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D727%26epage%3D728%26doi%3D10.1038%2Fnm880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S.</span></span> <span> </span><span class="NLM_article-title">“Shock and Kill”</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1038/487439a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2F487439a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=22836995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=439-440&author=S.+Deeks&title=%E2%80%9CShock+and+Kill%E2%80%9D&doi=10.1038%2F487439a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HIV Shock and kill</span></div><div class="casAuthors">Deeks, Steven G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">439-440</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antiretroviral therapies block HIV replication but they do not eliminate inactive viruses within cells.  A clin. trial shows that a drug can revive HIV in patients as a potential first step towards a cure.  See Letter p.482.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxs7bBcsLhO7Vg90H21EOLACvtfcHk0liPbR0rkiZaCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtb%252FK&md5=1b87dca65bc344cb41d50738dd0b61ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F487439a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F487439a%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DS.%26atitle%3D%25E2%2580%259CShock%2520and%2520Kill%25E2%2580%259D%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D439%26epage%3D440%26doi%3D10.1038%2F487439a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darcis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessche, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lint, G. V.</span></span> <span> </span><span class="NLM_article-title">HIV latency: should we shock or lock</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.it.2016.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.it.2016.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=28073694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGhsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=217-228&author=G.+Darcisauthor=B.+V.+Driesscheauthor=G.+V.+Lint&title=HIV+latency%3A+should+we+shock+or+lock&doi=10.1016%2Fj.it.2016.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">HIV Latency: Should We Shock or Lock?</span></div><div class="casAuthors">Darcis, Gilles; Van Driessche, Benoit; Van Lint, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-228</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combinatory antiretroviral therapy (cART) increases the survival and quality of life of HIV-1-infected patients.  However, interruption of therapy almost invariably leads to the re-emergence of detectable viral replication because HIV-1 persists in viral latent reservoirs.  Improved understanding of the mol. mechanisms involved in HIV-1 latency has paved the way for innovative strategies that attempt to purge latent virus.  In this article we discuss the results of the broadly explored 'shock and kill' strategy, and also highlight the major hurdles facing this approach.  Finally, we present recent innovative works suggesting that locking out latent proviruses could be a potential alternative therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7DyUCQiaq7Vg90H21EOLACvtfcHk0lj-HWEa9DZ9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGhsbnN&md5=31e923de60c14747b913fd9d370013f7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DDarcis%26aufirst%3DG.%26aulast%3DDriessche%26aufirst%3DB.%2BV.%26aulast%3DLint%26aufirst%3DG.%2BV.%26atitle%3DHIV%2520latency%253A%2520should%2520we%2520shock%2520or%2520lock%26jtitle%3DTrends%2520Immunol.%26date%3D2017%26volume%3D38%26spage%3D217%26epage%3D228%26doi%3D10.1016%2Fj.it.2016.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunstein, M.</span></span> <span> </span><span class="NLM_article-title">Histone acetylation in chromatin structure and transcription</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1038/38664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2F38664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=9311776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=349-352&author=M.+Grunstein&title=Histone+acetylation+in+chromatin+structure+and+transcription&doi=10.1038%2F38664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Histone acetylation in chromatin structure and transcription</span></div><div class="casAuthors">Grunstein, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6649</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A review with 75 refs.  The amino termini of histones extend from the nucleosomal core and are modified by acetyltransferase and deacetylases during the cell cycle.  These acetylation patterns may direct histone assembly and help regulate the unfolding and activity of genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodv2Ds8rzh-rVg90H21EOLACvtfcHk0lj-HWEa9DZ9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmsVWntLk%253D&md5=cdd287ff2d87e9c89944366b71aaf6d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F38664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F38664%26sid%3Dliteratum%253Aachs%26aulast%3DGrunstein%26aufirst%3DM.%26atitle%3DHistone%2520acetylation%2520in%2520chromatin%2520structure%2520and%2520transcription%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D349%26epage%3D352%26doi%3D10.1038%2F38664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pazin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadonaga, J. T.</span></span> <span> </span><span class="NLM_article-title">What’s up and down with histone deacetylation and transcription?</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80211-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS0092-8674%2800%2980211-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=9150131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK2sXjtFWisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=325-328&author=M.+J.+Pazinauthor=J.+T.+Kadonaga&title=What%E2%80%99s+up+and+down+with+histone+deacetylation+and+transcription%3F&doi=10.1016%2FS0092-8674%2800%2980211-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">What's up and down with histone deacetylation and transcription?</span></div><div class="casAuthors">Pazin, Michael J.; Kadonaga, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-328</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 20 refs., discussing sequence-specific transcriptional repressors that can recruit deacetylases to promoters, core histone deacetylation in relation to transcriptional repression, protein acetylation and regulation of transcription, and deacetylases involved in transcriptional activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtKwEWNsDbLLVg90H21EOLACvtfcHk0lj-HWEa9DZ9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtFWisLY%253D&md5=e6752279cff1afa2efbd95e586da3455</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980211-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980211-1%26sid%3Dliteratum%253Aachs%26aulast%3DPazin%26aufirst%3DM.%2BJ.%26aulast%3DKadonaga%26aufirst%3DJ.%2BT.%26atitle%3DWhat%25E2%2580%2599s%2520up%2520and%2520down%2520with%2520histone%2520deacetylation%2520and%2520transcription%253F%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D325%26epage%3D328%26doi%3D10.1016%2FS0092-8674%2800%2980211-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, W.</span></span> <span> </span><span class="NLM_article-title">HDAC expression and clinical prognosis in human malignancies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.10.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.canlet.2008.10.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=19103471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=168-176&author=W.+Weichert&title=HDAC+expression+and+clinical+prognosis+in+human+malignancies&doi=10.1016%2Fj.canlet.2008.10.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC expression and clinical prognosis in human malignancies</span></div><div class="casAuthors">Weichert, Wilko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-176</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases are known to play a central role in the regulation of several cellular properties intimately interlinked with the development and progression of cancer.  Consequently, a multitude of histone deacetylase (HDAC) inhibitors have been developed and are currently tested as anticancer agents in a variety of solid and hematol. malignancies.  However, only recently research began to focus on the actual expression patterns of specific HDAC isoforms in neoplasias.  The majority of studies investigating this issue reported an enhanced expression of class I HDAC isoforms in solid human tumors, both on mRNA and protein level, when compared to the resp. tissue of origin.  In most studies, class I HDAC expression was high in locally advanced, dedifferentiated, strongly proliferating tumors.  In some but not all entities elevated class I HDAC expression was assocd. with compromised patient prognosis, however, an assocn. of elevated class I HDAC expression with improved prognosis has also be reported for selected tumor entities.  In contrast to class I isoforms, expression of class II HDACs has been found reduced in tumors and high expression of these isoforms in some entities predicted better patient outcome.  Since all of these data point to a potential biol. role of differences in HDAC expression in human tumors, future translational studies will focus on the question, whether HDAC expression patterns are predictive for response to treatment with histone deacetylase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox6AkybidOQbVg90H21EOLACvtfcHk0ljaAi5YAiF4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jt70%253D&md5=cae20e78c0567e745f764d7aaaf1eeaf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.10.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.10.047%26sid%3Dliteratum%253Aachs%26aulast%3DWeichert%26aufirst%3DW.%26atitle%3DHDAC%2520expression%2520and%2520clinical%2520prognosis%2520in%2520human%2520malignancies%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D168%26epage%3D176%26doi%3D10.1016%2Fj.canlet.2008.10.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span> <span> </span><span class="NLM_article-title">Clinical use and applications of histone deacetylase inhibitors in multiple myeloma</span>. <i>Clin. Pharmacol.: Adv. Appl.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.2147/cpaa.s94021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.2147%2Fcpaa.s94021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=27226735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=35-44&author=S.+Kumarauthor=N.+Tandonauthor=V.+Ramakrishnan&title=Clinical+use+and+applications+of+histone+deacetylase+inhibitors+in+multiple+myeloma&doi=10.2147%2Fcpaa.s94021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use and applications of histone deacetylase inhibitors in multiple myeloma</span></div><div class="casAuthors">Tandon, Nidhi; Ramakrishnan, Vijay; Kumar, Shaji K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology: Advances and Applications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">CPAAGX</span>;
        ISSN:<span class="NLM_cas:issn">1179-1438</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The incorporation of various novel therapies has resulted in a significant survival benefit in newly diagnosed and relapsed patients with multiple myeloma (MM) over the past decade.  Despite these advances, resistance to therapy leads to eventual relapse and fatal outcomes in the vast majority of patients.  Hence, there is an unmet need for new safe and efficacious therapies for continued improvement in outcomes.  Given the role of epigenetic aberrations in the pathogenesis and progression of MM and the success of histone deacetylase inhibitors (HDACi) in other malignancies, many HDACi have been tried in MM.  Various preclin. studies helped us to understand the antimyeloma activity of different HDACi in MM as a single agent or in combination with conventional, novel, and immune therapies.  The early clin. trials of HDACi depicted only modest single-agent activity, but recent studies have revealed encouraging clin. response rates in combination with other antimyeloma agents, esp. proteasome inhibitors.  This led to the approval of the combination of panobinostat and bortezomib for the treatment of relapsed/refractory MM patients with two prior lines of treatment by the US Food and Drug Administration.  However, it remains yet to be defined how we can incorporate HDACi in the current therapeutic paradigms for MM that will help to achieve longer disease control and significant survival benefits.  In addn., isoform-selective and/or class-selective HDAC inhibition to reduce unfavorable side effects needs further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQBrcNeZHgx7Vg90H21EOLACvtfcHk0ljaAi5YAiF4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlertro%253D&md5=c5ad697e90297b2a2397737098dde73c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2Fcpaa.s94021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252Fcpaa.s94021%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTandon%26aufirst%3DN.%26aulast%3DRamakrishnan%26aufirst%3DV.%26atitle%3DClinical%2520use%2520and%2520applications%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520multiple%2520myeloma%26jtitle%3DClin.%2520Pharmacol.%253A%2520Adv.%2520Appl.%26date%3D2016%26volume%3D8%26spage%3D35%26epage%3D44%26doi%3D10.2147%2Fcpaa.s94021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liberty, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruc, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strain, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudgens, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1038/nature11286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fnature11286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=22837004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=482-485&author=N.+M.+Archinauthor=A.+L.+Libertyauthor=A.+D.+Kashubaauthor=S.+K.+Choudharyauthor=J.+D.+Kurucauthor=A.+M.+Crooksauthor=D.+C.+Parkerauthor=E.+M.+Andersonauthor=M.+F.+Kearneyauthor=M.+C.+Strainauthor=D.+D.+Richmanauthor=M.+G.+Hudgensauthor=R.+J.+Boschauthor=J.+M.+Coffinauthor=J.+J.+Eronauthor=D.+J.+Hazudaauthor=D.+M.+Margolis&title=Administration+of+vorinostat+disrupts+HIV-1+latency+in+patients+on+antiretroviral+therapy&doi=10.1038%2Fnature11286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy</span></div><div class="casAuthors">Archin, N. M.; Liberty, A. L.; Kashuba, A. D.; Choudhary, S. K.; Kuruc, J. D.; Crooks, A. M.; Parker, D. C.; Anderson, E. M.; Kearney, M. F.; Strain, M. C.; Richman, D. D.; Hudgens, M. G.; Bosch, R. J.; Coffin, J. M.; Eron, J. J.; Hazuda, D. J.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">482-485</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection.  Inducing the expression of latent genomes within resting CD4+ T cells is the primary strategy to clear this reservoir.  Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro, the utility of this approach has never been directly proven in a translational clin. study of HIV-infected patients.  Here we isolated the circulating resting CD4+ T cells of patients in whom viremia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir.  In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4+ cells (mean increase, 4.8-fold).  This demonstrates that a mol. mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK97t6JvwKNrVg90H21EOLACvtfcHk0ljaAi5YAiF4UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtrfP&md5=bfe1b9c441d7eeda40d46897a9801311</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature11286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11286%26sid%3Dliteratum%253Aachs%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DLiberty%26aufirst%3DA.%2BL.%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26aulast%3DChoudhary%26aufirst%3DS.%2BK.%26aulast%3DKuruc%26aufirst%3DJ.%2BD.%26aulast%3DCrooks%26aufirst%3DA.%2BM.%26aulast%3DParker%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DE.%2BM.%26aulast%3DKearney%26aufirst%3DM.%2BF.%26aulast%3DStrain%26aufirst%3DM.%2BC.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26aulast%3DHudgens%26aufirst%3DM.%2BG.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DCoffin%26aufirst%3DJ.%2BM.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DAdministration%2520of%2520vorinostat%2520disrupts%2520HIV-1%2520latency%2520in%2520patients%2520on%2520antiretroviral%2520therapy%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D482%26epage%3D485%26doi%3D10.1038%2Fnature11286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erikstrup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichterfeld, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogaard, O. S.</span></span> <span> </span><span class="NLM_article-title">Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group clinical trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e13</span>– <span class="NLM_lpage">e21</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(14)70014-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS2352-3018%2814%2970014-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=26423811" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=e13-e21&author=T.+A.+Rasmussenauthor=M.+Tolstrupauthor=C.+R.+Brinkmannauthor=R.+Olesenauthor=C.+Erikstrupauthor=A.+Solomonauthor=A.+Winckelmannauthor=S.+Palmerauthor=C.+Dinarelloauthor=M.+Buzonauthor=M.+Lichterfeldauthor=S.+R.+Lewinauthor=L.+Ostergaardauthor=O.+S.+Sogaard&title=Panobinostat%2C+a+histone+deacetylase+inhibitor%2C+for+latent-virus+reactivation+in+HIV-infected+patients+on+suppressive+antiretroviral+therapy%3A+a+phase+1%2F2%2C+single+group+clinical+trial&doi=10.1016%2FS2352-3018%2814%2970014-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2814%2970014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252814%252970014-1%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DBrinkmann%26aufirst%3DC.%2BR.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DErikstrup%26aufirst%3DC.%26aulast%3DSolomon%26aufirst%3DA.%26aulast%3DWinckelmann%26aufirst%3DA.%26aulast%3DPalmer%26aufirst%3DS.%26aulast%3DDinarello%26aufirst%3DC.%26aulast%3DBuzon%26aufirst%3DM.%26aulast%3DLichterfeld%26aufirst%3DM.%26aulast%3DLewin%26aufirst%3DS.%2BR.%26aulast%3DOstergaard%26aufirst%3DL.%26aulast%3DSogaard%26aufirst%3DO.%2BS.%26atitle%3DPanobinostat%252C%2520a%2520histone%2520deacetylase%2520inhibitor%252C%2520for%2520latent-virus%2520reactivation%2520in%2520HIV-infected%2520patients%2520on%2520suppressive%2520antiretroviral%2520therapy%253A%2520a%2520phase%25201%252F2%252C%2520single%2520group%2520clinical%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2014%26volume%3D1%26spage%3De13%26epage%3De21%26doi%3D10.1016%2FS2352-3018%2814%2970014-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graversen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleimann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hey-Cunningham, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantaleo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogsgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chomont, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span> <span> </span><span class="NLM_article-title">The depsipeptide romidepsin reverses HIV-1 latency in vivo</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e1005142</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1005142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1371%2Fjournal.ppat.1005142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=26379282" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&author=O.+S.+S%C3%B8gaardauthor=M.+E.+Graversenauthor=S.+Lethauthor=R.+Olesenauthor=C.+R.+Brinkmannauthor=S.+K.+Nissenauthor=A.+S.+Kjaerauthor=M.+H.+Schleimannauthor=P.+W.+Dentonauthor=W.+J.+Hey-Cunninghamauthor=K.+K.+Koelschauthor=G.+Pantaleoauthor=K.+Krogsgaardauthor=M.+Sommerfeltauthor=R.+Fromentinauthor=N.+Chomontauthor=T.+A.+Rasmussenauthor=L.+Astergaardauthor=M.+Tolstrup&title=The+depsipeptide+romidepsin+reverses+HIV-1+latency+in+vivo&doi=10.1371%2Fjournal.ppat.1005142"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005142%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B8gaard%26aufirst%3DO.%2BS.%26aulast%3DGraversen%26aufirst%3DM.%2BE.%26aulast%3DLeth%26aufirst%3DS.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DBrinkmann%26aufirst%3DC.%2BR.%26aulast%3DNissen%26aufirst%3DS.%2BK.%26aulast%3DKjaer%26aufirst%3DA.%2BS.%26aulast%3DSchleimann%26aufirst%3DM.%2BH.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DHey-Cunningham%26aufirst%3DW.%2BJ.%26aulast%3DKoelsch%26aufirst%3DK.%2BK.%26aulast%3DPantaleo%26aufirst%3DG.%26aulast%3DKrogsgaard%26aufirst%3DK.%26aulast%3DSommerfelt%26aufirst%3DM.%26aulast%3DFromentin%26aufirst%3DR.%26aulast%3DChomont%26aufirst%3DN.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3DAstergaard%26aufirst%3DL.%26aulast%3DTolstrup%26aufirst%3DM.%26atitle%3DThe%2520depsipeptide%2520romidepsin%2520reverses%2520HIV-1%2520latency%2520in%2520vivo%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26doi%3D10.1371%2Fjournal.ppat.1005142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano-Sarabia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Prospects for treatment of latent HIV</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1038/clpt.2012.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1038%2Fclpt.2012.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=23212106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=46-56&author=K.+Bartonauthor=B.+Burchauthor=N.+Soriano-Sarabiaauthor=D.+M.+Margolis&title=Prospects+for+treatment+of+latent+HIV&doi=10.1038%2Fclpt.2012.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for Treatment of Latent HIV</span></div><div class="casAuthors">Barton, K. M.; Burch, B. D.; Soriano-Sarabia, N.; Margolis, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-56</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection.  However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely.  Currently, the soln. to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding no. of people infected worldwide.  ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability.  Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection.  Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART.  This review will discuss these strategies in detail and their potential for clin. development.  Clin. Pharmacol. & Therapeutics (2013); 93 1, 46-56. doi:10.1038/clpt.2012.202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzlcZDCjSkvLVg90H21EOLACvtfcHk0lgv0HpNm9-aIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGms7rP&md5=72364092e1bcf5634cd21be17a47786e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.202%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%26aulast%3DBurch%26aufirst%3DB.%26aulast%3DSoriano-Sarabia%26aufirst%3DN.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DProspects%2520for%2520treatment%2520of%2520latent%2520HIV%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D93%26spage%3D46%26epage%3D56%26doi%3D10.1038%2Fclpt.2012.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleimann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Højen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graversen, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jørgensen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjær, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mørk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerfelt, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogsgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, S. O.</span></span> <span> </span><span class="NLM_article-title">Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e463</span>– <span class="NLM_lpage">e472</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(16)30055-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS2352-3018%2816%2930055-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=27658863" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e463-e472&author=S.+Lethauthor=H.+M.+Schleimannauthor=K.+S.+Nissenauthor=F.+J.+H%C3%B8jenauthor=R.+Olesenauthor=E.+M.+Graversenauthor=S.+J%C3%B8rgensenauthor=S.+A.+Kj%C3%A6rauthor=W.+P.+Dentonauthor=A.+M%C3%B8rkauthor=A.+M.+Sommerfeltauthor=K.+Krogsgaardauthor=L.+%C3%98stergaardauthor=A.+T.+Rasmussenauthor=M.+Tolstrupauthor=S.+O.+S%C3%B8gaard&title=Combined+effect+of+Vacc-4x%2C+recombinant+human+granulocyte+macrophage+colony-stimulating+factor+vaccination%2C+and+romidepsin+on+the+HIV-1+reservoir+%28REDUC%29%3A+a+single-arm%2C+phase+1B%2F2A+trial&doi=10.1016%2FS2352-3018%2816%2930055-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2816%2930055-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252816%252930055-8%26sid%3Dliteratum%253Aachs%26aulast%3DLeth%26aufirst%3DS.%26aulast%3DSchleimann%26aufirst%3DH.%2BM.%26aulast%3DNissen%26aufirst%3DK.%2BS.%26aulast%3DH%25C3%25B8jen%26aufirst%3DF.%2BJ.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DGraversen%26aufirst%3DE.%2BM.%26aulast%3DJ%25C3%25B8rgensen%26aufirst%3DS.%26aulast%3DKj%25C3%25A6r%26aufirst%3DS.%2BA.%26aulast%3DDenton%26aufirst%3DW.%2BP.%26aulast%3DM%25C3%25B8rk%26aufirst%3DA.%26aulast%3DSommerfelt%26aufirst%3DA.%2BM.%26aulast%3DKrogsgaard%26aufirst%3DK.%26aulast%3D%25C3%2598stergaard%26aufirst%3DL.%26aulast%3DRasmussen%26aufirst%3DA.%2BT.%26aulast%3DTolstrup%26aufirst%3DM.%26aulast%3DS%25C3%25B8gaard%26aufirst%3DS.%2BO.%26atitle%3DCombined%2520effect%2520of%2520Vacc-4x%252C%2520recombinant%2520human%2520granulocyte%2520macrophage%2520colony-stimulating%2520factor%2520vaccination%252C%2520and%2520romidepsin%2520on%2520the%2520HIV-1%2520reservoir%2520%2528REDUC%2529%253A%2520a%2520single-arm%252C%2520phase%25201B%252F2A%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2016%26volume%3D3%26spage%3De463%26epage%3De472%26doi%3D10.1016%2FS2352-3018%2816%2930055-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stöhr, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorrell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loes, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornhill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopycinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frater, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">888</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)32990-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2FS0140-6736%2819%2932990-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32085823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsValt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=888-898&author=S.+Fidlerauthor=W.+St%C3%B6hrauthor=M.+Paceauthor=L.+Dorrellauthor=A.+Leverauthor=S.+Pettauthor=K.+S.+Loesauthor=J.+Foxauthor=A.+Clarkeauthor=M.+Nelsonauthor=J.+Thornhillauthor=M.+Khanauthor=A.+Funauthor=M.+Bandaraauthor=D.+Kellyauthor=J.+Kopycinskiauthor=T.+Hankeauthor=H.+Yangauthor=R.+Bennettauthor=M.+Johnsonauthor=B.+Howellauthor=R.+Barnardauthor=G.+Wuauthor=S.+Kayeauthor=M.+Willsauthor=A.+Babikerauthor=J.+Frater&title=Antiretroviral+therapy+alone+versus+antiretroviral+therapy+with+a+kick+and+kill+approach%2C+on+measures+of+the+HIV+reservoir+in+participants+with+recent+HIV+infection+%28the+RIVER+trial%29%3A+a+phase+2%2C+randomised+trial&doi=10.1016%2FS0140-6736%2819%2932990-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial</span></div><div class="casAuthors">Fidler, Sarah; Stohr, Wolfgang; Pace, Matt; Dorrell, Lucy; Lever, Andrew; Pett, Sarah; Kinloch-de Loes, Sabine; Fox, Julie; Clarke, Amanda; Nelson, Mark; Thornhill, John; Khan, Maryam; Fun, Axel; Bandara, Mikaila; Kelly, Damian; Kopycinski, Jakub; Hanke, Tomas; Yang, Hongbing; Bennett, Rachel; Johnson, Margaret; Howell, Bonnie; Barnard, Richard; Wu, Guoxin; Kaye, Steve; Wills, Mark; Babiker, Abdel; Frater, John</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10227</span>),
    <span class="NLM_cas:pages">888-898</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells.  Approaches that force HIV transcription from these cells, making them susceptible to killing-termed kick and kill regimens-have been explored as a strategy towards an HIV cure.  RIVER is the first randomised trial to det. the effect of ART-only vs. ART plus kick and kill on markers of the HIV reservoir.  This phase 2, open-label, multicentre, randomised, controlled trial was undertaken at six clin. sites in the UK.  Patients aged 18-60 years who were confirmed as HIV-pos. within a max. of the past 6 mo and started ART within 1 mo from confirmed diagnosis were randomly assigned by a computer generated randomisation list to receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and replication-deficient viral vector T-cell inducing vaccines encoding conserved HIV sequences ChAdV63.  HIVconsv-prime and MVA.  HIVconsv-boost (the kill; ART + V + V; intervention).  The primary endpoint was total HIV DNA isolated from peripheral blood CD4+ T-cells at weeks 16 and 18 after randomisation.  Anal. was by intention to treat.  This trial is registered with ClinicalTrials.gov, NCT02336074.  Between June 14, 2015 and Jul 11, 2017, 60 men with HIV were randomly assigned to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants completed the study, with no loss-to-follow-up.  Mean total HIV DNA at weeks 16 and 18 after randomisation was 3·02 log10 copies HIV DNA per 106 CD4+ T-cells in the ART-only group vs. 3·06 log10 copies HIV DNA per 106 CD4+ T-cells in ART + V + V group, with no statistically significant difference between the two groups (mean difference of 0·04 log10 copies HIV DNA per 106 CD4+ T-cells [95% CI -0·03 to 0·11; p=0·26]).  There were no intervention-related serious adverse events.  This kick and kill approach conferred no significant benefit compared with ART alone on measures of the HIV reservoir.  Although this does not disprove the efficacy kick and kill strategy, for future trials enhancement of both kick and kill agents will be required.  Medical Research Council (MR/L00528X/1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2dUe5cxGGWbVg90H21EOLACvtfcHk0lh8ke-vpODtcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsValt7s%253D&md5=f8a9a837b92ca51b0e1f676a2d109bf9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2932990-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252932990-3%26sid%3Dliteratum%253Aachs%26aulast%3DFidler%26aufirst%3DS.%26aulast%3DSt%25C3%25B6hr%26aufirst%3DW.%26aulast%3DPace%26aufirst%3DM.%26aulast%3DDorrell%26aufirst%3DL.%26aulast%3DLever%26aufirst%3DA.%26aulast%3DPett%26aufirst%3DS.%26aulast%3DLoes%26aufirst%3DK.%2BS.%26aulast%3DFox%26aufirst%3DJ.%26aulast%3DClarke%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DThornhill%26aufirst%3DJ.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DFun%26aufirst%3DA.%26aulast%3DBandara%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DD.%26aulast%3DKopycinski%26aufirst%3DJ.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DBennett%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DHowell%26aufirst%3DB.%26aulast%3DBarnard%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DWills%26aufirst%3DM.%26aulast%3DBabiker%26aufirst%3DA.%26aulast%3DFrater%26aufirst%3DJ.%26atitle%3DAntiretroviral%2520therapy%2520alone%2520versus%2520antiretroviral%2520therapy%2520with%2520a%2520kick%2520and%2520kill%2520approach%252C%2520on%2520measures%2520of%2520the%2520HIV%2520reservoir%2520in%2520participants%2520with%2520recent%2520HIV%2520infection%2520%2528the%2520RIVER%2520trial%2529%253A%2520a%2520phase%25202%252C%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D888%26epage%3D898%26doi%3D10.1016%2FS0140-6736%2819%2932990-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marx-Blümel, L.</span>; <span class="NLM_string-name">Marx, C.</span>; <span class="NLM_string-name">Kühne, M.</span>; <span class="NLM_string-name">Sonnemann, J.</span></span> <span> </span><span class="NLM_article-title">Assessment of HDACi-induced cytotoxicity</span>. In  <i>Methods in Molecular Biology</i>; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">1510</span>, pp  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">45</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=23-45&author=L.+Marx-Bl%C3%BCmel&author=C.+Marx&author=M.+K%C3%BChne&author=J.+Sonnemann&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMarx-Bl%25C3%25BCmel%26aufirst%3DL.%26atitle%3DAssessment%2520of%2520HDACi-induced%2520cytotoxicity%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26pub%3DHumana%2520Press%26date%3D2017%26volume%3D1510%26spage%3D23%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llauger-Bufi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3453</span>– <span class="NLM_lpage">3456</span>, <span class="refDoi"> DOI: 10.1021/jm9004303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFWnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3453-3456&author=O.+Kinzelauthor=L.+Llauger-Bufiauthor=G.+Pescatoreauthor=M.+Rowleyauthor=C.+Schultz-Fademrechtauthor=E.+Monteagudoauthor=M.+Fonsiauthor=O.+G.+Pazauthor=F.+Fioreauthor=C.+Steink%C3%BChlerauthor=P.+Jones&title=Discovery+of+a+potent+class+I+selective+ketone+histone+deacetylase+inhibitor+with+antitumor+activity+in+vivo+and+optimized+pharmacokinetic+properties&doi=10.1021%2Fjm9004303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties</span></div><div class="casAuthors">Kinzel, Olaf; Llauger-Bufi, Laura; Pescatore, Giovanna; Rowley, Michael; Schultz-Fademrecht, Carsten; Monteagudo, Edith; Fonsi, Massimiliano; Gonzalez Paz, Odalys; Fiore, Fabrizio; Steinkuhler, Christian; Jones, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3453-3456</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of a potent, class I selective ketone HDAC inhibitor is shown.  It possesses optimized pharmacokinetic properties in preclin. species, has a clean off-target profile, and is neg. in a microbial mutagenicity (Ames) test.  In a mouse xenograft model it shows efficacy comparable to that of vorinostat at a 10-fold reduced dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHRRFS9TSYV7Vg90H21EOLACvtfcHk0lh8ke-vpODtcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFWnsb0%253D&md5=8674adc0c3892942a1fc7b154cbc84b4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm9004303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004303%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DO.%26aulast%3DLlauger-Bufi%26aufirst%3DL.%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DPaz%26aufirst%3DO.%2BG.%26aulast%3DFiore%26aufirst%3DF.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520class%2520I%2520selective%2520ketone%2520histone%2520deacetylase%2520inhibitor%2520with%2520antitumor%2520activity%2520in%2520vivo%2520and%2520optimized%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3453%26epage%3D3456%26doi%3D10.1021%2Fjm9004303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hokello, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">12291</span>– <span class="NLM_lpage">12303</span>, <span class="refDoi"> DOI: 10.1128/JVI.01383-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.01383-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=18829756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVymsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=12291-12303&author=R.+Pearsonauthor=Y.+K.+Kimauthor=J.+Hokelloauthor=K.+Lassenauthor=J.+Friedmanauthor=M.+Tyagiauthor=J.+Karn&title=Epigenetic+silencing+of+human+immunodeficiency+virus+%28HIV%29+transcription+by+formation+of+restrictive+chromatin+structures+at+the+viral+long+terminal+repeat+drives+the+progressive+entry+of+HIV+into+latency&doi=10.1128%2FJVI.01383-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency</span></div><div class="casAuthors">Pearson, Richard; Kim, Young Kyeung; Hokello, Joseph; Lassen, Kara; Friedman, Julia; Tyagi, Mudit; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">12291-12303</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The mol. mechanisms utilized by human immunodeficiency virus (HIV) to enter latency are poorly understood.  Following the infection of Jurkat T cells with lentiviral vectors that express Tat in cis, gene expression is progressively silenced.  Silencing is greatly enhanced when the lentiviral vectors carry an attenuated Tat gene with the H13L mutation.  Individual clones of lentivirus-infected cells showed a wide range of shutdown rates, with the majority showing a 50% silencing frequency between 30 to 80 days.  The silenced clones characteristically contained a small fraction (0 to 15%) of activated cells that continued to express d2EGFP.  When d2EGFP+ and d2EGFP- cell populations were isolated from the shutdown clones, they quickly reverted to the original distribution of inactive and active cells, suggesting that the d2EGFP+ cells arise from stochastic fluctuations in gene expression.  The detailed anal. of transcription initiation and elongation using chromatin immunopptn. (ChIP) assays confirms that Tat levels are restricted in the latently infected cells but gradually rise during proviral reactivation.  ChIP assays using clones of latently infected cells demonstrate that the latent proviruses carry high levels of deacetylated histones and trimethylated histones.  In contrast, the cellular genes IκBα and GAPDH had high levels of acetylated histones and no trimethylated histones.  The levels of trimethylated histone H3 and HP1-α assocd. with HIV proviruses fell rapidly after tumor necrosis factor alpha activation.  The progressive shutdown of HIV transcription following infection suggests that epigenetic mechanisms targeting chromatin structures selectively restrict HIV transcription initiation.  This decreases Tat prodn. below the levels that are required to sustain HIV gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf55wxe7XgyLVg90H21EOLACvtfcHk0ljrNx1vSe05ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVymsL%252FF&md5=e0d4a987dc7cf23512097146d83fb551</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FJVI.01383-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01383-08%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DY.%2BK.%26aulast%3DHokello%26aufirst%3DJ.%26aulast%3DLassen%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DTyagi%26aufirst%3DM.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEpigenetic%2520silencing%2520of%2520human%2520immunodeficiency%2520virus%2520%2528HIV%2529%2520transcription%2520by%2520formation%2520of%2520restrictive%2520chromatin%2520structures%2520at%2520the%2520viral%2520long%2520terminal%2520repeat%2520drives%2520the%2520progressive%2520entry%2520of%2520HIV%2520into%2520latency%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D12291%26epage%3D12303%26doi%3D10.1128%2FJVI.01383-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">6425</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1128/JVI.01519-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.01519-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=20410271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVehtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=6425-37&author=M.+Tyagiauthor=R.+J.+Pearsonauthor=J.+Karn&title=Establishment+of+HIV+latency+in+primary+CD4%2B+cells+is+due+to+epigenetic+transcriptional+silencing+and+P-TEFb+restriction&doi=10.1128%2FJVI.01519-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction</span></div><div class="casAuthors">Tyagi, Mudit; Pearson, Richard John; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6425-6437</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The development of suitable exptl. systems for studying HIV latency in primary cells that permit detailed biochem. analyses and the screening of drugs is a crit. step in the effort to develop viral eradication strategies.  Primary CD4+ T cells were isolated from peripheral blood and amplified by antibodies to the T-cell receptor (TCR).  The cells were then infected by lentiviral vectors carrying fluorescent reporters and either the wild-type Tat gene or the attenuated H13L Tat gene.  After sorting for the pos. cells and reamplification, the infected cells were allowed to spontaneously enter latency by long-term cultivation on the H80 feeder cell line in the absence of TCR stimulation.  By 6 wk almost all of the cells lost fluorescent protein marker expression; however, more than 95% of these latently infected cells could be reactivated after stimulation of the TCR by α-CD3/CD28 antibodies.  Chromatin immunopptn. assays showed that, analogously to Jurkat T cells, latent proviruses in primary CD4+ T cells are enriched in heterochromatic markers, including high levels of CBF-1, histone deacetylases, and methylated histones.  Upon TCR activation, there was recruitment of NF-κB to the promoter and conversion of heterochromatin structures present on the latent provirus to active euchromatin structures contg. acetylated histones.  Surprisingly, latently infected primary cells cannot be induced by tumor necrosis factor alpha because of a restriction in P-TEFb levels, which can be overcome by activation of the TCR.  Thus, a combination of restrictive chromatin structures at the HIV long terminal repeat and limiting P-TEFb levels contribute to transcriptional silencing leading to latency in primary CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3awVy2TqQSbVg90H21EOLACvtfcHk0ljrNx1vSe05ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVehtbs%253D&md5=705996c4ce33a8615dbd38692496ddef</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.01519-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01519-09%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DM.%26aulast%3DPearson%26aufirst%3DR.%2BJ.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEstablishment%2520of%2520HIV%2520latency%2520in%2520primary%2520CD4%252B%2520cells%2520is%2520due%2520to%2520epigenetic%2520transcriptional%2520silencing%2520and%2520P-TEFb%2520restriction%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D6425%26epage%3D37%26doi%3D10.1128%2FJVI.01519-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karn, J.</span></span> <span> </span><span class="NLM_article-title">Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9089</span>, <span class="refDoi"> DOI: 10.1128/JVI.00836-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1128%2FJVI.00836-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=21715480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=9078-9089&author=J.+Friedmanauthor=W.-K.+Choauthor=C.+K.+Chuauthor=K.+S.+Keedyauthor=N.+M.+Archinauthor=D.+M.+Margolisauthor=J.+Karn&title=Epigenetic+silencing+of+HIV-1+by+the+histone+H3+lysine+27+methyltransferase+enhancer+of+zeste+2&doi=10.1128%2FJVI.00836-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2</span></div><div class="casAuthors">Friedman, Julia; Cho, Won-Kyung; Chu, Chung K.; Keedy, Kara S.; Archin, Nancie M.; Margolis, David M.; Karn, Jonathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9078-9089</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Latent HIV proviruses are silenced as the result of deacetylation and methylation of histones located at the viral long terminal repeat (LTR).  Inhibition of histone deacetylases (HDACs) leads to the reemergence of HIV-1 from latency, but the contribution of histone lysine methyltransferases (HKMTs) to maintaining HIV latency remains uncertain.  Chromatin immunopptn. expts. using latently infected Jurkat T-cell lines demonstrated that the HKMT enhancer of Zeste 2 (EZH2) was present at high levels at the LTR of silenced HIV proviruses and was rapidly displaced following proviral reactivation.  Knockdown of EZH2, a key component of the Polycomb repressive complex 2 (PRC2) silencing machinery, and the enzyme which is required for tri-Me histone lysine 27 (H3K27me3) synthesis induced up to 40% of the latent HIV proviruses.  In contrast, there was less than 5% induction of latent proviruses following knockdown of SUV39H1, which is required for H3K9me3 synthesis.  Knockdown of EZH2 also sensitized latent proviruses to external stimuli, such as T-cell receptor stimulation, and slowed the reversion of reactivated proviruses to latency.  Similarly, cell populations that responded poorly to external stimuli carried HIV proviruses that were enriched in H3K27me3 and relatively depleted in H3K9me3.  Treating latently infected cells with the HKMT inhibitor 3-deazaneplanocin A, which targets EZH2, led to the reactivation of silenced proviruses, whereas chaetocin and BIX01294 showed only minimal reactivation activities.  These findings suggest that PRC2-mediated silencing is an important feature of HIV latency and that inhibitors of histone methylation may play a useful role in induction strategies designed to eradicate latent HIV pools.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNJWzxW8Sf7Vg90H21EOLACvtfcHk0ljrNx1vSe05ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKqtbbE&md5=a1236af4f0fe8a4dfb1857e4d884a5da</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FJVI.00836-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00836-11%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DW.-K.%26aulast%3DChu%26aufirst%3DC.%2BK.%26aulast%3DKeedy%26aufirst%3DK.%2BS.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26aulast%3DKarn%26aufirst%3DJ.%26atitle%3DEpigenetic%2520silencing%2520of%2520HIV-1%2520by%2520the%2520histone%2520H3%2520lysine%252027%2520methyltransferase%2520enhancer%2520of%2520zeste%25202%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D9078%26epage%3D9089%26doi%3D10.1128%2FJVI.00836-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolkenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of ethyl ketone-based HDAC-1,2,3 selective inhibitors for HIV latency reactivation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127197</span>– <span class="NLM_lpage">127204</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.bmcl.2020.127197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32331932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127197-127204&author=W.+Yuauthor=J.+Liuauthor=Y.+Yuauthor=V.+Zhangauthor=C.+Clausenauthor=J.+Kellyauthor=S.+Wolkenbergauthor=D.+Beshoreauthor=J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Discovery+of+ethyl+ketone-based+HDAC-1%2C2%2C3+selective+inhibitors+for+HIV+latency+reactivation&doi=10.1016%2Fj.bmcl.2020.127197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation</span></div><div class="casAuthors">Yu, Wensheng; Liu, Jian; Yu, Younong; Zhang, Vivian; Clausen, Dane; Kelly, Joseph; Wolkenberg, Scott; Beshore, Douglas; Duffy, Joseph L.; Chang, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">127197</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of Et ketone based HDACs 1, 2, and 3 selective inhibitors have been identified with good enzymic and cellular activity and high selectivity over HDACs 6 and 8.  These inhibitors contain a spirobicyclic group in the amide region.  Compd. 13 stands out as a lead due to its good potency, high selectivity, and reasonable rat and dog PK.  Compds. 33 and 34 show good potency and rat PK profiles as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRDknBquRfbVg90H21EOLACvtfcHk0lg3Q-LCoRzc4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D&md5=d0fb2e00f70938578cebc54129de8ce9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127197%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DClausen%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DWolkenberg%26aufirst%3DS.%26aulast%3DBeshore%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520ethyl%2520ketone-based%2520HDAC-1%252C2%252C3%2520selective%2520inhibitors%2520for%2520HIV%2520latency%2520reactivation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127197%26epage%3D127204%26doi%3D10.1016%2Fj.bmcl.2020.127197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, M.</span></span> <span> </span><span class="NLM_article-title">Role of hERG potassium channel assays in drug development</span>. <i>Channels</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.4161/chan.2.2.6004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.4161%2Fchan.2.2.6004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=18849661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A280%3ADC%252BC3cjpsFWmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2008&pages=87-93&author=B.+Priestauthor=M.+I.+Bellauthor=M.+Garcia&title=Role+of+hERG+potassium+channel+assays+in+drug+development&doi=10.4161%2Fchan.2.2.6004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Role of hERG potassium channel assays in drug development</span></div><div class="casAuthors">Priest Birgit T; Bell Ian M; Garcia Maria L</div><div class="citationInfo"><span class="NLM_cas:title">Channels (Austin, Tex.)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Numerous structurally and functionally unrelated drugs block the hERG potassium channel.  HERG channels are involved in cardiac action potential repolarization, and reduced function of hERG lengthens ventricular action potentials, prolongs the QT interval in an electrocardiogram, and increases the risk for potentially fatal ventricular arrhythmias.  In order to reduce the risk of investing resources in a drug candidate that fails preclinical safety studies because of QT prolongation, it is important to screen compounds for activity on hERG channels early in the lead optimization process.  A number of hERG assays are available, ranging from high throughput binding assays on stably expressed recombinant channels to very time consuming electrophysiological examinations in cardiac myocytes.  Depending on the number of compounds to be tested, binding assays or functional assays measuring membrane potential or Rb(+) flux, combined with electrophysiology on a few compounds, can be used to efficiently develop the structure-function relationship of hERG interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiaz7NnHSp2-98rul4nhSdfW6udTcc2eaav0XtR6L5MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjpsFWmsg%253D%253D&md5=a848fd2107a9af7ebac875a32bc08486</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.4161%2Fchan.2.2.6004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fchan.2.2.6004%26sid%3Dliteratum%253Aachs%26aulast%3DPriest%26aufirst%3DB.%26aulast%3DBell%26aufirst%3DM.%2BI.%26aulast%3DGarcia%26aufirst%3DM.%26atitle%3DRole%2520of%2520hERG%2520potassium%2520channel%2520assays%2520in%2520drug%2520development%26jtitle%3DChannels%26date%3D2008%26volume%3D2%26spage%3D87%26epage%3D93%26doi%3D10.4161%2Fchan.2.2.6004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newhard, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassaday, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadroni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R.</span></span> <span> </span><span class="NLM_article-title">In vitro pharmacokinetic/pharmacodynamic modeling of HIV latency reversal by novel HDAC inhibitors using an automated platform</span>. <i>SLAS Discovery</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, <span class="NLM_elocation-id">247255522098381</span> <span class="refDoi"> DOI: 10.1177/2472555220983810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1177%2F2472555220983810" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&author=W.+Newhardauthor=M.+Patelauthor=J.+Cassadayauthor=J.+Ballardauthor=B.+Squadroniauthor=G.+Wuauthor=J.+Liuauthor=W.+Yuauthor=J.+Kozlowskiauthor=P.+Zuckauthor=B.+Howellauthor=D.+Hazudaauthor=R.+Vargoauthor=R.+Barnard&title=In+vitro+pharmacokinetic%2Fpharmacodynamic+modeling+of+HIV+latency+reversal+by+novel+HDAC+inhibitors+using+an+automated+platform&doi=10.1177%2F2472555220983810"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F2472555220983810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555220983810%26sid%3Dliteratum%253Aachs%26aulast%3DNewhard%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DCassaday%26aufirst%3DJ.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DSquadroni%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DZuck%26aufirst%3DP.%26aulast%3DHowell%26aufirst%3DB.%26aulast%3DHazuda%26aufirst%3DD.%26aulast%3DVargo%26aufirst%3DR.%26aulast%3DBarnard%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%2520of%2520HIV%2520latency%2520reversal%2520by%2520novel%2520HDAC%2520inhibitors%2520using%2520an%2520automated%2520platform%26jtitle%3DSLAS%2520Discovery%26date%3D2021%26doi%3D10.1177%2F2472555220983810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span>; <span class="NLM_string-name">Clausen, D. J.</span>; <span class="NLM_string-name">Yu, W.</span>; <span class="NLM_string-name">Kelly, J. M.</span>; <span class="NLM_string-name">Kim, H. M.</span>; <span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Preparation of imidazole derivatives as inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection</span>. PCT Int. Appl. <span class="NLM_patent">WO2020028150</span><span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+Liu&author=D.+J.+Clausen&author=W.+Yu&author=J.+M.+Kelly&author=H.+M.+Kim&author=J.+A.+Kozlowski&title=Preparation+of+imidazole+derivatives+as+inhibitors+of+histone+deacetylase+useful+for+the+treatment+or+prevention+of+HIV+infection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520imidazole%2520derivatives%2520as%2520inhibitors%2520of%2520histone%2520deacetylase%2520useful%2520for%2520the%2520treatment%2520or%2520prevention%2520of%2520HIV%2520infection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127367</span>– <span class="NLM_lpage">127373</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1016%2Fj.bmcl.2020.127367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=32738976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127367-127373&author=D.+J.+Clausenauthor=J.+Liuauthor=W.+Yuauthor=J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Development+of+a+selective+HDAC+inhibitor+aimed+at+reactivating+the+HIV+latent+reservoir&doi=10.1016%2Fj.bmcl.2020.127367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir</span></div><div class="casAuthors">Clausen, Dane J.; Liu, Jian; Yu, Wensheng; Duffy, Joseph L.; Chung, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">127367</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and SAR development of a trisubstituted imidazole HDAC inhibitor is described.  The compds. were synthesized with high diastereocontrol by leveraging Ellman sulfinyl imine chem.  Structural elucidation provided insight into binding mode and supported design rational.  Pharmacokinetic properties of lead compds. were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqxEq8rSKpQLVg90H21EOLACvtfcHk0li3wxwB77muDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisrbP&md5=bb8221389e55066bd312eaeb11abb019</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127367%26sid%3Dliteratum%253Aachs%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DDuffy%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520selective%2520HDAC%2520inhibitor%2520aimed%2520at%2520reactivating%2520the%2520HIV%2520latent%2520reservoir%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127367%26epage%3D127373%26doi%3D10.1016%2Fj.bmcl.2020.127367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, J. O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, A. J.</span></span> <span> </span><span class="NLM_article-title">Selective class I HDAC inhibitors based on aryl ketone zinc binding induce HIV-1 protein for clearance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WmsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1476-1483&author=J.+Liuauthor=J.+Kellyauthor=W.+Yuauthor=D.+J.+Clausenauthor=Y.+Yuauthor=H.+Kimauthor=L.+J.+Duffyauthor=C.+C.+Changauthor=R.+W.+Myersauthor=S.+Carrollauthor=D.+J.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=J.+O.+R.+Barnardauthor=A.+J.+Kozlowski&title=Selective+class+I+HDAC+inhibitors+based+on+aryl+ketone+zinc+binding+induce+HIV-1+protein+for+clearance&doi=10.1021%2Facsmedchemlett.0c00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance</span></div><div class="casAuthors">Liu, Jian; Kelly, Joseph; Yu, Wensheng; Clausen, Dane; Yu, Younong; Kim, Hyunjin; Duffy, Joseph L.; Chung, Christine C.; Myers, Robert W.; Carroll, Steve; Klein, Daniel J.; Fells, James; Holloway, M. Katharine; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1476-1483</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV persistence in latently infected, resting CD4+ T cells is broadly considered a barrier to eradicate HIV.  Activation of the provirus using latency-reversing agents (LRAs) followed by immune-mediated clearance to purge reservoirs has been touted as a promising therapeutic approach.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) control the acetylation level of lysine residues in histones to regulate the gene transcription.  Several clin. HDAC inhibitors had been examd. as LRAs, which induced HIV activation in vitro and in vivo.  Here we report the discovery of a series of selective and potent class I HDAC inhibitors based on aryl ketones as a zinc binding group, which reversed HIV latency using a Jurkat model of HIV latency in 2C4 cells.  The SAR led to the discovery of a highly selective class I HDAC inhibitor 10(I) with excellent potency.  HDACi 10 induces the HIV gag P24 protein in patient latent CD4+ T cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDghJJZQUEyLVg90H21EOLACvtfcHk0li3wxwB77muDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WmsrrL&md5=b0b1ae6c4d5a06eb9f74ab59fcb46a8e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00302%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DClausen%26aufirst%3DD.%2BJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DL.%2BJ.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BW.%26aulast%3DCarroll%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DD.%2BJ.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DJ.%2BO.%2BR.%26aulast%3DKozlowski%26aufirst%3DA.%2BJ.%26atitle%3DSelective%2520class%2520I%2520HDAC%2520inhibitors%2520based%2520on%2520aryl%2520ketone%2520zinc%2520binding%2520induce%2520HIV-1%2520protein%2520for%2520clearance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1476%26epage%3D1483%26doi%3D10.1021%2Facsmedchemlett.0c00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanguinetti, C. M.</span></span> <span> </span><span class="NLM_article-title">Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K<sup>+</sup> channel</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1161/01.RES.78.3.499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=10.1161%2F01.RES.78.3.499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=8593709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;key=1%3ACAS%3A528%3ADyaK28XhtlWrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1996&pages=499-503&author=P.+S.+Spectorauthor=E.+M.+Curranauthor=T.+M.+Keatingauthor=C.+M.+Sanguinetti&title=Class+III+antiarrhythmic+drugs+block+HERG%2C+a+human+cardiac+delayed+rectifier+K%2B+channel&doi=10.1161%2F01.RES.78.3.499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel: open-channel block by methanesulfonanilides</span></div><div class="casAuthors">Spector, Peter S.; Curran, Mark E.; Keating, Mark T.; Sanguinetti, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The authors recently reported that mutations in HERG, a potassium channel gene, cause long QT syndrome.  Heterologous expression of HERG in Xenopus oocytes revealed that this channel had biophys. properties nearly identical to a cardiac delayed rectifier K+ current, IKr, but had dissimilar pharmacol. properties.  Class III antiarrhythmic drugs such as E-4031 and MK-499 are potent and specific blockers of IKr in cardiac myocytes.  The authors initial studies indicated that these compds. did not block HERG at a concn. of 1 μmol/L.  In the present study, the authors used std. two-microelectrode voltage-clamp techniques to further characterize the effects of these drugs on HERG channels expressed in oocytes.  Consistent with initial findings, 1 μmol/L MK-499 and E-4031 had no effect on HERG when oocytes were voltage clamped at a neg. potential and not pulsed during equilibration with the drug.  However, MK-499 did block HERG current if oocytes were repetitively pulsed, or clamped at a voltage pos. to the threshold potential for channel activation.  This finding is in contrast to previous studies that showed significant block of IKr in isolated myocytes by similar drugs, even in the absence of pulsing.  This apparent discrepancy may be due to differences in channel characteristics (HERG vs. guinea pig and mouse IKr), tissue (oocytes vs. myocytes), or specific drugs.  Under steady state conditions, block of HERG by MK-499 was half maximal at 123 nmol/L at a test potential of -20 mV.  MK-499 (150 nmol/L) did not affect the voltage dependence of activation and rectification nor the kinetics of activation and rectification nor the kinetics of activation and deactivation of HERG.  These data indicate that MK-499 preferentially blocks open HERG channels and further support the conclusion that HERG subunits form Ikr channels in cardiac myocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohpugjsvh4TrVg90H21EOLACvtfcHk0lhgc6A6Mk89gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtlWrt7Y%253D&md5=34d25ece3016497241f378e0c3839735</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1161%2F01.RES.78.3.499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.78.3.499%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DP.%2BS.%26aulast%3DCurran%26aufirst%3DE.%2BM.%26aulast%3DKeating%26aufirst%3DT.%2BM.%26aulast%3DSanguinetti%26aufirst%3DC.%2BM.%26atitle%3DClass%2520III%2520antiarrhythmic%2520drugs%2520block%2520HERG%252C%2520a%2520human%2520cardiac%2520delayed%2520rectifier%2520K%252B%2520channel%26jtitle%3DCirc.%2520Res.%26date%3D1996%26volume%3D78%26spage%3D499%26epage%3D503%26doi%3D10.1161%2F01.RES.78.3.499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ','PDB','6WBZ'); return false;">PDB: 6WBZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JS8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7JS8','PDB','7JS8'); return false;">PDB: 7JS8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i93"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02150">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24685"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02150?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02150</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Schemes S1–S11 for the synthesis of compounds <b>11</b>, <b>23</b>, <b>26</b>, <b>28</b>, <b>29</b>, <b>36</b>, <b>39</b>, <b>43</b>, <b>45</b>, <b>53</b>, and <b>56</b>; <sup>1</sup>H NMR spectra of compounds <b>3–56</b>; and <sup>13</sup>C NMR and LCMS spectra of compounds <b>31</b> and <b>48</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_001.pdf">jm0c02150_si_001.pdf (3.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02150/suppl_file/jm0c02150_si_002.csv">jm0c02150_si_002.csv (6.64 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02150&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-8%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02150%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02150" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992d110c04124c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
